

# 1 Appendix H: Meta-analysis and Network

# 2 meta-analysis Results

## 3 **H.1 Patient information**

- 4 • What information do people with cataracts and their carers find useful, and what format (for  
5 example written or verbal) do they prefer it to be provided in?
- 6 • What information on cataract surgery do people and their carers find useful when deciding  
7 whether surgery is appropriate for them, and before, during and after any operation(s) they  
8 elect to undergo? What format (for example written or verbal) do they prefer it to be provided  
9 in?

10 There were no meta-analyses conducted for these questions.

11

12    **H.2 Indicators for referral**

- 13    • What are the indicators for referral for cataract surgery?  
14    • What are the optimal clinical thresholds in terms of severity and impairment for referral for  
15    cataract surgery?

16    There were no meta-analyses conducted for these questions.  
17


### 18 H.3 Pre-operative assessment and biometry

- 19 What is the effectiveness of different techniques for undertaking biometry?
- 20 What are the most appropriate formulae to optimise intraocular lens biometry calculation?
- 21 What is the effectiveness of strategies used to select intraocular lens constants in order to  
22 optimise biometry calculation?
- 23 What other factors should be considered such as, who should undertake biometry and when  
24 should preoperative biometry be assessed?
- 25 What is the effectiveness of risk stratification techniques to reduce surgical complications?
- 26 What are the risk factors associated with increased surgical complications in cataract  
27 surgery?


#### 28 H.3.1 Biometry techniques - Forest plots of outcomes

##### 29 H.3.1.1 Ultrasound (immersion and contact) and optical biometry to measure axial length

###### 30 Mean absolute prediction errors



32

**Cumulative proportion of eyes within various ranges of absolute prediction errors**


33

**34 H.3.1.2 Keratometry (manual and automated) and topography to measure corneal curvature**

35


**Mean absolute prediction errors**

4



36

37

**Cumulative proportion of eyes within various ranges of absolute prediction errors**

38

39

40


41

**H.3.1.3 Observational studies in people undergoing phacoemulsification cataract surgery with a history of corneal refractive surgery**

Studies including mixed populations of individuals with a history of different types of refractive surgery (laser-assisted in situ keratomileusis, photorefractive keratectomy and radial keratotomy) for various indications (myopia, hyperopia)

42


43

**Mean prediction errors**

44

45

46

**Mean absolute prediction errors**


47

48  
49

## Studies including individuals with a history of laser-assisted in situ keratomileusis and photorefractive keratectomy for myopia

50


### Mean prediction errors: keratometry (SRK-T formula) vs topography (SRK-T formula)



51


52

### Mean prediction errors: keratometry (Haigis-L formula) vs topography (SRK-T formula)




53

**Cumulative proportion of eyes within various ranges of absolute prediction errors:  
keratometry (SRK-T formula) vs topography (SRK-T formula)**



57  
58

**Cumulative proportion of eyes within various ranges of absolute prediction errors:  
keratometry (Haigis-L formula) vs topography (SRK-T formula)**



59

60 **H.3.2 Intraocular lens formulas: Network meta-analyses results: Virgin eyes without a history of corneal refractive surgery**61 **H.3.2.1 Model fit statistics for all outcomes**62 **Table 1: Model fit statistics used to select fixed or random effect models for all comparisons and outcomes**

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
<b>VIRGIN EYES WITHOUT A HISTORY OF CORNEAL REFRACTIVE SURGERY</b>								
<b>Axial length less than 22.00mm</b>								
7 (Carifi, Cooke, Day, Doshi, Moschos, Ozcura, Srivannaboon)	Mean absolute error	FE	43.024	87.582	137.8	37	-	RE
		RE	- 44.558		36.72		0.267 (0.174, 0.424)	
5 (Aristodemou, Day, Eom, Kane, Srivannaboon)	Within 0.25D	FE	157.59 2	-1.143	22.47	28	-	FE
		RE	158.73 5		21.67		0.124 (0.004, 0.439)	
11 (Aristodemou, Carifi, Cooke, Day, Doshi, Eom, Kane, Moschos, Ozcura, Percival, Srivannaboon)	Within 0.5D	FE	344.21	28.658	97.82	52	-	RE
		RE	315.55 2		52.32		0.589 (0.345, 0.920)	
11 (Aristodemou, Carifi, Cooke, Day, Doshi, Eom, Kane, Moschos, Ozcura, Percival, Srivannaboon)	Within 1.0D	FE	295.16 4	18.295	83.66	52	-	RE
		RE	276.86 9		50.87		0.653 (0.367, 1.035)	
3 (Carifi, Kane, Ozcura)	Within 2.0D	FE	43.015	-1.091	9.174	12	-	FE
		RE	44.106		9.731		0.593 (0.024, 1.834)	
<b>Axial length 22.00 to 24.50mm</b>								
2 (Ozcura, Srivannaboon)	Mean absolute error	FE	- 20.877	-0.027	6.015	6	-	FE
		RE	-20.85		6.028		1004 (0.051, 1.948)	

Meta-analysis and network meta-analysis results

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
3 (Aristodemou, Kane, Srivannaboon)	Within 0.25D	FE	126.75 2	-1.491	12.98	14	-	FE
		RE	128.24 3		12.62		0.069 (0.005, 0.360)	
4 (Aristodemou, Kane, Ozcura, Srivannaboon)	Within 0.5D	FE	138.89	-2.357	12.8	16	-	FE
		RE	141.24 7		13.65		0.046 (0.002, 0.242)	
4 (Aristodemou, Kane, Ozcura, Srivannaboon)	Within 1.0D	FE	119.79 9	-1.358	13.68	16	-	FE
		RE	121.15 7		13.7		0.090 (0.003, 0.465)	
2 (Kane, Ozcura)	Within 2.0D	FE	43.439	-1.011	7.367	8	-	FE
		RE	44.45		7.782		0.745 (0.044, 1.918)	
<b>Axial length 24.50 to 26.00mm</b>								
1 (Srivannaboon)	Mean absolute error	FE	-6.133	0.009	3.991	4	-	FE
		RE	-6.142		3.986		0.964 (0.040, 1.949)	
3 (Aristodemou, Kane, Srivannaboon)	Within 0.25D	FE	99.785	-1.785	11.55	14	-	FE
		RE	101.57		12.01		0.132 (0.006, 0.726)	
4 (Aristodemou, Kane, Percival, Srivannaboon)	Within 0.5D	FE	113.31 9	-2.338	15	17	-	FE
		RE	115.65 7		15.63		0.129 (0.004, 0.755)	
6 (Aristodemou, El-Nafees, Kane, Mitra, Percival, Srivannaboon)	Within 1.0D	FE	113.40 2	-1.7	20.9	21	-	FE
		RE	115.10 2		20.49		0.227 (0.012, 1.052)	
1 (Kane)	Within 2.0D	FE	26.195	-0.029	6.666	6	-	FE


Meta-analysis and network meta-analysis results

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
		RE	26.224		6.711		1.010 (0.059, 1.948)	
<b>Axial length greater than 26.00mm</b>								
2 (Bang, Cooke)	Mean absolute error	FE	-19.062	1.227	16.31	13	-	FE
		RE	-20.289		13.25		0.294 (0.021, 1.623)	
2 (Aristodemou, Kane)	Within 0.25D	FE	73.422	-2.148	10.05	12	-	FE
		RE	75.57		10.93		0.260 (0.008, 1.540)	
5 (Aristodemou, Bang, Cooke, Kane, Percival)	Within 0.5D	FE	160.51	-1.369	24.45	28	-	FE
		RE	161.87 9		24.31		0.122 (0.007, 0.457)	
8 (Aristodemou, Bang, Cooke, El-Nafees, Kane, Mitra, Percival, Petermeier)	Within 1.0D	FE	196.07 4	19.255	64.1	35	-	RE
		RE	176.81 9		35.1		0.974 (0.506, 1724)	
2 (Bang, Kane)	Within 2.0D	FE	44.466	1.002	13.49	10	-	FE
		RE	43.464		10.79		1.033 (0.095, 1.933)	

63 H.3.2.2 Full dataset: Axial length subgroup – less than 22.00mm

64

MEAN ABSOLUTE ERROR – random effects model



65

66

67

**Figure 1: AL <22.0mm: Mean absolute error - random effects model – evidence network****Table 2: AL <22.0mm: Mean absolute error - random effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversal_I</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2_NoPreSurgRef</b>	<b>Holladay2_PresSurgRef</b>	<b>Holladay2-LT</b>	<b>LadasSuperFormula</b>	<b>Olsen_standalone</b>	<b>T2</b>
Cooke & (2016)	0.40 (0.51)	0.39 (0.48)	0.41 (0.51)	0.48 (0.49)		0.44 (0.47)	0.43 (0.47)		0.40 (0.48)	0.46 (0.57)	0.39 (0.49)
Doshi et al. (2017)	0.54 (0.46)		1.36 (0.75)	0.59 (0.36)							
Ozcura et al. (2016)	0.70 (0.64)			0.76 (0.65)							
Carifi et al. (2015)	1.34 (1.04)			1.03 (0.87)	0.95 (0.78)	0.82 (0.77)					
Srivannaboon et al. (2013)				0.44 (0.40)	0.42 (0.33)	0.44 (0.31)			0.45 (0.30)		
Day et al. (2012)	0.52 (0.42)			0.44 (0.35)	0.46 (0.39)						
Day et al. (2012)	0.50 (0.37)			0.37 (0.28)	0.50 (0.37)						
Day et al. (2012)	0.79 (0.56)			0.86 (0.58)	0.74 (0.58)						
Day et al. (2012)	0.85 (0.56)			0.77 (0.51)	0.83 (0.61)						
Moschos et al. (2014)	0.97 (0.38)			0.43 (0.22)	0.72 (0.51)						

68


69

**Table 3: AL <22.0mm: Mean absolute error - random effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standar dOne	T2
SRKT		-0.01 (-0.22, 0.20)	-0.03 (-0.30, 0.24)	-0.05 (-0.14, 0.04)	-0.52 (-1.00, - 0.04)	0.04 (-0.17, 0.25)	0.03 (-0.19, 0.24)	-	0.00 (-0.21, 0.21)	0.06 (-0.18, 0.29)	-0.01 (-0.22, 0.21)
BarrettUnivers all	-0.07 (-0.57, 0.44)		0.02 (-0.20, 0.23)	0.09 (-0.12, 0.30)	-	0.05 (-0.15, 0.26)	0.04 (-0.17, 0.24)	-	0.01 (-0.20, 0.22)	0.07 (-0.16, 0.29)	0.00 (-0.21, 0.21)
Haigis	-0.04 (-0.25, 0.18)	0.03 (-0.48, 0.54)		-0.03 (-0.22, 0.15)	-0.05 (-0.27, 0.17)	0.04 (-0.18, 0.25)	0.02 (-0.19, 0.23)	0.01 (-0.24, 0.26)	-0.01 (-0.22, 0.21)	0.05 (-0.18, 0.28)	-0.01 (-0.23, 0.20)
HofferQ	-0.06 (-0.27, 0.14)	0.01 (-0.49, 0.51)	-0.02 (-0.23, 0.18)		-0.02 (-0.22, 0.18)	-0.04 (-0.25, 0.17)	-0.06 (-0.26, 0.15)	0.03 (-0.20, 0.26)	-0.08 (-0.29, 0.13)	-0.03 (-0.25, 0.20)	-0.09 (-0.30, 0.12)
Holladay2	-0.16 (-0.58, 0.27)	-0.09 (-0.72, 0.54)	-0.12 (-0.53, 0.28)	-0.09 (-0.50, 0.30)		-	-	0.01 (-0.21, 0.23)	-	-	-
Holladay2_NoPreSurgRef	-0.02 (-0.51, 0.48)	0.05 (-0.54, 0.65)	0.02 (-0.48, 0.52)	0.04 (-0.46, 0.54)	0.14 (-0.49, 0.77)		-0.02 (-0.22, 0.19)	-	-0.04 (-0.25, 0.16)	0.02 (-0.21, 0.24)	-0.05 (-0.26, 0.16)
Holladay2_PreSurgRef	-0.04 (-0.54, 0.47)	0.03 (-0.57, 0.64)	0.00 (-0.51, 0.50)	0.02 (-0.48, 0.53)	0.12 (-0.50, 0.75)	-0.02 (-0.62, 0.57)		-	-0.03 (-0.23, 0.18)	0.03 (-0.19, 0.26)	-0.03 (-0.24, 0.18)
Holladay2-LT	-0.07 (-0.61, 0.47)	0.00 (-0.72, 0.72)	-0.03 (-0.56, 0.49)	-0.01 (-0.53, 0.52)	0.08 (-0.46, 0.65)	-0.05 (-0.76, 0.66)	-0.03 (-0.75, 0.68)		-	-	-
LadasSuperFormula	-0.06 (-0.56, 0.45)	0.01 (-0.60, 0.61)	-0.02 (-0.53, 0.48)	0.00 (-0.50, 0.51)	0.10 (-0.53, 0.72)	-0.04 (-0.63, 0.54)	-0.02 (-0.62, 0.58)	0.01 (-0.70, 0.72)		0.06 (-0.17, 0.28)	-0.01 (-0.22, 0.20)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2_LT	LadasSuperFo rmula	Olsen_standal one	T2
Olsen_standalone	0.00 (-0.52, 0.50)	0.07 (-0.54, 0.67)	0.04 (-0.49, 0.54)	0.06 (-0.46, 0.56)	0.16 (-0.48, 0.79)	0.02 (-0.59, 0.62)	0.04 (-0.57, 0.64)	0.07 (-0.65, 0.78)	0.06 (-0.55, 0.67)		-0.06 (-0.29, 0.17)
T2	-0.07 (-0.57, 0.43)	0.00 (-0.60, 0.60)	-0.03 (-0.54, 0.47)	-0.01 (-0.51, 0.49)	0.09 (-0.54, 0.71)	-0.05 (-0.65, 0.55)	-0.03 (-0.63, 0.56)	0.00 (-0.71, 0.71)	-0.01 (-0.61, 0.59)	-0.07 (-0.67, 0.53)	

72



73

Figure 2: AL <22.0mm: Mean absolute error - random effects model – relative effect of all options versus common comparator


74

75

**Table 4: AL <22.0mm: Mean absolute error - random effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.005	7 (2, 11)
BarrettUniversalII	0.122	5 (1, 11)
Haigis	0.012	6 (2, 10)
HofferQ	0.017	6 (2, 10)
Holladay2	0.214	3 (1, 11)
Holladay2_NoPreSurgRef	0.078	7 (1, 11)
Holladay2_PreSurgRef	0.090	6 (1, 11)
Holladay2-LT	0.155	5 (1, 11)
LadasSuperFormula	0.112	6 (1, 11)
Olsen_standalone	0.073	7 (1, 11)
T2	0.122	5 (1, 11)

76



77

**Figure 3: AL <22.0mm: Mean absolute error - random effects model – rank probability histograms**

78

79

**Table 5: AL <22.0mm: Mean absolute error - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
36.72 (compared to 37 datapoints)	-78.017	-111.476	33.459	-44.558	0.267 (95%CI: 0.174, 0.424)

80

81


**Table 6: AL <22.0mm: Mean absolute error - random effects model – notes**

- Continuous (normal; identity link); random effects
  - Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
  - 50000 burn-ins; 10000 recorded iterations

82

83

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**



84

**Figure 4: AL <22.0mm: Within 0.25D - fixed effects model – evidence network**

85

86

**Table 7: AL <22.0mm: Within 0.25D - fixed effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	51/156	48/156	57/156	44/156	49/156		52/156
Eom et al. (2014)			28/75	22/75			
Srivannaboon et al. (2013)			5/15	6/15	5/15	5/15	
Day et al. (2012)	11/32		12/32	10/32			
Day et al. (2012)	32/100		35/100	39/100			
Day et al. (2012)	2/19		3/19	3/19			
Day et al. (2012)	3/12		2/12	4/12			
Aristodemou et al. (2011)	50/151			44/151			
Aristodemou et al. (2011)	145/457			168/457			

87


88

89  
90**Table 8: AL <22.0mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUniversal all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		0.92 (0.57, 1.47)	1.16 (0.83, 1.61)	1.09 (0.90, 1.33)	0.94 (0.59, 1.52)	-	1.03 (0.64, 1.65)
BarrettUniversal all	1.01 (0.67, 1.53)		1.30 (0.81, 2.07)	0.88 (0.54, 1.44)	1.03 (0.64, 1.66)	-	1.13 (0.70, 1.81)

	SRKT	BarrettUnivers allII	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Haigis	1.23 (0.92, 1.64)	1.21 (0.79, 1.85)		0.86 (0.64, 1.15)	0.81 (0.52, 1.27)	1.00 (0.22, 4.56)	0.87 (0.55, 1.38)
HofferQ	1.09 (0.90, 1.32)	1.07 (0.71, 1.62)	0.88 (0.67, 1.16)		1.12 (0.70, 1.77)	0.75 (0.17, 3.33)	1.27 (0.79, 2.06)
Holladay2	1.04 (0.70, 1.55)	1.03 (0.64, 1.65)	0.85 (0.56, 1.27)	0.96 (0.64, 1.41)		1.00 (0.22, 4.56)	1.09 (0.68, 1.75)
Holladay2-LT	0.99 (0.26, 3.53)	0.98 (0.24, 3.57)	0.81 (0.21, 2.82)	0.92 (0.24, 3.20)	0.96 (0.25, 3.38)		-
T2	1.14 (0.76, 1.71)	1.13 (0.70, 1.83)	0.93 (0.61, 1.42)	1.05 (0.70, 1.57)	1.10 (0.69, 1.76)	1.15 (0.31, 4.64)	

91



92

Figure 5: AL <22.0mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator


93

94

**Table 9: AL <22.0mm: Within 0.25D - fixed effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.007	5 (2, 7)
BarrettUniversalll	0.066	5 (1, 7)
Haigis	0.286	2 (1, 6)
HofferQ	0.044	4 (1, 7)
Holladay2	0.074	5 (1, 7)
Holladay2-LT	0.327	5 (1, 7)
T2	0.196	3 (1, 7)

95



**Figure 6: AL <22.0mm: Within 0.25D - fixed effects model – rank probability histograms**

97

98

**Table 10: AL <22.0mm: Within 0.25D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
22.47 (compared to 28 datapoints)	142.482	127.373	15.109	157.592	

99

100


**Table 11: AL <22.0mm: Within 0.25D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

101

102

**PROPORTION WITHIN 0.5 DIOPTRES – random effects model**



103

**Figure 7: AL <22.0mm: Within 0.50D - random effects model – evidence network**

104

105

**Table 12: AL <22.0mm: Within 0.50D - random effects model – input data**

	<b>SRKT</b>	<b>AvgHofferQSRK_T</b>	<b>BarrettUniversal_II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2_NoPreSurgRef</b>	<b>Holladay2_PresurgRef</b>	<b>Holladay2_LT</b>	<b>LadasSuperFormula</b>	<b>Olsen_standalone</b>	<b>T2</b>
Cooke & (2016)	28/41		32/41	28/41	26/41		30/41	27/41		33/41	25/41	30/41
Doshi et al. (2017)	22/40			7/40	17/40							
Kane,J. et al. (2016)	93/156		97/156	98/156	87/156	96/156						94/156
Ozcura et al. (2016)	14/32				15/32							
Carifi et al. (2015)	6/28			12/28	11/28	12/28						
Eom et al. (2014)				50/75	47/75							
Srivannaboon et al. (2013)				6/15	9/15	7/15			7/15			
Day et al. (2012)	20/32			24/32	18/32							
Day et al. (2012)	54/100			68/100	60/100							
Day et al. (2012)	6/19			4/19	9/19							
Day et al. (2012)	4/12			4/12	4/12							
Aristodemou et al. (2011)	91/151				85/151							
Aristodemou et al. (2011)	276/457				293/457							
Percival et al. (2002)	25/54	36/54			35/54							
Moschos et al. (2014)	13/69			50/69	41/69							

106

**Table 13: AL <22.0mm: Within 0.50D - random effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
SRKT		2.32 (1.06, 5.05)	1.19 (0.79, 1.80)	1.38 (0.68, 2.80)	1.25 (0.92, 1.71)	1.47 (0.62, 3.45)	1.27 (0.49, 2.29)	0.90 (0.36, 2.25)	-	1.92 (0.69, 5.28)	0.73 (0.29, 1.80)	1.07 (0.71, 1.61)
AvgHofferQSRKT	1.82 (0.51, 6.65)		-	-	0.92 (0.42, 2.04)	-	-	-	-	-	-	-
BarrettUniversallII	1.65 (0.70, 3.92)	0.91 (0.20, 4.12)		0.94 (0.62, 1.42)	0.71 (0.47, 1.07)	0.97 (0.62, 1.54)	0.77 (0.28, 2.11)	0.54 (0.20, 1.45)	-	1.16 (0.40, 3.38)	0.44 (0.17, 1.16)	0.89 (0.59, 1.35)
Haigis	1.38 (0.84, 2.21)	0.76 (0.20, 2.80)	0.84 (0.34, 1.96)		0.90 (0.65, 1.26)	0.98 (0.65, 1.47)	1.27 (0.49, 3.29)	0.90 (0.36, 2.25)	1.31 (0.31, 5.58)	1.92 (0.69, 5.28)	0.73 (0.29, 1.80)	0.96 (0.63, 1.44)
HofferQ	1.30 (0.86, 1.96)	0.71 (0.20, 2.53)	0.79 (0.34, 1.85)	0.94 (0.61, 1.50)		1.18 (0.79, 1.76)	1.57 (0.62, 4.02)	1.11 (0.45, 2.75)	0.58 (0.14, 2.48)	2.38 (0.88, 6.47)	0.90 (0.37, 2.20)	1.26 (0.84, 1.90)
Holladay2	1.45 (0.66, 3.17)	0.80 (0.18, 3.42)	0.88 (0.31, 2.43)	1.05 (0.49, 2.31)	1.11 (0.52, 2.41)		-	-	1.00 (0.24, 4.20)	-	-	0.95 (0.60, 1.49)
Holladay2_NoPreSurgRef	1.53 (0.43, 5.53)	0.84 (0.14, 4.98)	0.93 (0.23, 3.75)	1.11 (0.32, 4.08)	1.17 (0.34, 4.21)	1.06 (0.26, 4.40)		0.71 (0.27, 1.82)	-	1.51 (0.54, 4.26)	0.57 (0.23, 1.46)	1.00 (0.38, 2.66)
Holladay2_PreSurgRef	1.07 (0.31, 3.67)	0.59 (0.10, 3.36)	0.65 (0.17, 2.50)	0.78 (0.23, 2.69)	0.83 (0.24, 2.81)	0.74 (0.18, 2.95)	0.70 (0.15, 3.30)		-	2.14 (0.78, 5.85)	0.81 (0.33, 1.99)	1.41 (0.55, 3.64)
Holladay2-LT	1.23 (0.24, 6.19)	0.67 (0.09, 5.14)	0.75 (0.13, 4.28)	0.90 (0.18, 4.45)	0.95 (0.19, 4.60)	0.85 (0.16, 4.39)	0.80 (0.11, 5.95)	1.14 (0.16, 8.35)		-	-	-

Meta-analysis and network meta-analysis results

---

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standal one	T2
LadasSuperFormula	2.36 (0.64, 8.96)	1.30 (0.21, 7.91)	1.44 (0.35, 6.04)	1.73 (0.47, 6.49)	1.82 (0.49, 6.79)	1.64 (0.39, 7.07)	1.55 (0.31, 7.85)	2.21 (0.46, 10.94)	1.94 (0.26, 14.95)	0.38 (0.14, 1.02)	0.66 (0.23, 1.86)	
Olsen_standalone	0.86 (0.25, 2.98)	0.47 (0.08, 2.72)	0.52 (0.14, 2.01)	0.62 (0.18, 2.17)	0.66 (0.19, 2.25)	0.59 (0.15, 2.41)	0.56 (0.12, 2.64)	0.80 (0.18, 3.69)	0.70 (0.10, 5.04)	0.36 (0.07, 1.73)	1.75 (0.69, 4.44)	
T2	1.42 (0.60, 3.35)	0.78 (0.17, 3.48)	0.86 (0.31, 2.36)	1.03 (0.44, 2.47)	1.09 (0.47, 2.56)	0.98 (0.35, 2.72)	0.93 (0.23, 3.64)	1.32 (0.35, 4.97)	1.15 (0.20, 6.75)	0.60 (0.14, 2.43)	1.65 (0.43, 6.43)	




Figure 8: AL <22.0mm: Within 0.50D - random effects model – relative effect of all options versus common comparator


111

112

Table 14: AL <22.0mm: Within 0.50D - random effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.000	10 (5, 12)
AvgHofferQSRKT	0.217	4 (1, 12)
BarrettUniversallI	0.074	4 (1, 11)
Haigis	0.006	6 (2, 10)
HofferQ	0.002	7 (3, 11)
Holladay2	0.034	6 (1, 11)
Holladay2_NoPreSurgRef	0.113	5 (1, 12)
Holladay2_PreSurgRef	0.032	9 (1, 12)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2-LT	0.122	8 (1, 12)
LadasSuperFormula	0.357	2 (1, 11)
Olsen_standalone	0.014	11 (2, 12)
T2	0.031	6 (1, 12)



114

**Figure 9: AL <22.0mm: Within 0.50D - random effects model – rank probability histograms**

115

116

**Table 15: AL <22.0mm: Within 0.50D - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
52.32 (compared to 52 datapoints)	272.542	229.532	43.01	315.552	0.589 (95%CI: 0.345, 0.920)

117

118


**Table 16: AL <22.0mm: Within 0.50D - random effects model – notes**

- Dichotomous synchronic (binomial; logit link); random effects
  - Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
  - 50000 burn-ins; 10000 recorded iterations

119

120

**PROPORTION WITHIN 1.0 DIOPTRE – random effects model**



**Figure 10:** AL <22.0mm: Within 1.0D - random effects model – evidence network

121

122

123

**Table 17: AL <22.0mm: Within 1.0D - random effects model – input data**

	SRKT	AvgHofferQSRKT	BarrettUniversal <sub>II</sub>	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PresSurgRef	Holladay2_LT	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	39/41		38/41	39/41	36/41		36/41	38/41		38/41	39/41	39/41
Doshi et al. (2017)	33/40			14/40	36/40							
Kane,J. et al. (2016)	144/156		144/156	142/156	142/156	143/156						145/156
Ozcura et al. (2016)	24/32				26/32							
Carifi et al. (2015)	12/28			13/28	17/28	18/28						
Eom et al. (2014)				66/75	66/75							
Srivannaboon et al. (2013)				11/15	13/15	13/15			13/15			
Day et al. (2012)	28/32			31/32	28/32							
Day et al. (2012)	89/100			93/100	92/100							
Day et al. (2012)	14/19			12/19	14/19							
Day et al. (2012)	6/12			7/12	6/12							
Aristodemou et al. (2011)	130/151				131/151							
Aristodemou et al. (2011)	399/457				408/457							
Percival et al. (2002)	43/54	45/54			48/54							
Moschos et al. (2014)	47/69			64/69	59/69							

124


**Table 18: AL <22.0mm: Within 1.0D - random effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
SRKT		1.28 (0.48, 3.39)	0.93 (0.44, 1.99)	1.10 (0.49, 2.48)	1.29 (1.02, 1.65)	1.39 (0.55, 3.53)	0.37 (0.07, 2.02)	0.65 (0.10, 4.11)	-	0.65 (0.10, 4.11)	1.00 (0.13, 7.46)	1.08 (0.50, 2.37)
AvgHofferQSRKT	1.05 (0.23, 4.61)		-	-	1.60 (0.53, 4.86)	-	-	-	-	-	-	-
BarrettUniversallII	1.27 (0.43, 3.83)	1.21 (0.20, 7.73)		0.93 (0.44, 1.95)	0.77 (0.38, 1.57)	0.92 (0.40, 2.08)	0.57 (0.13, 2.55)	1.00 (0.19, 5.27)	-	1.00 (0.19, 5.27)	1.54 (0.24, 9.73)	1.17 (0.54, 2.52)
Haigis	1.07 (0.62, 1.88)	1.02 (0.22, 4.95)	0.84 (0.28, 2.50)		1.18 (0.63, 2.20)	1.44 (0.79, 2.63)	0.37 (0.07, 2.02)	0.65 (0.10, 4.11)	2.36 (0.36, 15.45)	0.65 (0.10, 4.11)	1.00 (0.13, 7.46)	1.25 (0.58, 2.68)
HofferQ	1.32 (0.81, 2.11)	1.26 (0.28, 5.75)	1.04 (0.34, 3.00)	1.23 (0.71, 2.10)		1.10 (0.60, 2.03)	1.00 (0.27, 3.75)	1.76 (0.39, 7.90)	1.00 (0.12, 8.21)	1.76 (0.39, 7.90)	2.71 (0.49, 14.84)	1.49 (0.71, 3.13)
Holladay2	1.56 (0.63, 4.02)	1.48 (0.27, 8.68)	1.23 (0.35, 4.38)	1.45 (0.59, 3.70)	1.18 (0.48, 3.04)		-	-	1.00 (0.12, 8.21)	-	-	1.20 (0.52, 2.76)
Holladay2_NoPreSurgRef	0.63 (0.13, 3.23)	0.60 (0.07, 5.29)	0.50 (0.09, 2.81)	0.59 (0.12, 2.94)	0.48 (0.10, 2.41)	0.41 (0.07, 2.40)		1.76 (0.39, 7.90)	-	1.76 (0.39, 7.90)	2.71 (0.49, 14.84)	2.71 (0.49, 14.84)
Holladay2_PreSurgRef	1.20 (0.22, 8.15)	1.16 (0.12, 13.02)	0.95 (0.15, 7.30)	1.12 (0.20, 7.69)	0.91 (0.16, 6.23)	0.77 (0.12, 6.00)	1.90 (0.25, 16.72)		-	1.00 (0.19, 5.27)	1.54 (0.24, 9.73)	1.54 (0.24, 9.73)
Holladay2-LT	2.00 (0.26, 22.38)	1.94 (0.16, 32.60)	1.58 (0.17, 21.34)	1.87 (0.25, 21.28)	1.52 (0.20, 17.15)	1.29 (0.16, 14.88)	3.20 (0.24, 55.29)	1.70 (0.10, 30.39)		-	-	-

Meta-analysis and network meta-analysis results

---

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standal one	T2
LadasSuperFormula	1.18 (0.21, 7.80)	1.14 (0.12, 12.03)	0.94 (0.14, 6.75)	1.11 (0.20, 7.26)	0.90 (0.16, 5.99)	0.76 (0.11, 5.82)	1.87 (0.24, 16.44)	0.99 (0.10, 9.58)	0.59 (0.03, 8.93)		1.54 (0.24, 9.73)	1.54 (0.24, 9.73)
Olsen_standalone	2.00 (0.31, 20.29)	1.96 (0.17, 27.07)	1.58 (0.21, 16.97)	1.86 (0.28, 18.71)	1.51 (0.24, 15.13)	1.29 (0.17, 14.30)	3.21 (0.35, 38.30)	1.66 (0.15, 22.15)	1.01 (0.05, 19.87)	1.69 (0.16, 21.88)		1.00 (0.13, 7.46)
T2	1.57 (0.53, 4.94)	1.50 (0.24, 9.77)	1.23 (0.34, 4.73)	1.46 (0.48, 4.64)	1.19 (0.40, 3.73)	1.01 (0.28, 3.68)	2.46 (0.43, 14.60)	1.31 (0.17, 8.54)	0.79 (0.06, 7.53)	1.32 (0.17, 8.98)	0.78 (0.07, 6.03)	



128 **Figure 11:** AL <22.0mm: Within 1.0D - random effects model – relative effect of all options versus common comparator


129

130

**Table 19:** AL <22.0mm: Within 1.0D - random effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.001	8 (4, 12)
AvgHofferQSRKT	0.058	8 (1, 12)
BarrettUniversallI	0.032	6 (1, 12)
Haigis	0.002	8 (3, 11)
HofferQ	0.006	6 (2, 10)
Holladay2	0.056	5 (1, 11)
Holladay2_NoPreSurgRef	0.012	11 (2, 12)
Holladay2_PreSurgRef	0.095	7 (1, 12)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2-LT	0.298	3 (1, 12)
LadasSuperFormula	0.093	7 (1, 12)
Olsen_standalone	0.273	3 (1, 12)
T2	0.075	5 (1, 11)



132

**Figure 12: AL <22.0mm: Within 1.0D - random effects model – rank probability histograms**

133

134

**Table 20: AL <22.0mm: Within 1.0D - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
50.87 (compared to 52 datapoints)	236.411	195.954	40.458	276.869	0.653 (95%CI: 0.367, 1.035)

135


136

**Table 21: AL <22.0mm: Within 1.0D - random effects model – notes**

- Dichotomous synchronic (binomial; logit link); random effects
  - Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
  - 50000 burn-ins; 10000 recorded iterations

137

138

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**

139

**Figure 13:** AL <22.0mm: Within 2.0D - fixed effects model – evidence network

140

141

**Table 22:** AL <22.0mm: Within 2.0D - fixed effects model – input data

	SRKT	BarrettUniversalII	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	155/156	156/156	156/156	156/156	156/156	155/156


	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
Ozcura et al. (2016)	31/32			31/32		
Carifi et al. (2015)	22/28		24/28	25/28	26/28	

142

143  
144**Table 23: AL <22.0mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUniversal all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
SRKT		3.02 (0.12, 74.69)	1.83 (0.51, 6.48)	2.05 (0.61, 6.86)	3.42 (0.76, 15.35)	1.00 (0.06, 16.13)
BarrettUniversalII	4.65 (0.25, 2033.00)		1.00 (0.02, 50.71)	1.00 (0.02, 50.71)	1.00 (0.02, 50.71)	0.33 (0.01, 8.19)
Haigis	1.77 (0.51, 7.04)	0.38 (0.00, 8.10)		1.33 (0.30, 5.81)	1.90 (0.38, 9.54)	0.33 (0.01, 8.19)
HofferQ	2.14 (0.63, 8.20)	0.46 (0.00, 9.67)	1.21 (0.28, 5.31)		1.44 (0.27, 7.74)	0.33 (0.01, 8.19)
Holladay2	3.61 (0.85, 21.95)	0.77 (0.00, 20.64)	2.03 (0.40, 13.61)	1.67 (0.32, 11.15)		0.33 (0.01, 8.19)
T2	0.91 (0.10, 12.74)	0.20 (0.00, 6.00)	0.51 (0.05, 7.38)	0.42 (0.04, 6.24)	0.25 (0.02, 4.14)	

145



146 **Figure 14:** AL <22.0mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator


147

148

**Table 24:** AL <22.0mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.003	5 (3, 6)
BarrettUniversalII	0.492	2 (1, 6)
Haigis	0.052	4 (1, 6)
HofferQ	0.089	3 (1, 6)
Holladay2	0.309	2 (1, 5)
T2	0.055	5 (1, 6)

149



150 **Figure 15:** AL <22.0mm: Within 2.0D - fixed effects model – rank probability histograms  
151

152 **Table 25:** AL <22.0mm: Within 2.0D - fixed effects model – model fit statistics  
153

Residual deviance	Dbar	Dhat	pD	DIC	
9.174 (compared to 12 datapoints)	35.541	28.066	7.474	43.015	

154

155

**Table 26: AL <22.0mm: Within 2.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

156

157 H.3.2.3 Full dataset: Axial length subgroup – 22.00 to 24.50mm

158 MEAN ABSOLUTE ERROR – fixed effects model



159

**Figure 16: AL 22.0-24.5mm: Mean absolute error - fixed effects model – evidence network**

160

161

**Table 27: AL 22.0-24.5mm: Mean absolute error - fixed effects model – input data**

	<b>SRKT</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>
Ozcura et al. (2016)	0.51 (0.42)		0.55 (0.44)		
Srivannaboon et al. (2013)		0.40 (0.33)	0.39 (0.33)	0.41 (0.31)	0.42 (0.30)

162

163


164

165

**Table 28: AL 22.0-24.5mm: Mean absolute error - fixed effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	<b>SRKT</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>
SRKT		-	0.04 (-0.02, 0.10)	-	-
Haigis	0.05 (-0.05, 0.15)		-0.01 (-0.09, 0.07)	0.01 (-0.07, 0.09)	0.02 (-0.06, 0.10)
HofferQ	0.04 (-0.02, 0.10)	-0.01 (-0.09, 0.07)		0.02 (-0.06, 0.10)	0.03 (-0.05, 0.11)
Holladay2	0.06 (-0.04, 0.16)	0.01 (-0.07, 0.09)	0.02 (-0.06, 0.10)		0.01 (-0.07, 0.09)
Holladay2-LT	0.07 (-0.03, 0.17)	0.02 (-0.06, 0.10)	0.03 (-0.05, 0.11)	0.01 (-0.07, 0.09)	

166



167 **Figure 17: AL 22.0-24.5mm: Mean absolute error - fixed effects model – relative effect of all options versus common comparator**


168

169

**Table 29: AL 22.0-24.5mm: Mean absolute error - fixed effects model – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT	0.739	1 (1, 4)
Haigis	0.123	3 (1, 5)
HofferQ	0.037	3 (1, 5)
Holladay2	0.068	4 (1, 5)
Holladay2-LT	0.032	4 (1, 5)

170



171 **Figure 18:** AL 22.0-24.5mm: Mean absolute error - fixed effects model – rank probability histograms

172

173

**Table 30:** AL 22.0-24.5mm: Mean absolute error - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	
6.015 (compared to 6 datapoints)	-26.891	-32.905	6.014	-20.877	

174

175

176


**Table 31: AL 22.0-24.5mm: Mean absolute error - fixed effects model – notes**

- Continuous (normal; identity link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

177

178

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**



179

**Figure 19: AL 22.0-24.5mm: Within 0.25D - fixed effects model – evidence network**

180

181

**Table 32: AL 22.0-24.5mm: Within 0.25D - fixed effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	1018/2638	1126/2638	1029/2638	1029/2638	1000/2638		1029/2638
Srivannaboon et al. (2013)			52/124	50/124	45/124	46/124	
Aristodemou et al. (2011)	599/1508			609/1508			
Aristodemou et al. (2011)	1985/4699			1900/4699			

182

183

184


185

**Table 33: AL 22.0-24.5mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		1.19 (1.06, 1.32)	1.02 (0.91, 1.14)	0.97 (0.91, 1.03)	0.97 (0.87, 1.09)	-	1.02 (0.91, 1.14)
BarrettUniversalll	1.16 (1.05, 1.28)		0.86 (0.77, 0.96)	0.86 (0.77, 0.96)	0.82 (0.73, 0.92)	-	0.86 (0.77, 0.96)
Haigis	1.00 (0.90, 1.10)	0.86 (0.77, 0.96)		1.00 (0.89, 1.11)	0.95 (0.85, 1.05)	0.82 (0.49, 1.36)	1.00 (0.90, 1.12)
HofferQ	0.97 (0.91, 1.03)	0.84 (0.76, 0.93)	0.97 (0.88, 1.08)		0.95 (0.85, 1.06)	0.87 (0.52, 1.46)	1.00 (0.90, 1.12)
Holladay2	0.94 (0.85, 1.04)	0.82 (0.73, 0.91)	0.95 (0.85, 1.06)	0.97 (0.88, 1.07)		1.04 (0.62, 1.74)	1.05 (0.94, 1.17)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2-LT	0.87 (0.57, 1.33)	0.76 (0.49, 1.15)	0.88 (0.57, 1.33)	0.90 (0.59, 1.36)	0.93 (0.60, 1.41)	-	-
T2	0.99 (0.90, 1.10)	0.86 (0.77, 0.96)	1.00 (0.89, 1.11)	1.02 (0.93, 1.13)	1.05 (0.94, 1.18)	1.14 (0.75, 1.76)	-

186



187

**Figure 20:** AL 22.0-24.5mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator

188

189

**Table 34:** AL 22.0-24.5mm: Within 0.25D - fixed effects model – rankings for each comparator


	Probability best	Median rank (95%CI)
SRKT	0.001	3 (2, 6)
BarrettUniversalll	0.895	1 (1, 2)
Haigis	0.003	4 (2, 7)
HofferQ	0.000	5 (2, 7)

Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.000	6 (3, 7)
Holladay2-LT	0.098	7 (1, 7)
T2	0.003	4 (2, 7)

190



**Figure 21:** AL 22.0-24.5mm: Within 0.25D - fixed effects model – rank probability histograms

192

193

**Table 35: AL 22.0-24.5mm: Within 0.25D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
12.98 (compared to 14 datapoints)	116.779	106.805	9.974	126.752	

194

195


**Table 36: AL 22.0-24.5mm: Within 0.25D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

196

197

**PROPORTION WITHIN 0.5 DIOPTRES – fixed effects model**



198

**Figure 22: AL 22.0-24.5mm: Within 0.5D - fixed effects model – evidence network**

199

200

**Table 37: AL 22.0-24.5mm: Within 0.5D - fixed effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	1868/2638	1881/2638	1820/2638	1796/2638	1796/2638		1833/2638
Ozcura et al. (2016)	245/422			221/422			
Srivannaboon et al. (2013)			82/124	84/124	87/124	89/124	
Aristodemou et al. (2011)	1062/1508			1033/1508			
Aristodemou et al. (2011)	3353/4699			3266/4699			

201

202


203

**Table 38: AL 22.0-24.5mm: Within 0.5D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		1.02 (0.91, 1.15)	0.92 (0.82, 1.03)	0.90 (0.84, 0.96)	0.88 (0.78, 0.99)	-	0.94 (0.83, 1.06)
BarrettUniversalll	1.04 (0.93, 1.15)		0.90 (0.80, 1.01)	0.86 (0.76, 0.97)	0.86 (0.76, 0.97)	-	0.92 (0.81, 1.03)
Haigis	0.92 (0.83, 1.03)	0.89 (0.79, 1.00)		0.96 (0.86, 1.08)	0.97 (0.86, 1.09)	1.30 (0.76, 2.23)	1.02 (0.91, 1.15)
HofferQ	0.90 (0.84, 0.96)	0.87 (0.78, 0.96)	0.97 (0.88, 1.08)		1.01 (0.90, 1.13)	1.21 (0.70, 2.08)	1.07 (0.95, 1.20)
Holladay2	0.89 (0.81, 0.99)	0.86 (0.77, 0.97)	0.97 (0.86, 1.09)	1.00 (0.90, 1.11)		1.08 (0.62, 1.87)	1.07 (0.95, 1.20)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2-LT	1.09 (0.70, 1.73)	1.05 (0.67, 1.68)	1.18 (0.75, 1.87)	1.21 (0.78, 1.92)	1.22 (0.78, 1.93)	-	-
T2	0.95 (0.85, 1.06)	0.92 (0.81, 1.03)	1.03 (0.92, 1.16)	1.06 (0.95, 1.17)	1.06 (0.95, 1.19)	0.87 (0.55, 1.37)	-

204



205

Figure 23: AL 22.0-24.5mm: Within 0.5D - fixed effects model – relative effect of all options versus common comparator

206

207

Table 39: AL 22.0-24.5mm: Within 0.5D - fixed effects model – rankings for each comparator


	Probability best	Median rank (95%CI)
SRKT	0.094	3 (1, 5)
BarrettUniversall	0.318	2 (1, 4)
Haigis	0.004	5 (2, 7)
HofferQ	0.000	6 (4, 7)

Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.000	6 (3, 7)
Holladay2-LT	0.569	1 (1, 7)
T2	0.016	4 (2, 7)

208



**Figure 24:** AL 22.0-24.5mm: Within 0.5D - fixed effects model – rank probability histograms

210

211

**Table 40: AL 22.0-24.5mm: Within 0.5D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
12.8 (compared to 16 datapoints)	127.886	116.882	11.004	138.89	

212

213


**Table 41: AL 22.0-24.5mm: Within 0.5D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

214

215

**PROPORTION WITHIN 1.0 DIOPTRE – fixed effects model**



216

**Figure 25:** AL 22.0-24.5mm: Within 1.0D - fixed effects model – evidence network

217

218

**Table 42: AL 22.0-24.5mm: Within 1.0D - fixed effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	2477/2638	2485/2638	2453/2638	2451/2638	2480/2638		2467/2638
Ozcura et al. (2016)	374/422			374/422			
Srivannaboon et al. (2013)			114/124	118/124	118/124	118/124	
Aristodemou et al. (2011)	1398/1508			1400/1508			
Aristodemou et al. (2011)	4430/4699			4432/4699			

219

220

221


222

**Table 43: AL 22.0-24.5mm: Within 1.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		1.06 (0.84, 1.33)	0.86 (0.69, 1.07)	0.96 (0.86, 1.08)	1.02 (0.81, 1.28)	-	0.94 (0.75, 1.17)
BarrettUniversalll	1.12 (0.91, 1.38)		0.82 (0.65, 1.02)	0.81 (0.65, 1.01)	0.97 (0.77, 1.22)	-	0.89 (0.71, 1.11)
Haigis	0.90 (0.75, 1.10)	0.81 (0.65, 1.00)		1.01 (0.82, 1.24)	1.20 (0.97, 1.49)	1.73 (0.61, 4.90)	1.09 (0.88, 1.35)
HofferQ	0.96 (0.86, 1.08)	0.86 (0.70, 1.05)	1.07 (0.88, 1.29)		1.19 (0.96, 1.48)	1.00 (0.31, 3.19)	1.10 (0.89, 1.36)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2	1.09 (0.89, 1.33)	0.97 (0.77, 1.22)	1.21 (0.97, 1.49)	1.13 (0.92, 1.38)		1.00 (0.31, 3.19)	0.92 (0.74, 1.15)
Holladay2-LT	1.25 (0.51, 3.57)	1.12 (0.45, 3.25)	1.39 (0.57, 3.99)	1.30 (0.54, 3.70)	1.15 (0.47, 3.29)		-
T2	1.00 (0.82, 1.22)	0.89 (0.71, 1.11)	1.10 (0.89, 1.37)	1.03 (0.85, 1.27)	0.92 (0.73, 1.14)	0.79 (0.28, 1.97)	

223



224

Figure 26: AL 22.0-24.5mm: Within 1.0D - fixed effects model – relative effect of all options versus common comparator


225

226

Table 44: AL 22.0-24.5mm: Within 1.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.017	4 (2, 7)
BarrettUnivers all	0.245	2 (1, 6)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Haigis	0.001	6 (3, 7)
HofferQ	0.003	5 (2, 7)
Holladay2	0.141	3 (1, 6)
Holladay2-LT	0.562	1 (1, 7)
T2	0.029	4 (1, 7)



**Figure 27:** AL 22.0-24.5mm: Within 1.0D - fixed effects model – rank probability histograms

229

230

**Table 45: AL 22.0-24.5mm: Within 1.0D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
13.68 (compared to 16 datapoints)	108.82	97.841	10.979	119.799	

231


232

**Table 46: AL 22.0-24.5mm: Within 1.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

233

234

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**

235

**Figure 28:** AL 22.0-24.5mm: Within 2.0D - fixed effects model – evidence network

236

237

**Table 47:** AL 22.0-24.5mm: Within 2.0D - fixed effects model – input data

	SRKT	BarrettUniversalII	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	2633/2638	2635/2638	2627/2638	2627/2638	2630/2638	2630/2638

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
Ozcura et al. (2016)	420/422			415/422		


238

239

240  
241**Table 48: AL 22.0-24.5mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
SRKT		1.67 (0.40, 6.99)	0.45 (0.16, 1.31)	0.39 (0.16, 0.93)	0.62 (0.20, 1.91)	0.62 (0.20, 1.91)
BarrettUniversalll	1.57 (0.41, 7.93)		0.27 (0.08, 0.98)	0.27 (0.08, 0.98)	0.37 (0.10, 1.41)	0.37 (0.10, 1.41)
Haigis	0.39 (0.14, 1.05)	0.25 (0.05, 0.83)		1.00 (0.43, 2.31)	1.38 (0.55, 3.43)	1.38 (0.55, 3.43)
HofferQ	0.37 (0.14, 0.87)	0.24 (0.05, 0.77)	0.95 (0.41, 2.14)		1.38 (0.55, 3.43)	1.38 (0.55, 3.43)
Holladay2	0.54 (0.18, 1.59)	0.35 (0.07, 1.23)	1.39 (0.56, 3.66)	1.46 (0.61, 3.71)		1.00 (0.37, 2.67)
T2	0.55 (0.18, 1.59)	0.35 (0.07, 1.25)	1.39 (0.56, 3.70)	1.46 (0.61, 3.75)	1.00 (0.36, 2.75)	

242



243

**Figure 29:** AL 22.0-24.5mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator


244

245

**Table 49:** AL 22.0-24.5mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.242	2 (1, 4)
BarrettUniversalII	0.714	1 (1, 3)
Haigis	0.002	5 (3, 6)
HofferQ	0.001	5 (3, 6)
Holladay2	0.020	4 (2, 6)
T2	0.022	4 (2, 6)

246



247 **Figure 30:** AL 22.0-24.5mm: Within 2.0D - fixed effects model – rank probability histograms

248

249

**Table 50:** AL 22.0-24.5mm: Within 2.0D - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	
7.367 (compared to 8 datapoints)	36.6	29.761	6.839	43.439	

250

251

252

**Table 51: AL 22.0-24.5mm: Within 2.0D - fixed effects model – notes**


- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

253

254 H.3.2.4 Full dataset: Axial length subgroup – 24.50 to 26.00mm

255

**MEAN ABSOLUTE ERROR – fixed effects model**



256

**Figure 31: AL 24.5-26.0mm: Mean absolute error - fixed effects model – evidence network**

257

258

**Table 52: AL 24.5-26.0mm: Mean absolute error - fixed effects model – input data**

	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>
Srivannaboon et al. (2013)	0.39 (0.32)	0.45 (0.35)	0.38 (0.34)	0.39 (0.33)


259

260

261  
262**Table 53: AL 24.5-26.0mm: Mean absolute error - fixed effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>
Haigis		0.06 (-0.13, 0.25)	-0.01 (-0.20, 0.18)	0.00 (-0.18, 0.18)
HofferQ	0.06 (-0.13, 0.25)		-0.07 (-0.27, 0.13)	-0.06 (-0.25, 0.13)
Holladay2	-0.01 (-0.20, 0.18)	-0.07 (-0.27, 0.13)		0.01 (-0.18, 0.20)
Holladay2-LT	0.00 (-0.18, 0.18)	-0.06 (-0.25, 0.13)	0.01 (-0.18, 0.20)	

263



264 **Figure 32:** AL 24.5-26.0mm: Mean absolute error - fixed effects model – relative effect of all options versus common comparator


265

266

**Table 54:** AL 24.5-26.0mm: Mean absolute error - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
Haigis	0.280	2 (1, 4)
HofferQ	0.085	4 (1, 4)
Holladay2	0.349	2 (1, 4)
Holladay2-LT	0.286	2 (1, 4)

267



268      **Figure 33:** AL 24.5-26.0mm: Mean absolute error - fixed effects model – rank probability histograms

269

270

**Table 55:** AL 24.5-26.0mm: Mean absolute error - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	
3.991 (compared to 4 datapoints)	-10.123	-14.114	3.991	-6.133	

271

272

273


**Table 56: AL 24.5-26.0mm: Mean absolute error - fixed effects model – notes**

- Continuous (normal; identity link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

274

275

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**



276

**Figure 34: AL 24.5-26.0mm: Within 0.25D - fixed effects model – evidence network**

277

278

**Table 57: AL 24.5-26.0mm: Within 0.25D - fixed effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	144/372	172/372	143/372	130/372	154/372		147/372
Srivannaboon et al. (2013)			12/24	10/24	14/24	12/24	
Aristodemou et al. (2011)	105/234			104/234			
Aristodemou et al. (2011)	272/712			275/712			

279

280

281


282

**Table 58: AL 24.5-26.0mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		1.36 (1.02, 1.82)	0.99 (0.74, 1.33)	0.96 (0.82, 1.13)	1.12 (0.83, 1.50)	-	1.03 (0.77, 1.39)
BarrettUniversalll	1.45 (1.12, 1.89)		0.73 (0.54, 0.97)	0.62 (0.47, 0.84)	0.82 (0.61, 1.10)	-	0.76 (0.57, 1.02)
Haigis	1.06 (0.81, 1.38)	0.73 (0.54, 0.97)		0.85 (0.64, 1.13)	1.15 (0.86, 1.52)	1.00 (0.32, 3.10)	1.05 (0.78, 1.40)
HofferQ	0.96 (0.82, 1.12)	0.66 (0.51, 0.86)	0.91 (0.70, 1.18)		1.35 (1.01, 1.80)	1.40 (0.45, 4.38)	1.22 (0.90, 1.64)
Holladay2	1.21 (0.93, 1.57)	0.83 (0.63, 1.11)	1.15 (0.86, 1.52)	1.27 (0.98, 1.64)		0.71 (0.23, 2.23)	0.92 (0.69, 1.24)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2-LT	1.07 (0.41, 2.76)	0.74 (0.28, 1.94)	1.01 (0.39, 2.61)	1.12 (0.43, 2.89)	0.88 (0.34, 2.30)	-	-
T2	1.10 (0.85, 1.44)	0.76 (0.57, 1.01)	1.05 (0.78, 1.40)	1.15 (0.88, 1.51)	0.91 (0.68, 1.22)	1.04 (0.39, 2.73)	-

283



284

Figure 35: AL 24.5-26.0mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator

285

286

Table 59: AL 24.5-26.0mm: Within 0.25D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.001	5 (3, 7)
BarrettUniversalll	0.658	1 (1, 3)
Haigis	0.005	4 (2, 7)
HofferQ	0.000	6 (3, 7)

Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.065	3 (1, 6)
Holladay2-LT	0.256	4 (1, 7)
T2	0.015	4 (2, 7)

287




Figure 36: AL 24.5-26.0mm: Within 0.25D - fixed effects model – rank probability histograms

289

290

**Table 60: AL 24.5-26.0mm: Within 0.25D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
11.55 (compared to 14 datapoints)	89.771	79.757	10.014	99.785	

291

292

293


**Table 61: AL 24.5-26.0mm: Within 0.25D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

294

295

**PROPORTION WITHIN 0.5 DIOPTRES – fixed effects model**



296

**Figure 37: AL 24.5-26.0mm: Within 0.5D - fixed effects model – evidence network**

297

298

**Table 62: AL 24.5-26.0mm: Within 0.5D - fixed effects model – input data**

	<b>SRKT</b>	<b>AvgHofferQSRK T</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	248/372		285/372	255/372	256/372	250/372		265/372
Srivannaboon et al. (2013)				19/24	14/24	17/24	14/24	
Aristodemou et al. (2011)	170/234				173/234			
Aristodemou et al. (2011)	481/712				473/712			
Percival et al. (2002)	20/26	21/26			20/26			

299

300

301


302

**Table 63: AL 24.5-26.0mm: Within 0.5D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>AvgHofferQSR KT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		1.26 (0.33, 4.79)	1.64 (1.19, 2.26)	1.09 (0.80, 1.48)	1.01 (0.86, 1.19)	1.02 (0.75, 1.39)	-	1.24 (0.91, 1.69)
AvgHofferQSRKT	1.30 (0.41, 4.73)		-	-	0.79 (0.21, 3.02)	-	-	-
BarrettUniversalll	1.59 (1.19, 2.15)	1.21 (0.33, 4.02)		0.67 (0.48, 0.92)	0.67 (0.49, 0.93)	0.63 (0.45, 0.86)	-	0.76 (0.54, 1.05)
Haigis	1.08 (0.82, 1.43)	0.83 (0.22, 2.75)	0.68 (0.49, 0.94)		0.95 (0.71, 1.29)	0.92 (0.68, 1.24)	0.37 (0.10, 1.32)	1.14 (0.83, 1.55)

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
HofferQ	1.00 (0.85, 1.17)	0.77 (0.21, 2.45)	0.63 (0.47, 0.84)	0.92 (0.70, 1.22)		0.97 (0.72, 1.30)	1.00 (0.32, 3.15)	1.12 (0.82, 1.54)
Holladay2	1.00 (0.76, 1.31)	0.76 (0.21, 2.53)	0.63 (0.46, 0.86)	0.92 (0.68, 1.24)	1.00 (0.76, 1.31)		0.58 (0.17, 1.91)	1.21 (0.88, 1.65)
Holladay2-LT	0.63 (0.24, 1.72)	0.48 (0.10, 2.21)	0.40 (0.15, 1.10)	0.58 (0.22, 1.58)	0.63 (0.24, 1.70)	0.63 (0.24, 1.71)		-
T2	1.20 (0.91, 1.60)	0.92 (0.25, 3.07)	0.76 (0.54, 1.05)	1.11 (0.81, 1.52)	1.20 (0.90, 1.60)	1.20 (0.88, 1.63)	1.90 (0.69, 5.16)	

303



304

Figure 38: AL 24.5-26.0mm: Within 0.5D - fixed effects model – relative effect of all options versus common comparator


305

306

**Table 64: AL 24.5-26.0mm: Within 0.5D - fixed effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.000	6 (3, 8)
AvgHofferQSRKT	0.373	2 (1, 8)
BarrettUniversalll	0.574	1 (1, 3)
Haigis	0.003	4 (2, 7)
HofferQ	0.000	6 (3, 8)
Holladay2	0.001	6 (2, 8)
Holladay2-LT	0.025	8 (2, 8)
T2	0.025	3 (2, 7)

307



**Figure 39:** AL 24.5-26.0mm: Within 0.5D - fixed effects model – rank probability histograms

309

310

**Table 65: AL 24.5-26.0mm: Within 0.5D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
15 (compared to 17 datapoints)	101.303	89.288	12.015	113.319	

311

312

313


**Table 66: AL 24.5-26.0mm: Within 0.5D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

314

315

**PROPORTION WITHIN 1.0 DIOPTRE – fixed effects model**



316

**Figure 40: AL 24.5-26.0mm: Within 1.0D - fixed effects model – evidence network**

317

318

**Table 67: AL 24.5-26.0mm: Within 1.0D - fixed effects model – input data**

	<b>SRKT</b>	<b>AvgHofferQSRK<sub>T</sub></b>	<b>BarrettUniversal<sub>II</sub></b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
Kane,J. et al. (2016)	351/372		364/372	349/372	350/372	348/372		353/372
Srivannaboon et al. (2013)				24/24	22/24	20/24	20/24	
Aristodemou et al. (2011)	215/234				224/234			
Aristodemou et al. (2011)	673/712				672/712			
Percival et al. (2002)	26/26	26/26			26/26			
Mitra et al. (2014)	17/43				19/43			
El-Nafees et al. (2010)	44/53			44/53				

319

320

321


322

**Table 68: AL 24.5-26.0mm: Within 1.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>AvgHofferQSR<sub>KT</sub></b>	<b>BarrettUniversall</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2-LT</b>	<b>T2</b>
SRKT		1.00 (0.02, 52.29)	2.72 (1.19, 6.23)	0.93 (0.55, 1.57)	1.12 (0.82, 1.52)	0.87 (0.47, 1.59)	-	1.11 (0.59, 2.10)
AvgHofferQSRKT	1.58 (0.03, 769.90)		-	-	1.00 (0.02, 52.29)	-	-	-
BarrettUniversall	3.03 (1.46, 7.12)	1.96 (0.00, 130.80)		0.33 (0.15, 0.76)	0.35 (0.15, 0.80)	0.32 (0.14, 0.72)	-	0.41 (0.18, 0.94)

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Haigis	1.07 (0.67, 1.73)	0.67 (0.00, 42.56)	0.35 (0.15, 0.75)		0.95 (0.53, 1.71)	0.81 (0.46, 1.42)	0.09 (0.00, 1.83)	1.22 (0.66, 2.29)
HofferQ	1.11 (0.82, 1.51)	0.71 (0.00, 43.61)	0.37 (0.16, 0.76)	1.04 (0.64, 1.71)		0.85 (0.48, 1.49)	0.45 (0.07, 2.76)	1.17 (0.62, 2.20)
Holladay2	0.88 (0.53, 1.46)	0.55 (0.00, 34.21)	0.29 (0.12, 0.61)	0.82 (0.48, 1.42)	0.79 (0.48, 1.32)		1.00 (0.22, 4.56)	1.28 (0.69, 2.38)
Holladay2-LT	0.51 (0.14, 2.12)	0.32 (0.00, 24.96)	0.17 (0.04, 0.77)	0.48 (0.13, 1.94)	0.46 (0.13, 1.87)	0.59 (0.16, 2.35)		-
T2	1.21 (0.70, 2.18)	0.77 (0.00, 48.51)	0.40 (0.16, 0.90)	1.14 (0.63, 2.14)	1.09 (0.63, 1.99)	1.39 (0.76, 2.60)	2.37 (0.55, 9.43)	

323



324

**Figure 41:** AL 24.5-26.0mm: Within 1.0D - fixed effects model – relative effect of all options versus common comparator

325

326

**Table 69: AL 24.5-26.0mm: Within 1.0D - fixed effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.000	5 (3, 8)
AvgHofferQSRKT	0.386	2 (1, 8)
BarrettUniversalll	0.598	1 (1, 2)
Haigis	0.001	5 (2, 7)
HofferQ	0.001	4 (2, 7)
Holladay2	0.000	6 (3, 8)
Holladay2-LT	0.007	8 (2, 8)
T2	0.007	3 (2, 7)

327




Figure 42: AL 24.5-26.0mm: Within 1.0D - fixed effects model – rank probability histograms

329

330

**Table 70: AL 24.5-26.0mm: Within 1.0D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
20.9 (compared to 21 datapoints)	99.813	86.224	13.589	113.402	

331

332

333


**Table 71: AL 24.5-26.0mm: Within 1.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

334

335

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**



336

**Figure 43: AL 24.5-26.0mm: Within 2.0D - fixed effects model – evidence network**

337

338

**Table 72: AL 24.5-26.0mm: Within 2.0D - fixed effects model – input data**

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	371/372	372/372	370/372	370/372	371/372	371/372

339

340


341

342

**Table 73: AL 24.5-26.0mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	T2
SRKT		3.01 (0.12, 74.08)	0.50 (0.05, 5.52)	0.50 (0.05, 5.52)	1.00 (0.06, 16.05)	1.00 (0.06, 16.05)
BarrettUniversalll	5.33 (0.18, 2510.00)		0.20 (0.01, 4.16)	0.20 (0.01, 4.16)	0.33 (0.01, 8.19)	0.33 (0.01, 8.19)
Haigis	0.56 (0.04, 4.75)	0.11 (0.00, 2.01)		1.00 (0.14, 7.14)	2.01 (0.18, 22.21)	2.01 (0.18, 22.21)
HofferQ	0.56 (0.04, 4.76)	0.11 (0.00, 1.99)	1.01 (0.14, 7.20)		2.01 (0.18, 22.21)	2.01 (0.18, 22.21)
Holladay2	1.04 (0.07, 15.34)	0.19 (0.00, 5.79)	1.83 (0.22, 24.22)	1.83 (0.22, 25.09)		1.00 (0.06, 16.05)
T2	1.03 (0.07, 15.35)	0.20 (0.00, 5.62)	1.83 (0.21, 24.40)	1.82 (0.21, 24.37)	1.00 (0.07, 14.99)	

343



344 **Figure 44:** AL 24.5-26.0mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator


345

346

**Table 74:** AL 24.5-26.0mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.097	3 (1, 6)
BarrettUniversalII	0.651	1 (1, 5)
Haigis	0.021	5 (2, 6)
HofferQ	0.021	5 (2, 6)
Holladay2	0.104	3 (1, 6)
T2	0.106	3 (1, 6)

347



348 **Figure 45:** AL 24.5-26.0mm: Within 2.0D - fixed effects model – rank probability histograms

349

350

**Table 75:** AL 24.5-26.0mm: Within 2.0D - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	
6.666 (compared to 6 datapoints)	20.791	15.387	5.404	26.195	

351

352

353

**Table 76: AL 24.5-26.0mm: Within 2.0D - fixed effects model – notes**

- |  |
|--|
| <ul style="list-style-type: none"><li>• Dichotomous synchronic (binomial; logit link); fixed effects</li><li>• 50000 burn-ins; 10000 recorded iterations</li></ul> |
|--|


354

355

356

357 H.3.2.5 Full dataset: Axial length subgroup – Greater than 26.00mm

358 MEAN ABSOLUTE ERROR – fixed effects model



359 Figure 46: AL >26.0mm: Mean absolute error - fixed effects model – evidence network

360

361

**Table 77: AL >26.0mm: Mean absolute error - fixed effects model – input data**

	<b>SRKT</b>	<b>BarrettUniversalII</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2_NoPreSurgRef</b>	<b>Holladay2_PresSurgRef</b>	<b>LadasSuperFormula</b>	<b>Olsen_standalone</b>	<b>T2</b>
Cooke & (2016)	0.40 (0.45)	0.30 (0.38)	0.28 (0.37)	0.43 (0.45)		0.39 (0.41)	0.41 (0.43)	0.35 (0.40)	0.29 (0.35)	0.32 (0.40)
Bang et al. (2011)	0.62 (0.77)		0.52 (0.63)	1.02 (0.88)	0.81 (0.81)					

362

363

364


365

**Table 78: AL >26.0mm: Mean absolute error - fixed effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUniversalII</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>Holladay2_NoPreSurgRef</b>	<b>Holladay2_PresSurgRef</b>	<b>LadasSuperFormula</b>	<b>Olsen_standalone</b>	<b>T2</b>
SRKT		-0.10 (-0.25, 0.06)	-0.11 (-0.25, 0.02)	0.11 (-0.04, 0.26)	0.19 (-0.11, 0.49)	-0.01 (-0.17, 0.15)	0.01 (-0.16, 0.17)	-0.05 (-0.21, 0.11)	-0.11 (-0.26, 0.04)	-0.08 (-0.24, 0.08)
BarrettUniversalII	-0.07 (-0.22, 0.08)		-0.02 (-0.16, 0.12)	0.13 (-0.03, 0.28)	-	0.09 (-0.06, 0.24)	0.10 (-0.05, 0.26)	0.05 (-0.10, 0.19)	-0.01 (-0.15, 0.12)	0.02 (-0.13, 0.16)
Haigis	-0.11 (-0.25, 0.02)	-0.04 (-0.18, 0.09)		0.23 (0.09, 0.36)	0.29 (0.01, 0.57)	0.11 (-0.04, 0.26)	0.13 (-0.02, 0.28)	0.07 (-0.08, 0.21)	0.01 (-0.13, 0.15)	0.04 (-0.11, 0.18)
HofferQ	0.11 (-0.04, 0.26)	0.18 (0.03, 0.33)	0.22 (0.09, 0.36)		-0.21 (-0.53, 0.11)	-0.04 (-0.20, 0.12)	-0.02 (-0.19, 0.14)	-0.08 (-0.24, 0.08)	-0.14 (-0.29, 0.01)	-0.11 (-0.27, 0.05)
Holladay2	0.12 (-0.15, 0.38)	0.19 (-0.09, 0.46)	0.23 (-0.02, 0.48)	0.01 (-0.26, 0.27)		-	-	-	-	-
Holladay2_NoPreSurgRef	0.02 (-0.14, 0.17)	0.09 (-0.06, 0.24)	0.13 (-0.01, 0.27)	-0.09 (-0.25, 0.06)	-0.10 (-0.38, 0.18)		0.02 (-0.14, 0.17)	-0.04 (-0.19, 0.11)	-0.10 (-0.24, 0.04)	-0.07 (-0.22, 0.08)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	LadasSuperFo rmula	Olsen_standal one	T2
Holladay2_PreSurgRef	0.03 (-0.13, 0.19)	0.10 (-0.05, 0.26)	0.15 (0.00, 0.29)	-0.08 (-0.24, 0.08)	-0.08 (-0.36, 0.20)	0.02 (-0.14, 0.17)		-0.06 (-0.22, 0.10)	-0.12 (-0.26, 0.03)	-0.09 (-0.24, 0.07)
LadasSuperFormula	-0.02 (-0.18, 0.13)	0.05 (-0.10, 0.19)	0.09 (-0.05, 0.23)	-0.14 (-0.29, 0.02)	-0.14 (-0.42, 0.14)	-0.04 (-0.19, 0.11)	-0.06 (-0.21, 0.10)		-0.06 (-0.20, 0.08)	-0.03 (-0.18, 0.12)
Olsen_standalone	-0.08 (-0.23, 0.06)	-0.01 (-0.15, 0.13)	0.03 (-0.10, 0.16)	-0.19 (-0.34, -0.05)	-0.20 (-0.47, 0.07)	-0.10 (-0.24, 0.04)	-0.12 (-0.26, 0.03)	-0.06 (-0.20, 0.09)		0.03 (-0.11, 0.17)
T2	-0.05 (-0.21, 0.10)	0.02 (-0.13, 0.16)	0.06 (-0.08, 0.20)	-0.17 (-0.32, -0.01)	-0.17 (-0.45, 0.11)	-0.07 (-0.22, 0.08)	-0.09 (-0.25, 0.07)	-0.03 (-0.18, 0.12)	0.03 (-0.11, 0.17)	

366



367

368

**Figure 47: AL >26.0mm: Mean absolute error - fixed effects model – relative effect of all options versus common comparator**


369

370

**Table 79: AL >26.0mm: Mean absolute error - fixed effects model – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT	0.012	6 (2, 9)
BarrettUniversalll	0.153	3 (1, 8)
Haigis	0.450	2 (1, 5)
HofferQ	0.000	9 (6, 10)
Holladay2	0.025	9 (1, 10)
Holladay2_NoPreSurgRef	0.008	7 (2, 10)
Holladay2_PreSurgRef	0.004	7 (3, 10)
LadasSuperFormula	0.038	5 (1, 9)
Olsen_standalone	0.204	3 (1, 7)
T2	0.105	4 (1, 8)

371



372

**Figure 48: AL >26.0mm: Mean absolute error - fixed effects model – rank probability histograms**

373

374

**Table 80: AL >26.0mm: Mean absolute error - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
16.31 (compared to 13 datapoints)	-30.087	-41.112	11.025	-19.062	

375

376


377

**Table 81: AL >26.0mm: Mean absolute error - fixed effects model – notes**

- Continuous (normal; identity link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

378

379

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**

380

**Figure 49:** AL >26.0mm: Within 0.25D - fixed effects model – evidence network

381

382

**Table 82: AL >26.0mm: Within 0.25D - fixed effects model – input data**

	SRKT	BarrettUniversalII	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	30/77	26/77	28/77	26/77	25/77	24/77

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
Aristodemou et al. (2011)	21/47			18/47		
Aristodemou et al. (2011)	111/271			96/271		
Aristodemou et al. (2011)	5/17			2/17		


383

384

385  
386**Table 83: AL >26.0mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUniversal all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
SRKT		0.80 (0.41, 1.54)	0.90 (0.47, 1.72)	0.77 (0.58, 1.02)	0.75 (0.39, 1.46)	0.71 (0.36, 1.38)
BarrettUniversalII	0.78 (0.43, 1.41)		1.12 (0.58, 2.17)	1.00 (0.51, 1.95)	0.94 (0.48, 1.85)	0.89 (0.45, 1.74)
Haigis	0.88 (0.48, 1.57)	1.12 (0.58, 2.21)		0.89 (0.46, 1.73)	0.84 (0.43, 1.64)	0.79 (0.41, 1.55)
HofferQ	0.77 (0.58, 1.02)	0.98 (0.55, 1.80)	0.88 (0.49, 1.61)		0.94 (0.48, 1.85)	0.89 (0.45, 1.74)
Holladay2	0.74 (0.40, 1.32)	0.94 (0.48, 1.84)	0.84 (0.43, 1.63)	0.96 (0.52, 1.71)		0.94 (0.48, 1.86)
T2	0.69 (0.38, 1.25)	0.88 (0.45, 1.74)	0.79 (0.40, 1.55)	0.90 (0.49, 1.63)	0.94 (0.48, 1.85)	

387



388

**Figure 50:** AL >26.0mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator


389

390

**Table 84:** AL >26.0mm: Within 0.25D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.490	2 (1, 4)
BarrettUniversalll	0.119	4 (1, 6)
Haigis	0.247	3 (1, 6)
HofferQ	0.011	4 (2, 6)
Holladay2	0.079	4 (1, 6)
T2	0.053	5 (1, 6)

391



392      **Figure 51: AL >26.0mm: Within 0.25D - fixed effects model – rank probability histograms**

393

394

**Table 85: AL >26.0mm: Within 0.25D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
10.05 (compared to 12 datapoints)	64.405	55.388	9.017	73.422	

395

396

397


**Table 86: AL >26.0mm: Within 0.25D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

398

399

**PROPORTION WITHIN 0.5 DIOPTRES – fixed effects model**



400

**Figure 52: AL >26.0mm: Within 0.5D - fixed effects model – evidence network**

401

402

**Table 87: AL >26.0mm: Within 0.5D - fixed effects model – input data**

	SRKT	AvgHofferQSRKT	BarrettUniversalII	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PresSurgRef	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	41/54		41/54	44/54	34/54		37/54	37/54	41/54	45/54	44/54
Kane,J. et al. (2016)	48/77		48/77	44/77	41/77	44/77					49/77
Bang et al. (2011)	27/53			30/53	18/53	22/53					
Aristodemou et al. (2011)	37/47				33/47						
Aristodemou et al. (2011)	197/271				167/271						
Aristodemou et al. (2011)	10/17				3/17						
Percival et al. (2002)	16/20	15/20			12/20						

403

404

405


406

**Table 88: AL >26.0mm: Within 0.5D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversalII	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PresSurgRef	LadasSuperFormula	Olsen_standalone	T2
SRKT		0.75 (0.17, 3.33)	1.00 (0.59, 1.69)	1.05 (0.68, 1.62)	0.57 (0.44, 0.73)	0.75 (0.46, 1.23)	0.69 (0.30, 1.61)	0.69 (0.30, 1.61)	1.00 (0.41, 2.42)	1.59 (0.61, 4.10)	1.16 (0.68, 1.98)
AvgHofferQSRKT	0.98 (0.29, 3.72)		-	-	0.50 (0.13, 1.93)	-	-	-	-	-	-

Meta-analysis and network meta-analysis results

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	LadasSuperFo rmula	Olsen_standal one	T2
BarrettUniversalll	0.97 (0.61, 1.54)	0.98 (0.25, 3.65)		0.96 (0.57, 1.63)	0.63 (0.38, 1.04)	0.81 (0.42, 1.54)	0.69 (0.30, 1.61)	0.69 (0.30, 1.61)	1.00 (0.41, 2.42)	1.59 (0.61, 4.10)	1.16 (0.68, 1.98)
Haigis	1.03 (0.69, 1.53)	1.05 (0.26, 3.74)	1.07 (0.64, 1.74)		0.56 (0.36, 0.86)	0.78 (0.48, 1.27)	0.49 (0.20, 1.21)	0.49 (0.20, 1.21)	0.72 (0.28, 1.81)	1.14 (0.42, 3.06)	1.21 (0.70, 2.07)
HofferQ	0.56 (0.43, 0.72)	0.57 (0.15, 1.95)	0.58 (0.37, 0.91)	0.54 (0.37, 0.80)		1.25 (0.76, 2.05)	1.28 (0.58, 2.84)	1.28 (0.58, 2.84)	1.86 (0.81, 4.27)	2.94 (1.19, 7.26)	1.85 (1.10, 3.10)
Holladay2	0.75 (0.49, 1.17)	0.76 (0.19, 2.79)	0.77 (0.45, 1.32)	0.73 (0.45, 1.17)	1.34 (0.87, 2.08)		-	-	-	-	1.31 (0.69, 2.51)
Holladay2_NoPreSurgRef	0.63 (0.33, 1.27)	0.65 (0.15, 2.62)	0.65 (0.32, 1.37)	0.61 (0.30, 1.27)	1.13 (0.58, 2.26)	0.84 (0.40, 1.82)		1.00 (0.44, 2.25)	1.45 (0.62, 3.38)	2.30 (0.92, 5.75)	2.02 (0.83, 4.95)
Holladay2_PreSurgRef	0.63 (0.33, 1.28)	0.64 (0.15, 2.63)	0.65 (0.32, 1.38)	0.61 (0.31, 1.27)	1.13 (0.58, 2.26)	0.84 (0.40, 1.82)	1.00 (0.44, 2.29)		1.45 (0.62, 3.38)	2.30 (0.92, 5.75)	2.02 (0.83, 4.95)
LadasSuperFormula	0.93 (0.46, 1.97)	0.95 (0.21, 3.93)	0.96 (0.45, 2.12)	0.90 (0.44, 1.95)	1.65 (0.82, 3.48)	1.23 (0.57, 2.80)	1.46 (0.62, 3.52)	1.46 (0.63, 3.50)		1.59 (0.61, 4.10)	1.40 (0.55, 3.53)
Olsen_standalone	1.50 (0.69, 3.52)	1.53 (0.32, 6.72)	1.54 (0.68, 3.79)	1.45 (0.65, 3.49)	2.66 (1.23, 6.27)	1.99 (0.86, 4.99)	2.37 (0.94, 6.21)	2.36 (0.95, 6.21)	1.62 (0.62, 4.35)		0.88 (0.33, 2.37)
T2	1.13 (0.71, 1.81)	1.14 (0.28, 4.25)	1.16 (0.68, 1.99)	1.09 (0.66, 1.81)	2.01 (1.26, 3.22)	1.50 (0.87, 2.58)	1.78 (0.85, 3.66)	1.78 (0.84, 3.65)	1.22 (0.55, 2.58)	0.75 (0.31, 1.72)	



408 **Figure 53:** AL >26.0mm: Within 0.5D - fixed effects model – relative effect of all options versus common comparator

409

410

**Table 89: AL >26.0mm: Within 0.5D - fixed effects model – rankings for each comparator**


	Probability best	Median rank (95%CI)
SRKT	0.017	5 (2, 8)
AvgHofferQSRKT	0.231	5 (1, 11)
BarrettUniversallI	0.029	5 (1, 9)
Haigis	0.035	4 (1, 8)
HofferQ	0.000	10 (8, 11)
Holladay2	0.002	8 (3, 11)
Holladay2_NoPreSurgRef	0.005	9 (3, 11)
Holladay2_PreSurgRef	0.004	9 (3, 11)
LadasSuperFormula	0.069	6 (1, 11)

Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Olsen_standalone	0.508	1 (1, 8)
T2	0.100	3 (1, 8)

411



412

**Figure 54: AL >26.0mm: Within 0.5D - fixed effects model – rank probability histograms**

413

414

**Table 90: AL >26.0mm: Within 0.5D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
24.45 (compared to 28 datapoints)	143.413	126.316	17.097	160.51	

415

416

417


**Table 91: AL >26.0mm: Within 0.5D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
  - 50000 burn-ins; 10000 recorded iterations

418

419

**PROPORTION WITHIN 1.0 DIOPTRE – random effects model**



420

**Figure 55: AL >26.0mm: Within 1.0D - random effects model – evidence network**

421

422

**Table 92: AL >26.0mm: Within 1.0D - random effects model – input data**

	SRKT	AvgHofferQSRK <sub>T</sub>	BarrettUniversal <sub>II</sub>	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PresSurgRef	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	53/54		53/54	53/54	52/54		53/54	53/54	52/54	53/54	53/54
Kane,J. et al. (2016)	71/77		71/77	68/77	64/77	68/77					67/77
Bang et al. (2011)	35/53			39/53	32/53	33/53					
Aristodemou et al. (2011)	44/47				43/47						
Aristodemou et al. (2011)	253/271				239/271						
Aristodemou et al. (2011)	14/17				12/17						
Petermeier et al. (2009)	50/50			32/50	50/50						
Percival et al. (2002)	19/20	17/20			17/20						
Mitra et al. (2014)	17/43				19/43						
El-Nafees et al. (2010)	44/53			44/53							

423


424

425  
426**Table 93: AL >26.0mm: Within 1.0D - random effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRK <sub>T</sub>	BarrettUniversal <sub>II</sub>	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PresSurgRef	LadasSuperFormula	Olsen_standalone	T2
SRKT		0.30 (0.03, 3.15)	1.00 (0.34, 2.96)	0.71 (0.28, 1.78)	0.65 (0.45, 0.92)	0.77 (0.40, 1.46)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	0.61 (0.22, 1.65)

	SRKT	AvgHofferQSRKT	BarrettUniversalll	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	LadasSuperFormula	Olsen_standalone	T2
AvgHofferQSRKT	0.46 (0.04, 5.92)		-	-	1.00 (0.18, 5.67)	-	-	-	-	-	-
BarrettUniversalll	1.05 (0.19, 6.08)	2.28 (0.12, 47.00)		0.68 (0.25, 1.86)	0.43 (0.17, 1.10)	0.64 (0.22, 1.89)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	0.61 (0.22, 1.65)
Haigis	0.48 (0.16, 1.36)	1.04 (0.07, 15.16)	0.46 (0.07, 2.53)		1.07 (0.30, 3.81)	0.74 (0.39, 1.38)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	0.90 (0.36, 2.23)
HofferQ	0.65 (0.27, 1.49)	1.40 (0.11, 17.29)	0.62 (0.11, 3.36)	1.35 (0.46, 4.25)		1.25 (0.69, 2.27)	2.04 (0.18, 23.17)	2.04 (0.18, 23.17)	1.00 (0.14, 7.37)	2.04 (0.18, 23.17)	1.43 (0.62, 3.30)
Holladay2	0.63 (0.15, 2.59)	1.35 (0.08, 23.34)	0.59 (0.08, 4.24)	1.31 (0.30, 6.02)	0.97 (0.23, 4.04)		-	-	-	-	0.89 (0.34, 2.32)
Holladay2_NoPreSurgRef	1.07 (0.07, 41.13)	2.48 (0.06, 174.90)	1.03 (0.05, 46.32)	2.24 (0.14, 88.12)	1.64 (0.11, 63.46)	1.75 (0.09, 77.21)		1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)
Holladay2_PreSurgRef	1.08 (0.07, 46.67)	2.46 (0.06, 215.20)	1.03 (0.05, 49.49)	2.22 (0.14, 104.20)	1.66 (0.11, 72.32)	1.73 (0.09, 89.57)	1.01 (0.01, 77.45)		0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)
LadasSuperFormula	0.42 (0.03, 5.61)	0.91 (0.03, 32.60)	0.40 (0.03, 6.94)	0.87 (0.07, 12.61)	0.64 (0.06, 9.08)	0.68 (0.04, 11.28)	0.38 (0.01, 10.65)	0.38 (0.01, 11.08)		2.04 (0.18, 23.17)	2.04 (0.18, 23.17)
Olsen_standalone	1.10 (0.07, 45.60)	2.43 (0.06, 207.10)	1.05 (0.05, 49.59)	2.28 (0.14, 97.44)	1.71 (0.10, 69.48)	1.79 (0.09, 83.45)	1.01 (0.02, 70.36)	0.98 (0.01, 70.90)	2.64 (0.09, 158.90)		1.00 (0.06, 16.41)
T2	0.68 (0.13, 3.61)	1.48 (0.08, 30.72)	0.64 (0.09, 4.94)	1.41 (0.28, 8.25)	1.05 (0.21, 5.74)	1.10 (0.17, 7.52)	0.63 (0.01, 12.17)	0.63 (0.01, 12.54)	1.62 (0.10, 23.86)	0.62 (0.01, 12.23)	

427

428  
Figure 56: AL >26.0mm: Within 1.0D - random effects model – relative effect of all options versus common comparator


429

430

Table 94: AL &gt;26.0mm: Within 1.0D - random effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.045	4 (1, 8)
AvgHofferQSRKT	0.066	8 (1, 11)
BarrettUniversallI	0.102	4 (1, 10)
Haigis	0.002	8 (3, 11)
HofferQ	0.004	7 (3, 10)
Holladay2	0.022	7 (2, 11)
Holladay2_NoPreSurgRef	0.227	4 (1, 11)
Holladay2_PreSurgRef	0.229	4 (1, 11)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
LadasSuperFormula	0.042	9 (1, 11)
Olsen_standalone	0.226	4 (1, 11)
T2	0.035	6 (1, 11)



432

**Figure 57: AL >26.0mm: Within 1.0D - random effects model – rank probability histograms**

433

434

**Table 95: AL >26.0mm: Within 1.0D - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
35.1 (compared to 35 datapoints)	147.479	118.139	29.34	176.819	0.974 (95%CI: 0.506, 1.724)

435

436


437

**Table 96: AL >26.0mm: Within 1.0D - random effects model – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations

438

439

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**

440

**Figure 58:** AL >26.0mm: Within 2.0D - fixed effects model – evidence network

441

442

**Table 97:** AL >26.0mm: Within 2.0D - fixed effects model – input data

	SRKT	BarrettUniversal =	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	75/77	77/77	76/77	76/77	75/77	77/77

	<b>SRKT</b>	<b>BarrettUniversal II</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
Bang et al. (2011)	51/53		52/53	42/53	50/53	


443

444

445  
446**Table 98: AL >26.0mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT</b>	<b>BarrettUnivers all</b>	<b>Haigis</b>	<b>HofferQ</b>	<b>Holladay2</b>	<b>T2</b>
<b>SRKT</b>		5.13 (0.24, 108.68)	2.03 (0.37, 11.30)	0.31 (0.10, 0.97)	0.79 (0.21, 3.03)	5.13 (0.24, 108.68)
<b>BarrettUniversalll</b>	5.53 (0.33, 2725.00)		0.33 (0.01, 8.20)	0.33 (0.01, 8.20)	0.19 (0.01, 4.13)	1.00 (0.02, 51.04)
<b>Haigis</b>	1.93 (0.39, 12.36)	0.36 (0.00, 7.38)		0.15 (0.03, 0.68)	0.39 (0.07, 2.05)	3.04 (0.12, 75.77)
<b>HofferQ</b>	0.31 (0.09, 0.90)	0.06 (0.00, 0.76)	0.16 (0.03, 0.58)		2.61 (0.89, 7.67)	3.04 (0.12, 75.77)
<b>Holladay2</b>	0.79 (0.20, 3.02)	0.14 (0.00, 2.21)	0.41 (0.07, 1.85)	2.55 (0.92, 8.15)		5.13 (0.24, 108.68)
<b>T2</b>	5.32 (0.34, 2364.00)	0.98 (0.00, 635.90)	2.75 (0.13, 1348.00)	17.49 (1.34, 7933.00)	6.84 (0.44, 3162.00)	

447



448 **Figure 59:** AL >26.0mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator


449

450

**Table 99:** AL >26.0mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.014	4 (2, 5)
BarrettUniversalII	0.445	2 (1, 5)
Haigis	0.096	3 (1, 5)
HofferQ	0.000	6 (5, 6)
Holladay2	0.005	5 (2, 6)
T2	0.440	2 (1, 5)

451



452      **Figure 60:** AL >26.0mm: Within 2.0D - fixed effects model – rank probability histograms

453

454

**Table 100:** AL >26.0mm: Within 2.0D - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	
13.49 (compared to 10 datapoints)	38.132	31.797	6.335	44.466	

455

456

457

**Table 101: AL >26.0mm: Within 2.0D - fixed effects model – notes**

- |  |
|--|
| <ul style="list-style-type: none"><li>• Dichotomous synchronic (binomial; logit link); fixed effects</li><li>• 50000 burn-ins; 10000 recorded iterations</li></ul> |
|--|

458

## 459 H.3.3 Intraocular lens formulas: Network meta-analyses results: Eyes with a history of myopic LASIK/LASEK/PRK

## 460 H.3.3.1 Model fit statistics for all outcomes

461 Table 102: Model fit statistics used to select fixed or random effect models for all comparisons and outcomes

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
<b>FULL DATASET: HISTORICAL AND NO HISTORICAL DATA METHODS</b>								
2 (Fam, Savini)	Mean absolute error	FE	9.833		38.54	27	-	RE
		RE	0.2		27.1		0.81 (0.24, 1.89)	
5 (Fam, Huang, Kim, Savini, Xu)	Prediction error	FE	62.1	46.7	79.7	31	-	RE
		RE	15.3		31		1.42 (0.72, 1.97)	
5 (Fam, Huang, Kim, Saiki, Xu)	Within 0.5D	FE	144.0	0.7	29.8	26	-	RE
		RE	143.3		27.4		0.96 (0.07, 1.93)	
5 (Fam, Huang, Kim, Saiki, Xu)	Within 1.0D	FE	151.7	5.8	34.7	26	-	RE
		RE	145.9		27.0		1.21 (0.29, 1.95)	
1 ( <i>Kim – pairwise comparison</i> )	Within 1.5D	FE	-	-	-	-	-	FE
1 (Fam)	Within 2.0D	FE	29.4	-	6.4	6	-	FE
1 ( <i>Kim – pairwise comparison</i> )		FE	-	-	-	-	-	FE
<b>NO HISTORICAL DATA METHODS ONLY</b>								
4 (Huang, Kim, Saiki, Xu)	Within 0.5D	FE	78.7	1.1	17.5	14	-	RE
		RE	77.6		14.9		0.94 (0.07, 1.93)	
4 (Huang, Kim, Saiki, Xu)	Within 1.0D	FE	86.0	6.1	22.4	14	-	RE
		RE	79.9		14.5		1.20 (0.30, 1.95)	
<b>HISTORICAL DATA METHODS ONLY</b>								
2 (Fam, Savini)	Mean absolute error	FE	9.8	9.7	32.5	21	-	RE
		RE	0.13		21.0		0.82 (0.24, 1.89)	
2 (Fam, Saiki) – NB: network connector (SRKT DK) uses historical data in Fam but no historical data in Saiki	Within 0.5D	FE	60.0	-	11.4	11	-	FE


Meta-analysis and network meta-analysis results

---

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
2 (Fam, Saiki) – NB: network connector (SRKT DK) uses historical data in Fam but no historical data in Saiki	Within 1.0D	FE	60.5	-	11.3	11	-	FE
1 (Fam)	Within 2.0D	FE	29.4	-	6.4	6	-	FE

462 H.3.3.2 Full dataset: historical and no historical methods

463 MEAN ABSOLUTE ERROR – random effects model



464

Figure 61: Myopic corneal refractive surgery: Mean absolute error – evidence network

465

466

**Table 103: Myopic corneal refractive surgery: Mean absolute error – input data**

	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shamma	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Savini et al. (2010)	1.62 (1.25)	1.41 (0.76)			0.93 (0.48)		1.33 (1.03)	1.00 (0.57)	1.79 (1.13)	0.62 (0.52)	0.56 (0.45)	0.53 (0.46)	1.60 (0.98)	1.87 (1.44)	2.04 (1.48)	2.18 (1.52)	1.08 (0.86)	0.76 (0.49)	3.64 (1.45)	1.94 (1.01)
Fam & (2008)			0.75 (0.52)	0.75 (0.62)		1.32 (0.73)		0.76 (0.60)						0.93 (0.83)		0.80 (0.63)				

467

468

469

**Table 104: Myopic corneal refractive surgery: Mean absolute error – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**


	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shamma	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Clinical history	-0.21 (-0.75, 0.33)	-	-	-0.69 (-1.19, -0.19)	-	-0.29 (-0.89, 0.31)	-0.62 (-1.13, -0.11)	0.17 (-0.45, 0.79)	-1.00 (-1.50, -0.50)	-1.06 (-1.55, -0.57)	-1.09 (-1.58, -0.60)	-0.02 (-0.61, 0.57)	0.25 (-0.46, 0.96)	0.42 (-0.30, 1.14)	0.56 (-0.17, 1.29)	-0.54 (-1.10, 0.02)	-0.86 (-1.36, -0.36)	2.02 (1.31, 2.73)	0.32 (-0.28, 0.92)	
Camellin-Calossi	-0.20 (-5.27, 4.82)		-	-	-0.48 (-0.81, -0.15)	-	-0.08 (-0.55, 0.39)	-0.41 (-0.76, -0.06)	0.38 (-0.12, 0.88)	-0.79 (-1.13, -0.45)	-0.85 (-1.18, -0.52)	-0.88 (-1.21, -0.55)	0.19 (-0.27, 0.65)	0.46 (-0.14, 1.06)	0.63 (0.01, 1.25)	0.77 (0.14, 1.40)	-0.33 (-0.76, 0.10)	-0.65 (-0.98, -0.32)	2.23 (1.62, 2.84)	0.53 (0.06, 1.00)
HofferQ DK	-0.06 (-5.75, 6.04)	0.14 (-5.72, 6.24)		0.00 (-0.26, 0.26)	-	0.57 (0.28, 0.86)	-	0.01 (-0.25, 0.27)	-	-	-	-	0.18 (-0.14, 0.50)	-	0.05 (-0.21, 0.31)	-	-	-	-	
Holladay2 DK	-0.07 (-5.66, 5.96)	0.13 (-5.52, 6.08)	0.00 (-5.08, 5.04)		-	0.57 (0.26, 0.88)	-	0.01 (-0.27, 0.29)	-	-	-	-	0.18 (-0.15, 0.51)	-	0.05 (-0.23, 0.33)	-	-	-	-	

Meta-analysis and network meta-analysis results

	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Shammas-PL	-0.69 (-5.55, 4.63)	-0.48 (-5.36, 4.81)	-0.62 (-6.50, 5.44)	-0.62 (-6.57, 5.45)		-	0.40 (-0.02, 0.82)	0.07 (-0.21, 0.35)	0.86 (0.41, 1.31)	-0.31 (-0.57, 0.05)	-0.37 (-0.61, 0.13)	-0.40 (-0.65, 0.15)	0.67 (0.27, 1.07)	0.94 (0.38, 1.50)	1.11 (0.53, 1.69)	1.25 (0.66, 1.84)	0.15 (-0.21, 0.51)	-0.17 (-0.42, 0.08)	2.71 (2.14, 3.28)	1.01 (0.60, 1.42)
SRKT Clinical history	0.49 (-5.24, 6.52)	0.69 (-5.09, 6.67)	0.56 (-4.64, 5.56)	0.57 (-4.59, 5.72)	1.18 (-4.75, 7.02)		-	-0.56 (-0.86, 0.26)	--	-	-	-	-0.39 (-0.75, 0.03)	-	-0.52 (-0.83, 0.21)	-	-	-	-	
SRKT Diehl	-0.28 (-5.11, 4.98)	-0.08 (-5.10, 5.04)	-0.22 (-6.08, 5.43)	-0.21 (-6.11, 5.52)	0.41 (-4.81, 5.39)	-0.79 (-6.63, 4.93)		-0.33 (-0.77, 0.11)	0.46 (-0.11, 1.03)	-0.71 (-1.14, 0.28)	-0.77 (-1.19, 0.35)	-0.80 (-1.22, 0.38)	0.27 (-0.26, 0.80)	0.54 (-0.12, 1.20)	0.71 (0.04, 1.38)	0.85 (0.17, 1.53)	-0.25 (-0.75, 0.25)	-0.57 (-0.99, 0.15)	2.31 (1.65, 2.97)	0.61 (0.08, 1.14)
SRKT DK	-0.34 (-4.78, 4.35)	-0.13 (-4.75, 4.46)	-0.27 (-4.96, 4.26)	-0.26 (-4.94, 4.28)	0.35 (-4.45, 4.87)	-0.84 (-5.45, 3.67)	-0.06 (-4.72, 4.51)		0.79 (0.32, 1.26)	-0.38 (-0.67, 0.09)	-0.44 (-0.71, 0.17)	-0.47 (-0.74, 0.20)	0.60 (0.18, 1.02)	0.48 (-0.20, 1.16)	1.04 (0.45, 1.63)	0.58 (-0.54, 1.69)	0.08 (-0.30, 0.46)	-0.24 (-0.52, 0.04)	2.64 (2.06, 3.22)	0.94 (0.51, 1.37)
SRKT DK Awwad	0.16 (-4.64, 5.51)	0.37 (-4.53, 5.70)	0.23 (-5.66, 6.36)	0.23 (-5.65, 6.23)	0.85 (-4.26, 6.06)	-0.34 (-6.03, 5.68)	0.45 (-4.63, 5.37)	0.50 (-4.03, 5.37)		-1.17 (-1.63, 0.71)	-1.23 (-1.68, 0.78)	-1.26 (-1.71, 0.81)	-0.19 (-0.60, 0.76)	0.08 (-0.44, 0.94)	0.25 (-0.31, 1.09)	0.39 (-1.24, 0.57)	-0.71 (-1.49, 0.18)	-1.03 (-1.49, 0.57)	1.85 (1.17, 2.53)	0.15 (-0.41, 0.71)
SRKT DK Savini	-1.01 (-5.76, 4.24)	-0.79 (-5.77, 4.31)	-0.93 (-6.95, 4.98)	-0.93 (-6.75, 4.98)	-0.31 (-5.57, 4.78)	-1.51 (-7.46, 4.35)	-0.72 (-5.93, 4.37)	-0.66 (-5.29, 4.06)	-1.17 (-6.33, 3.91)		-0.06 (-0.31, 0.19)	-0.09 (-0.35, 0.17)	0.98 (0.57, 1.39)	1.25 (0.68, 1.82)	1.42 (0.84, 2.00)	1.56 (0.96, 2.16)	0.46 (0.09, 0.83)	0.14 (-0.12, 0.40)	3.02 (2.45, 3.59)	1.32 (0.90, 1.74)
SRKT DK Seitz/Speicher	-1.07 (-6.07, 4.11)	-0.86 (-5.94, 4.32)	-0.99 (-6.94, 4.78)	-0.99 (-6.95, 4.83)	-0.37 (-5.54, 4.71)	-1.56 (-7.36, 4.29)	-0.78 (-5.86, 4.31)	-0.72 (-5.41, 3.94)	-1.22 (-6.50, 3.77)	-0.06 (-5.23, 5.07)		-0.03 (-0.27, 0.21)	1.04 (0.64, 1.44)	1.31 (0.75, 1.87)	1.48 (0.91, 2.05)	1.62 (1.03, 2.21)	0.52 (0.16, 0.88)	0.20 (-0.05, 0.45)	3.08 (2.52, 3.64)	1.38 (0.97, 1.79)
SRKT DK Seitz/Speicher/Savini	-1.09 (-5.98, 4.07)	-0.88 (-5.81, 4.25)	-1.01 (-6.86, 4.76)	-1.02 (-6.86, 4.77)	-0.40 (-5.64, 4.62)	-1.58 (-7.32, 4.29)	-0.81 (-5.89, 4.32)	-0.74 (-5.33, 3.95)	-1.25 (-6.41, 3.64)	-0.08 (-5.09, 5.02)	-0.02 (-4.99, 5.09)		1.07 (0.67, 1.47)	1.34 (0.78, 1.90)	1.51 (0.94, 2.08)	1.65 (1.06, 2.24)	0.55 (0.19, 0.91)	0.23 (-0.02, 0.48)	3.11 (2.55, 3.67)	1.41 (1.00, 1.82)
SRKT DK Shammas	-0.02 (-4.87, 5.06)	0.18 (-4.81, 5.29)	0.05 (-5.84, 5.89)	0.05 (-5.80, 5.73)	0.66 (-4.41, 5.53)	-0.52 (-6.31, 5.21)	0.26 (-4.80, 5.28)	0.32 (-4.19, 4.86)	-0.18 (-5.41, 4.62)	0.97 (-4.14, 5.94)	1.05 (-4.10, 6.06)	1.07 (-4.03, 6.04)		0.27 (-0.38, 1.10)	0.44 (-0.22, 1.25)	0.58 (-0.09, 1.25)	-0.52 (-1.00, 0.04)	-0.84 (-1.25, 0.43)	2.04 (1.39, 2.69)	0.34 (-0.18, 0.86)
SRKT Feiz-Mannis	0.15 (-4.37, 5.01)	0.37 (-4.18, 5.07)	0.23 (-4.41, 4.92)	0.25 (-4.42, 4.84)	0.86 (-3.89, 5.49)	-0.33 (-4.88, 4.30)	0.46 (-4.12, 5.00)	0.50 (-3.03, 4.17)	0.00 (-4.84, 4.52)	1.16 (-3.53, 5.86)	1.23 (-3.40, 5.81)	1.26 (-3.32, 5.86)	0.19 (-4.39, 4.81)		0.17 (-0.59, 0.93)	-0.05 (-0.38, 0.27)	-0.79 (-1.41, 0.17)	-1.11 (-1.67, 0.55)	1.77 (1.01, 2.53)	0.07 (-0.58, 0.72)
SRKT Feiz-Mannis nomogram	0.42 (-4.33, 5.70)	0.63 (-4.36, 5.80)	0.49 (-5.33, 6.26)	0.49 (-5.33, 6.27)	1.11 (-4.03, 6.21)	-0.09 (-5.86, 5.73)	0.71 (-4.41, 5.78)	0.76 (-3.74, 5.37)	0.26 (-4.95, 5.27)	1.42 (-3.73, 6.61)	1.49 (-3.51, 6.52)	1.51 (-3.51, 6.53)	0.44 (-4.67, 5.70)	0.25 (-4.34, 4.97)		0.14 (-0.65, 0.93)	-0.96 (-1.59, 0.33)	-1.28 (-1.86, 0.70)	1.60 (0.83, 2.37)	-0.10 (-0.76, 0.56)
SRKT Ladas-Stark	0.22 (-4.17, 5.10)	0.42 (-4.00, 5.17)	0.28 (-4.35, 4.96)	0.28 (-4.22, 4.92)	0.91 (-3.77, 5.64)	-0.29 (-4.81, 4.42)	0.50 (-4.14, 5.12)	0.56 (-3.01, 4.22)	0.05 (-4.68, 4.62)	1.22 (-3.35, 6.03)	1.28 (-3.20, 5.94)	1.30 (-3.29, 5.90)	0.23 (-4.35, 4.91)	0.05 (-4.33, 3.61)	-0.20 (-4.80, 4.46)		-1.10 (-1.75, 0.45)	-1.42 (-2.01, 0.83)	1.46 (0.68, 2.24)	-0.24 (-0.92, 0.44)

Meta-analysis and network meta-analysis results

	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Dienl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
SRKT Latkany	-0.54 (-5.45, 4.70)	-0.33 (-5.39, 4.96)	-0.48 (-6.28, 5.38)	-0.47 (-6.36, 5.33)	0.15 (-5.04, 5.26)	-1.05 (-6.79, 4.90)	-0.26 (-5.31, 4.84)	-0.20 (-4.78, 4.50)	-0.71 (-5.95, 4.30)	0.46 (-4.64, 5.58)	0.52 (-4.45, 5.72)	0.55 (-4.36, 5.59)	-0.52 (-5.56, 4.62)	-0.70 (-5.33, 3.98)	-0.96 (-6.06, 4.03)	-0.76 (-5.48, 3.98)		-0.32 (-0.69, 0.05)	2.56 (1.94, 3.18)	0.86 (0.37, 1.35)
SRKT Masket	-0.85 (-5.63, 4.47)	-0.64 (-5.63, 4.64)	-0.79 (-6.55, 5.18)	-0.78 (-6.73, 5.25)	-0.17 (-5.32, 5.06)	-1.35 (-7.20, 4.68)	-0.57 (-5.48, 4.63)	-0.51 (-4.99, 4.31)	-1.01 (-6.22, 4.22)	0.15 (-4.70, 5.27)	0.21 (-4.79, 5.33)	0.25 (-4.75, 5.35)	-0.83 (-5.79, 4.36)	-1.02 (-5.63, 3.79)	-1.27 (-6.28, 3.94)	-1.06 (-5.65, 3.67)	-0.32 (-5.36, 4.90)		2.88 (2.31, 3.45)	1.18 (0.76, 1.60)
SRKT SK Ferrara	2.01 (-2.79, 7.30)	2.21 (-2.73, 7.42)	2.08 (-3.74, 7.90)	2.09 (-3.64, 7.93)	2.71 (-2.43, 7.68)	1.51 (-4.14, 7.46)	2.30 (-2.82, 7.50)	2.35 (-2.19, 7.18)	1.86 (-3.29, 6.81)	3.01 (-1.95, 8.27)	3.07 (-1.90, 8.20)	3.10 (-1.84, 8.09)	2.03 (-2.83, 7.19)	1.85 (-2.62, 6.53)	1.59 (-2.48, 6.71)	1.80 (-2.85, 6.53)	2.55 (-2.38, 7.80)	2.86 (-2.16, 7.84)		-1.70 (-2.35, -1.05)
SRKT SK Rosa	0.32 (-4.47, 5.49)	0.53 (-4.42, 5.75)	0.40 (-5.53, 6.31)	0.40 (-5.49, 6.19)	1.01 (-4.04, 6.02)	-0.17 (-5.93, 5.83)	0.61 (-4.44, 5.66)	0.67 (-3.90, 5.44)	0.16 (-5.09, 5.32)	1.32 (-3.66, 6.33)	1.39 (-3.69, 6.51)	1.41 (-3.58, 6.56)	0.34 (-4.64, 5.47)	0.16 (-4.43, 4.86)	-0.09 (-5.13, 5.03)	0.11 (-4.50, 4.68)	0.86 (-4.16, 5.96)	1.18 (-4.00, 6.21)	-1.69 (-6.78, 3.31)	



471

Figure 62: Myopic corneal refractive surgery: Mean absolute error – relative effect of all options versus common comparator

472


473

**Table 105: Myopic corneal refractive surgery: Mean absolute error – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Clinical history	0.019	12 (2, 19)
Camellin-Calossi	0.024	10 (2, 19)
HofferQ DK	0.035	11 (1, 20)
Holladay2 DK	0.035	11 (1, 20)
Shammas-PL	0.067	6 (1, 18)
SRKT Clinical history	0.017	16 (2, 20)
SRKT Diehl	0.030	9 (1, 19)
SRKT DK	0.011	9 (2, 17)
SRKT DK Awwad	0.014	13 (2, 20)
SRKT DK Savini	0.157	4 (1, 18)
SRKT DK Seitz/Speicher	0.186	4 (1, 17)
SRKT DK Seitz/Speicher/Savini	0.200	4 (1, 17)
SRKT DK Shammas	0.018	12 (2, 19)
SRKT Feiz-Mannis	0.004	13 (4, 19)
SRKT Feiz-Mannis nomogram	0.010	15 (3, 20)
SRKT Ladas-Stark	0.004	14 (4, 19)
SRKT Latkany	0.051	7 (1, 19)
SRKT Masket	0.106	5 (1, 18)
SRKT SK Ferrara	0.002	20 (7, 20)
SRKT SK Rosa	0.012	15 (2, 20)

474

## Meta-analysis and network meta-analysis results



475

**Figure 63: Myopic corneal refractive surgery: Mean absolute error – rank probability histograms**

476

477

**Table 106: Myopic corneal refractive surgery: Mean absolute error – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
23.18 (compared to 23 datapoints)	-23.582	-46.65	23.068	-0.513	1.053 (95%CI: 0.250, 7.282)

478

479


**Table 107: Myopic corneal refractive surgery: Mean absolute error – notes**

- Continuous (normal; identity link); random effects
  - Prior distribution for between-study heterogeneity: uniform (Min=0; Max=10)
  - 50000 burn-ins; 10000 recorded iterations

480

481

**PREDICTION ERROR – random effects model**



482

**Figure 64:** Myopic corneal refractive surgery: prediction error – evidence network

483

**Table 108: Myopic corneal refractive surgery: prediction error – input data**

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
Xu et al. (2014)					1.5 8 (1.20)	- 2.3 0 (1.25)													1.6 4 (0.93)					- 1.7 9 (1.11)	
Huang et al. (2013)			0.1 4 (0.83)					0.2 4 (0.82)																	
Kim et al. (2013)			0.0 3 (1.06)																1.6 8 (1.34)						
Savini et al. (2010)	1.0 8 (1.75)	1.3 7 (0.83)						0.5 0 (0.94)		0.8 3 (1.48)	- 0.8 8 (0.75)	1.7 3 (1.23)	0.2 1 (0.79)	0.0 5 (0.73)	0.0 9 (0.70)	1.6 0 (0.98)	1.3 7 (1.94)	2.0 0 (1.53)		1.8 3 (1.95)	0.8 0 (1.13)	- 0.2 7 (0.88)	3.6 4 (1.45)	1.9 0 (1.10)	
Fam & (2008)				0.1 9 (0.90)		- 0.0 4 (0.98)		1.1 5 (0.99)		- 0.1 9 (0.95)						- 0.5 1 (1.15)		- 0.0 1 (1.02)							

**Table 109: Myopic corneal refractive surgery: prediction error – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa	SRKT DK Shammas	SRKT DK Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT K	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
Clinical history	0.29 (-0.43, 1.01)	-	-	-	-	-	-	-0.58 (-1.32, 0.16)	-	-0.25 (-1.10, 0.60)	-1.96 (-2.67, -1.25)	0.65 (-0.14, 0.16)	-0.87 (-1.58, -0.33)	-1.03 (-1.73, -0.29)	-0.99 (-1.69, -1.26)	0.52 (-0.22, 1.26)	0.29 (-0.68, 1.78)	0.92 (0.06, -1.78)	-	0.75 (-0.22, 1.72)	-0.28 (-1.05, 0.49)	-1.35 (-2.08, 0.62)	2.56 (1.72, 3.40)	0.82 (0.05, 1.59)	-
Camellin-Calossi	0.30 (-2.67, 3.28)	-	-	-	-	-	-	-0.87 (-1.33, 0.41)	-	-0.54 (-1.17, 0.09)	-2.25 (-2.66, -1.84)	0.36 (-0.19, 0.91)	-1.16 (-1.58, -0.74)	-1.32 (-1.73, -0.91)	-1.28 (-1.68, -0.88)	0.23 (-0.25, 0.71)	0.00 (-0.78, 0.78)	0.63 (-0.01, 1.27)	-	0.46 (-0.32, 1.24)	-0.57 (-1.09, 0.05)	-1.64 (-2.09, 1.19)	2.27 (1.65, 2.89)	0.53 (0.02, 1.04)	-
Haigis-L	-0.66 (-4.85, 3.58)	-0.94 (-5.14, 3.22)	-	-	-	-	-	0.10 (-0.24, 0.44)	-	-	-	-	-	-	-	-	-	1.65 (1.16, 2.14)	-	-	-	-	-	-	
HofferQ DK	0.06 (-3.35, 3.57)	-0.24 (-3.64, 3.25)	0.71 (-3.80, 5.18)	-	-	-	-0.23 (-0.66, 0.20)	-	0.96 (0.53, 1.39)	-	-0.38 (-0.80, 0.04)	-	-	-	-	-	-0.70 (-1.17, -0.23)	-	-0.20 (-0.64, 0.24)	-	-	-	-	-	
HofferQ K	0.95 (-5.07, 6.96)	0.65 (-5.28, 6.55)	1.59 (-2.61, 5.80)	0.87 (-5.31, 7.03)	-	-3.88 (-4.44, -3.32)	-	-	-	-	-	-	-	-	-	-	-	0.06 (-0.43, 0.55)	-	-	-	-	-	-3.37 (-3.90, -2.84)	
HofferQ TNP	-2.93 (-8.90, 3.01)	-3.24 (-9.18, 2.68)	-2.29 (-6.49, 1.92)	-3.01 (-9.14, 3.14)	-3.88 (-6.82, -0.93)	-	-	-	-	-	-	-	-	-	-	-	-	3.94 (3.44, 4.44)	-	-	-	-	-	0.51 (-0.03, 1.05)	
Holladay2 DK	-0.16 (-3.60, 3.33)	-0.45 (-3.84, 3.05)	0.50 (-4.03, 5.02)	-0.21 (-3.15, 2.76)	-1.12 (-7.27, 5.15)	2.79 (-3.37, 8.96)	-	1.19 (0.74, 1.64)	-	-0.15 (-0.59, 0.29)	-	-	-	-	-	-	-0.47 (-0.96, 0.02)	-	0.03 (-0.43, 0.49)	-	-	-	-	-	
Shammas-PL	-0.56 (-3.54, 2.49)	-0.86 (-3.82, 2.11)	0.08 (-2.88, 3.02)	-0.63 (-4.01, 2.77)	-1.51 (-6.65, 3.68)	2.36 (-2.79, 7.54)	-0.41 (-3.83, 3.01)	-	0.33 (-0.32, 0.98)	-1.38 (-1.83, -0.93)	1.23 (-0.66, 1.80)	-0.29 (-0.74, 0.16)	-0.45 (-0.89, -0.01)	-0.41 (-0.84, 0.02)	1.10 (0.60, 1.60)	0.87 (0.07, 1.67)	1.50 (0.83, -2.17)	-	1.33 (0.53, 2.13)	0.30 (-0.24, 0.84)	-0.77 (3.14 (2.50, 3.78))	1.40 (0.86, -1.94)	-		

Meta-analysis and network meta-analysis results

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holiday2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT TK	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP	
SRKT Clinical history	1.03 (-2.38, 4.57)	0.74 (-2.63, 4.18)	1.68 (-2.86, 6.23)	0.97 (-1.94, 3.88)	0.10 (-6.02, 6.33)	3.96 (-2.18, 10.18)	1.19 (-1.77, 4.13)	1.60 (-1.81, 5.02)		-1.34 (-1.78, 0.90)					-1.66 (-2.15, 1.17)		-1.16 (-1.62, 0.70)				-0.29)				
SRKT Diehl	-0.24 (-3.26, 2.79)	-0.54 (-3.53, 2.45)	0.41 (-3.77, 4.64)	-0.32 (-3.78, 3.12)	-1.18 (-7.09, 4.82)	2.67 (-3.21, 8.67)	-0.10 (-3.56, 3.30)	0.33 (-2.69, 3.26)	-1.27 (-4.76, 2.10)		-1.71 (-2.32, 1.10)	0.90 (0.19, 1.61)	-0.62 (-1.24, 0.00)	-0.78 (-1.39, 0.17)	-0.74 (-1.35, 0.13)	0.77 (0.11, 1.43)	0.54 (-0.36, 1.44)	1.17 (0.38, 1.96)	1.00 (0.09, 1.91)	-0.03 (-0.72, 0.66)	-1.10 (-1.74, 0.46)	2.81 (2.04, 3.58)	1.07 (0.39, 1.75)		
SRKT DK	-1.13 (-3.84, 1.61)	-1.43 (-4.14, 1.31)	-0.47 (-4.53, 3.52)	-1.19 (-3.91, 1.49)	-2.06 (-7.87, 3.85)	1.80 (-4.00, 7.71)	-0.98 (-3.69, 1.67)	-0.56 (-3.28, 2.12)	-2.16 (-4.87, 0.52)	-0.89 (-3.61, 1.84)		2.61 (2.08, 3.14)	1.09 (0.69, 1.49)	0.93 (0.54, 1.32)	0.97 (0.59, 1.35)	2.48 (2.02, 2.94)	0.95 (-1.57, 3.46)	2.88 (2.25, 3.51)	1.42 (-1.05, 3.90)	1.68 (1.18, 2.18)	0.61 (0.18, 1.04)	4.52 (3.92, 5.12)	2.78 (2.29, 3.27)		
SRKT DK Awwad	0.66 (-2.35, 3.71)	0.36 (-2.63, 3.36)	1.30 (-2.90, 5.50)	0.59 (-2.87, 4.04)	-0.29 (-6.28, 5.70)	3.56 (-2.36, 9.53)	0.81 (-2.63, 4.22)	1.24 (-1.76, 4.18)	-0.39 (-3.85, 3.08)	0.90 (-2.12, 3.90)	1.79 (-0.93, 4.50)		-1.52 (-2.06, 0.98)	-1.68 (-2.21, 1.15)	-1.64 (-2.16, 1.12)	-0.13 (-0.71, 0.45)	-0.36 (-1.21, 0.49)	0.27 (-0.46, 1.00)	0.10 (-0.75, 0.95)	-0.93 (-1.55, 0.31)	-2.00 (-2.56, 1.44)	1.91 (1.21, 2.61)	0.17 (-0.44, 0.78)		
SRKT DK Savini	-0.85 (-3.87, 2.19)	-1.16 (-4.14, 1.79)	-0.21 (-4.46, 3.98)	-0.93 (-4.39, 2.47)	-1.81 (-7.78, 4.14)	2.06 (-3.86, 8.10)	-0.70 (-4.20, 2.68)	-0.29 (-3.28, 2.65)	-1.89 (-5.35, 1.49)	-0.62 (-3.63, 2.39)	0.26 (-2.46, 2.94)	-1.51 (-4.48, 1.49)		-0.16 (-0.56, 0.24)	-0.12 (-0.51, 0.27)	1.39 (0.92, 1.86)	1.16 (0.38, 1.94)	1.79 (1.15, 2.43)	1.62 (0.84, 2.40)	0.59 (0.08, 1.10)	-0.48 (-0.92, 0.04)	3.43 (2.82, 4.04)	1.69 (1.19, 2.19)		
SRKT DK Seitz/Speicher	-1.02 (-4.00, 1.97)	-1.32 (-4.31, 1.64)	-0.38 (-4.59, 3.81)	-1.08 (-4.56, 2.28)	-1.97 (-7.93, 4.00)	1.92 (-4.05, 7.89)	-0.87 (-4.36, 2.51)	-0.46 (-3.43, 2.47)	-2.05 (-5.51, 1.27)	-0.77 (-3.76, 2.20)	0.11 (-2.63, 2.76)	-1.68 (-3.08, 1.28)	-0.15 (-2.90, 2.80)		0.04 (-0.33, 0.41)	1.55 (1.10, 2.00)	1.32 (0.55, 2.09)	1.95 (1.32, 2.58)	1.78 (1.01, 2.55)	0.75 (0.25, 1.25)	-0.32 (-0.74, 0.10)	3.59 (2.99, 4.19)	1.85 (1.36, 2.34)		
SRKT DK Seitz/Speicher/Savini	-0.99 (-3.98, 2.02)	-1.28 (-4.26, 1.70)	-0.35 (-4.53, 3.84)	-1.04 (-4.57, 2.36)	-1.93 (-7.83, 4.04)	1.95 (-3.99, 7.96)	-0.83 (-4.28, 2.53)	-0.42 (-3.38, 2.54)	-2.01 (-5.47, 1.39)	-0.74 (-3.73, 2.24)	0.14 (-2.60, 2.84)	-1.64 (-4.67, 1.32)	-0.12 (-3.08, 2.85)	0.04 (-2.91, 3.02)	1.51 (1.06, 1.96)	1.28 (0.52, 2.04)	1.91 (1.29, 2.53)		1.74 (0.97, 2.51)	0.71 (0.22, 1.20)	-0.36 (-0.78, 0.06)	3.55 (2.95, 4.15)	1.81 (1.33, 2.29)		
SRKT DK Shammas	0.53 (-2.44, 3.54)	0.22 (-2.71, 3.18)	1.16 (-3.01, 5.37)	0.46 (-3.04, 3.81)	-0.44 (-6.39, 5.58)	3.43 (-2.46, 9.42)	0.68 (-2.79, 4.08)	1.08 (-1.87, 4.05)	-0.51 (-3.98, 2.89)	0.77 (-2.20, 3.73)	1.66 (-1.05, 4.37)	-0.13 (-3.13, 2.83)	1.39 (-1.54, 4.33)	1.55 (-1.39, 4.50)	1.50 (-1.48, 4.51)		-0.23 (-1.04, 1.07)	0.40 (-0.27, 1.07)	0.23 (-0.58, 1.04)	-0.80 (-1.35, 2.36)	-1.87 (-1.39, 2.69)	2.04 (-0.25, 0.85)	0.30 (-0.25, -		

Meta-analysis and network meta-analysis results

	Clinical history	Carmellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holiday2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz-Speicher	SRKT DK Seitz/Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP	
SRKT Feiz-Mannis	-0.20 (-2.89, 2.58)	-0.49 (-3.20, 2.25)	0.47 (-3.62, 4.48)	-0.25 (-2.97, 2.42)	-1.14 (-6.93, 4.77)	2.74 (-3.06, 8.65)	-0.04 (-2.75, 2.65)	0.37 (-2.36, 3.10)	-1.22 (-3.96, 1.45)	0.06 (-2.68, 2.82)	0.93 (-1.16, 3.05)	-0.85 (-3.58, 1.90)	0.67 (-2.04, 3.43)	0.83 (-1.87, 3.60)	0.80 (-1.92, 3.51)	-0.71 (-3.42, 2.02)	0.63 (-0.29, 1.55)	-	0.49 (0.05, 0.94)	-0.57 (-1.40, 0.26)	-1.64 (-2.43, 0.85)	2.27 (1.37, 3.17)	0.53 (-0.30, 1.36)	-
SRKT Feiz-Mannis nomogram	0.93 (-2.11, 3.98)	0.64 (-2.37, 3.63)	1.59 (-2.66, 5.82)	0.87 (-2.58, 4.27)	-0.01 (-6.01, 5.96)	3.86 (-9.87, 4.49)	1.10 (-2.11, 4.49)	1.51 (-1.52, 4.49)	-0.09 (-3.57, 3.35)	1.18 (-1.84, 4.22)	2.08 (-0.65, 4.80)	0.28 (-2.77, 3.28)	1.80 (-1.19, 4.81)	1.96 (-1.01, 4.94)	1.92 (-1.04, 4.90)	0.42 (-2.58, 3.41)	1.13 (-1.66, 3.87)	-	-0.17 (-1.09, 0.75)	-1.20 (-1.90, 0.50)	-2.27 (-2.92, 1.62)	1.64 (0.86, 2.42)	-0.10 (-0.80, 0.60)	-
SRKT K	1.00 (-4.17, 6.16)	0.71 (-4.40, 5.83)	1.65 (-1.29, 4.59)	0.93 (-4.43, 6.35)	0.06 (-2.87, 3.01)	3.94 (-0.95, 6.94)	1.13 (-4.30, 6.54)	1.59 (-2.59, 5.75)	-0.03 (-5.41, 5.42)	1.25 (-3.89, 6.40)	2.14 (-2.89, 7.10)	0.33 (-4.73, 5.52)	1.87 (-3.27, 7.06)	2.03 (-3.12, 7.17)	1.99 (-3.15, 7.08)	0.49 (-4.72, 5.65)	1.19 (-3.79, 5.21)	0.08 (-5.15, 5.21)	-	-	-	-	-	-3.43 (-3.90, 2.96)
SRKT Ladas-Stark	0.28 (-2.47, 3.08)	-0.02 (-2.72, 2.76)	0.92 (-3.09, 4.96)	0.23 (-2.51, 2.94)	-0.67 (-6.47, 5.18)	3.20 (-2.56, 9.13)	0.44 (-2.28, 3.14)	0.86 (-1.86, 3.58)	-0.76 (-3.46, 1.94)	0.53 (-2.23, 3.29)	1.42 (-0.70, 3.51)	-0.37 (-3.15, 2.38)	1.13 (-1.57, 3.90)	1.30 (-1.39, 4.07)	1.27 (-1.41, 4.04)	-0.23 (-2.95, 2.51)	0.47 (-1.67, 2.61)	-0.66 (-3.39, 2.15)	-0.71 (-5.72, 4.26)	-1.03 (-1.86, 0.20)	-2.10 (-2.89, 1.31)	1.81 (0.91, 0.76)	0.07 (-0.90)	-
SRKT Latkany	-0.26 (-3.27, 2.69)	-0.57 (-3.51, 2.40)	0.38 (-3.88, 4.57)	-0.34 (-3.72, 3.05)	-1.21 (-7.16, 4.82)	2.66 (-3.28, 8.69)	-0.12 (-3.55, 3.25)	0.31 (-2.66, 3.28)	-1.31 (-4.72, 2.07)	-0.03 (-3.01, 2.96)	0.87 (-1.85, 3.54)	-0.93 (-3.91, 2.05)	0.59 (-2.39, 3.57)	0.75 (-2.17, 3.72)	0.73 (-2.23, 3.67)	-0.78 (-3.74, 2.16)	-0.08 (-4.19, 1.74)	-1.21 (-6.37, 3.91)	-1.27 (-4.19, 2.14)	-0.54 (-3.31, 0.54)	-1.07 (-1.60, 0.54)	2.84 (2.16, 3.52)	1.10 (0.52, 1.68)	-
SRKT Masket	-1.35 (-4.33, 1.66)	-1.64 (-4.59, 1.27)	-0.71 (-4.88, 3.49)	-1.41 (-4.87, 2.01)	-2.29 (-8.23, 3.68)	1.58 (-4.37, 7.59)	-1.20 (-4.63, 2.14)	-0.77 (-3.79, 1.02)	-2.37 (-5.82, 1.86)	-1.09 (-4.05, 2.47)	-0.22 (-2.94, 2.47)	-2.00 (-5.03, 0.98)	-0.48 (-3.47, 2.48)	-0.33 (-3.26, 2.65)	-0.36 (-3.32, 2.58)	-1.87 (-4.84, 1.08)	-1.16 (-3.88, 1.53)	-2.28 (-5.29, 0.65)	-2.35 (-5.29, 2.75)	-1.63 (-7.42, 1.06)	-1.08 (-4.38, 1.84)	3.91 (3.28, 4.54)	2.17 (1.65, 2.69)	-
SRKT SK Ferrara	2.56 (-0.48, 5.57)	2.27 (-0.74, 5.29)	3.20 (-1.05, 7.41)	2.49 (-0.99, 5.92)	1.61 (-4.35, 7.61)	5.49 (-0.50, 11.47)	2.71 (-0.78, 6.13)	3.13 (-0.08, 5.01)	1.52 (-0.20, 5.87)	2.80 (-0.20, 6.42)	3.69 (-1.14, 4.93)	1.91 (-0.92, 6.42)	3.43 (-1.14, 4.93)	3.59 (-0.46, 6.62)	3.55 (-0.50, 6.52)	2.04 (-0.22, 5.46)	2.76 (-0.02, 4.65)	1.62 (-0.02, 6.71)	1.56 (-0.02, 4.65)	2.28 (-0.02, 5.80)	2.83 (-0.17, 6.89)	3.91 (0.93, 6.89)	-1.74 (-2.41, 1.07)	-
SRKT SK Rosa	0.82 (-)	0.53 (-)	1.46 (-)	0.77 (-)	-0.12 (-)	3.76 (-)	0.98 (-)	1.39 (-)	-0.22 (-)	1.07 (-)	1.96 (-)	0.16 (-)	1.68 (-)	1.84 (-)	1.82 (-)	0.30 (-)	1.02 (-)	-0.11 (-)	-0.17 (-)	0.54 (-)	1.09 (-)	2.18 (-)	-1.74 (-)	-

Meta-analysis and network meta-analysis results

---

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT TK	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
	2.17, 3.82)	2.43, 3.48)	2.68, 5.67)	2.71, 4.16)	5.99, 5.79)	2.19, 9.77)	2.51, 4.39)	1.59, 4.35)	3.65, 3.22)	1.92, 4.08)	0.78, 4.65)	2.83, 3.20)	1.28, 4.66)	1.12, 4.87)	1.14, 4.78)	2.66, 3.27)	1.72, 3.75)	3.07, 2.91)	5.26, 4.97)	2.22, 3.29)	1.89, 4.09)	0.78, 5.13)	4.71, 1.27)		
SRKT TNP	-2.43 (- 8.33, 3.58)	-2.73 (- 8.57, 3.24)	-1.78 (- 5.94, 2.38)	-2.51 (- 8.63, 3.68)	-3.37 (- 6.34, 0.37)	0.49 (- 3.50)	-2.30 (- 2.50, 3.81)	-1.87 (- 6.94, 2.67)	-3.45 (- 9.62, 2.67)	-2.20 (- 8.18, 3.74)	-1.28 (- 7.14, 4.48)	-3.10 (- 9.01, 2.83)	-1.56 (- 7.54, 4.42)	-1.40 (- 7.32, 4.50)	-1.43 (- 7.37, 4.45)	-2.94 (- 8.88, 2.98)	-2.25 (- 8.88, 3.59)	-3.36 (- 9.26, 2.55)	-3.44 (- 6.38, 0.45)	-2.71 (- 8.52, 3.09)	-2.15 (- 8.04, 3.79)	-1.09 (- 6.95, 4.84)	-4.98 (- 10.99, 1.03)	-3.25 (- 9.16, 2.62)	




Figure 65: Myopic corneal refractive surgery: prediction error – relative effect of all options versus common comparator

491


492

**Table 110: Myopic corneal refractive surgery: prediction error – rankings for each comparator**

	Probability best	Median rank (95%CI)
Clinical history	0.009	14 (3, 24)
Camellin-Calossi	0.004	16 (4, 24)
Haigis-L	0.014	9 (2, 23)
HofferQ DK	0.013	14 (2, 24)
HofferQ K	0.001	20 (3, 25)
HofferQ TNP	0.423	2 (1, 22)
Holladay2 DK	0.018	13 (2, 24)
Shammas-PL	0.007	10 (3, 21)
SRKT Clinical history	0.002	20 (5, 25)
SRKT Diehl	0.013	12 (2, 23)
SRKT DK	0.039	7 (1, 17)
SRKT DK Awwad	0.002	18 (5, 25)
SRKT DK Savini	0.038	8 (1, 21)
SRKT DK Seitz/Speicher	0.048	7 (1, 20)
SRKT DK Seitz/Speicher/Savini	0.046	7 (1, 20)
SRKT DK Shammas	0.002	17 (5, 24)
SRKT Feiz-Mannis	0.003	13 (4, 22)
SRKT Feiz-Mannis nomogram	0.001	20 (6, 25)
SRKT K	0.000	20 (4, 25)
SRKT Ladas-Stark	0.001	16 (5, 23)
SRKT Latkany	0.012	12 (2, 23)
SRKT Masket	0.084	6 (1, 19)
SRKT SK Ferrara	0.000	24 (15, 25)
SRKT SK Rosa	0.001	19 (6, 25)
SRKT TNP	0.218	2 (1, 22)

493

## Meta-analysis and network meta-analysis results



494

**Figure 66: Myopic corneal refractive surgery: prediction error – rank probability histograms**

495

**Table 111: Myopic corneal refractive surgery: prediction error – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
31 (compared to 31 datapoints)	-15.563	-46.424	30.86	15.297	1.416 (95%CI: 0.720, 1.966)


496

**Table 112: Myopic corneal refractive surgery: prediction error – notes**

- Continuous (normal; identity link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

497

**PROPORTION WITHIN 0.5 DIOPTRES – random effects model**



498

**Figure 67: Myopic corneal refractive surgery: within 0.5D – evidence network**

**Table 113:** Myopic corneal refractive surgery: within 0.5D – input data

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
Xu et al. (2014)								6/37	3/37									4/37	3/37	
Huang et al. (2013)						21/46							21/46							
Kim et al. (2013)						30/47												5/47		
Saiki et al. (2013)		3/28	9/19	4/12	1/12	6/25					4/12	5/12	7/28	13/28	12/25	5/28				5/28
Fam & (2008)	5/37						13/37		17/37						19/37	15/37	17/37			

**Table 114:** Myopic corneal refractive surgery: within 0.5D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)


	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
SRKT Clinical history	-	-	-	-	-	3.47 (1.09, 11.05)	-	-	5.44 (1.73, 17.06)	-	-	-	-	-	6.76 (2.16, 21.16)	4.36 (1.38, 13.76)	-	5.44 (1.73, 17.06)	-	
BESSt	3.88 (0.08, 180.60)		7.50 (1.68, 33.56)	4.17 (0.76, 22.71)	0.76 (0.07, 8.12)	2.63 (0.58, 11.90)	-	-	-	4.17 (0.76, 22.71)	5.95 (1.13, 31.26)	2.78 (0.64, 12.10)	7.22 (1.76, 29.56)	7.69 (1.84, 32.20)	1.81 (0.39, 8.44)	-	-	-	1.81 (0.39, 8.44)	
Camellin-Calossi	32.89 (0.76, 1490.00)	8.63 (0.54, 149.10)		0.56 (0.12, 2.49)	0.10 (0.01, 0.95)	0.35 (0.10, 1.27)	-	-	-	0.56 (0.12, 2.49)	0.79 (0.18, 3.41)	0.37 (0.11, 1.28)	0.96 (0.30, 3.09)	1.03 (0.31, 3.39)	0.24 (0.06, 0.91)	-	-	-	0.24 (0.06, 0.91)	
Double-K	17.55 (0.36, 820.50)	4.53 (0.25, 90.35)	0.53 (0.03, 8.48)		0.18 (0.02, 1.95)	0.63 (0.14, 2.86)	-	-	-	1.00 (0.18, 5.46)	1.43 (0.27, 7.52)	0.67 (0.15, 7.11)	1.73 (0.42, 7.74)	1.85 (0.44, 7.03)	0.43 (0.09, 2.03)	-	-	-	0.43 (0.09, 2.03)	

Meta-analysis and network meta-analysis results

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
Feiz-Mannis	2.20 (0.02, 145.80)	0.59 (0.01, 15.97)	0.07 (0.00, 1.64)	0.13 (0.00, 3.46)		3.47 (0.37, 32.74)	-	-	-	5.50 (0.51, 59.01)	7.86 (0.75, 82.13)	3.67 (0.40, 33.71)	9.53 (1.08, 84.14)	10.15 (1.13, 90.94)	2.39 (0.25, 23.01)	-	-	-	-	2.39 (0.25, 23.01)
Haigis-L	15.45 (0.44, 630.20)	4.00 (0.33, 61.03)	0.47 (0.04, 5.51)	0.88 (0.07, 11.93)	6.75 (0.37, 328.20)		-	-	-	1.58 (0.35, 7.17)	2.26 (0.52, 9.83)	1.02 (0.51, 2.02)	2.74 (0.84, 8.94)	2.92 (0.87, 9.78)	0.69 (0.18, 2.61)	-	0.07 (0.02, 0.20)	-	0.69 (0.18, 2.61)	
HofferQ DK	3.68 (0.26, 50.80)	0.97 (0.02, 44.53)	0.11 (0.00, 4.34)	0.22 (0.00, 10.12)	1.68 (0.03, 184.60)	0.24 (0.01, 7.79)		-	-	1.57 (0.62, 4.00)	-	-	-	-	1.95 (0.77, 4.96)	1.26 (0.49, 3.23)	-	1.57 (0.62, 4.00)		
HofferQ K	6.00 (0.08, 518.00)	1.56 (0.05, 63.77)	0.18 (0.01, 6.20)	0.34 (0.01, 13.15)	2.78 (0.06, 261.40)	0.39 (0.02, 7.74)	1.60 (0.02, 125.70)		0.46 (0.10, 1.98)	-	-	-	-	-	-	-	0.63 (0.16, 2.43)	-	0.46 (0.10, 1.98)	
HofferQ TNP	2.53 (0.03, 198.90)	0.66 (0.02, 27.58)	0.08 (0.00, 2.82)	0.14 (0.00, 6.06)	1.15 (0.02, 119.30)	0.16 (0.01, 3.52)	0.67 (0.01, 57.33)	0.42 (0.03, 6.24)		-	-	-	-	-	-	-	-	1.37 (0.29, 6.61)	1.00 (0.19, 5.31)	
Holladay2 DK	5.83 (0.42, 82.42)	1.56 (0.04, 72.66)	0.18 (0.00, 6.71)	0.34 (0.01, 15.19)	2.71 (0.04, 294.60)	0.38 (0.01, 12.49)	1.58 (0.13, 20.93)	0.99 (0.01, 69.46)	2.34 (0.03, 182.90)		-	-	-	-	1.24 (0.50, 3.09)	0.80 (0.32, 2.02)	-	1.00 (0.40, 2.50)		
Masket	17.47 (0.38, 814.40)	4.51 (0.26, 87.62)	0.52 (0.03, 8.83)	0.99 (0.06, 18.32)	7.79 (0.31, 467.40)	1.12 (0.08, 13.95)	4.64 (0.11, 208.30)	2.88 (0.08, 95.93)	6.88 (0.17, 270.30)	2.94 (0.07, 128.20)		1.43 (0.27, 7.52)	0.67 (0.15, 2.91)	1.73 (0.42, 7.11)	1.85 (0.44, 7.74)	0.43 (0.09, 2.03)	-	-	-	0.43 (0.09, 2.03)
Modified Masket	25.83 (0.58, 1224.00)	6.73 (0.37, 128.50)	0.78 (0.05, 12.25)	1.47 (0.09, 26.82)	11.47 (0.46, 681.20)	1.67 (0.13, 20.40)	6.85 (0.17, 301.80)	4.29 (0.12, 134.10)	10.23 (0.27, 362.90)	4.31 (0.11, 201.20)	1.49 (0.08, 25.81)		0.47 (0.11, 1.95)	1.21 (4.76)	1.29 (5.19)	0.30 (1.37)	-	-	-	0.30 (0.07, 1.37)
Shammas-PL	13.19 (0.36, 515.30)	3.45 (0.26, 50.02)	0.40 (0.03, 4.76)	0.76 (0.06, 10.23)	5.86 (0.31, 286.60)	0.86 (0.14, 4.99)	3.56 (0.10, 133.40)	2.20 (0.09, 52.58)	5.28 (0.18, 150.60)	2.24 (0.07, 83.46)	0.76 (0.06, 10.92)	0.51 (0.04, 7.03)		2.60 (0.84, 8.07)	2.77 (8.84)	0.65 (2.37)	-	-	-	0.65 (0.18, 2.37)
SRKT A-P	32.41 (0.79, 1340.00)	8.36 (0.54, 141.30)	0.96 (0.07, 13.33)	1.84 (0.12, 30.37)	14.38 (0.66, 757.50)	2.08 (0.19, 22.65)	8.58 (0.22, 341.20)	5.34 (0.16, 159.30)	12.68 (0.37, 466.30)	5.39 (0.14, 214.50)	1.84 (0.12, 30.10)	1.24 (0.08, 19.41)	2.39 (0.21, 26.76)		1.07 (0.36, 3.14)	0.25 (0.07, 0.85)	-	-	-	0.25 (0.07, 0.85)
SRKT C-P	34.02 (0.83, 1408.00)	8.83 (0.58, 145.40)	1.03 (0.08, 14.14)	1.95 (0.13, 30.74)	15.09 (0.68, 831.20)	2.21 (0.19, 23.11)	9.07 (0.24, 373.40)	5.70 (0.18, 163.20)	13.73 (0.38, 458.20)	5.69 (0.16, 230.60)	1.97 (0.13, 30.91)	1.32 (0.09, 19.92)	2.55 (0.23, 29.17)	1.06 (0.08, 14.37)		0.24 (0.07, 0.82)	-	-	-	0.24 (0.07, 0.82)

Meta-analysis and network meta-analysis results

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Halgis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
SRKT DK	7.35 (0.53, 104.30)	1.94 (0.12, 35.33)	0.23 (0.01, 3.24)	0.42 (0.03, 7.05)	3.31 (0.14, 190.00)	0.48 (0.04, 5.34)	1.97 (0.16, 26.69)	1.23 (0.04, 37.44)	2.94 (0.08, 104.20)	1.25 (0.10, 16.39)	0.43 (0.03, 6.89)	0.29 (0.02, 4.42)	0.56 (0.04, 6.64)	0.23 (0.02, 3.10)	0.22 (0.02, 2.97)		0.65 (0.26, 1.62)	-	0.81 (0.32, 2.01)	1.00 (0.25, 3.93)
SRKT Feiz-Mannis	4.67 (0.34, 67.63)	1.22 (0.03, 56.19)	0.14 (0.00, 5.68)	0.27 (0.01, 11.82)	2.11 (0.04, 236.80)	0.30 (0.01, 10.31)	1.27 (0.10, 16.86)	0.79 (0.01, 54.08)	1.86 (0.02, 151.40)	0.80 (0.06, 10.32)	0.27 (0.01, 11.89)	0.18 (0.00, 7.91)	0.35 (0.01, 12.94)	0.15 (0.00, 5.68)	0.14 (0.00, 5.32)	0.63 (0.05, 8.18)		-	1.25 (0.50, 3.13)	-
SRKT K	2.04 (0.04, 124.20)	0.53 (0.03, 14.55)	0.06 (0.00, 1.34)	0.12 (0.01, 2.90)	0.94 (0.03, 66.34)	0.13 (0.02, 1.27)	0.54 (0.01, 34.83)	0.34 (0.03, 5.01)	0.81 (0.06, 14.05)	0.34 (0.01, 20.26)	0.12 (0.01, 2.82)	0.08 (0.00, 1.86)	0.15 (0.01, 2.31)	0.06 (0.00, 1.34)	0.06 (0.00, 1.32)	0.27 (0.02, 6.20)	0.43 (0.01, 25.76)		0.73 (0.15, 3.50)	
SRKT Ladas-Stark	5.86 (0.42, 84.94)	1.57 (0.03, 69.48)	0.18 (0.00, 6.77)	0.34 (0.01, 14.92)	2.68 (0.05, 284.60)	0.39 (0.01, 12.06)	1.59 (0.13, 20.83)	0.98 (0.01, 65.53)	2.35 (0.03, 186.80)	1.00 (0.08, 12.46)	0.34 (0.01, 14.34)	0.23 (0.01, 9.70)	0.45 (0.01, 15.39)	0.19 (0.00, 6.86)	0.17 (0.00, 6.28)	0.80 (0.06, 9.94)	1.26 (0.10, 15.77)	2.97 (0.05, 124.20)		-
SRKT TNP	4.50 (0.11, 187.50)	1.17 (0.08, 19.22)	0.14 (0.01, 1.87)	0.26 (0.02, 3.98)	2.01 (0.09, 107.30)	0.29 (0.04, 2.33)	1.21 (0.03, 49.20)	0.76 (0.05, 9.75)	1.77 (0.11, 28.02)	0.76 (0.02, 30.60)	0.26 (0.02, 3.90)	0.17 (0.01, 2.59)	0.34 (0.03, 3.39)	0.14 (0.01, 1.76)	0.13 (0.01, 1.74)	0.61 (0.04, 8.43)	0.96 (0.03, 38.36)	2.19 (0.22, 18.56)	0.75 (0.02, 29.15)	



**Figure 68: Myopic corneal refractive surgery: within 0.5D – relative effect of all options versus common comparator**

505


**Table 115: Myopic corneal refractive surgery: within 0.5D – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.001	19 (8, 20)
BESSt	0.002	14 (5, 20)
Camellin-Calossi	0.199	3 (1, 14)
Double-K	0.069	6 (1, 17)
Feiz-Mannis	0.002	16 (5, 20)
Haigis-L	0.017	7 (2, 15)
HofferQ DK	0.011	14 (3, 20)
HofferQ K	0.028	12 (1, 19)
HofferQ TNP	0.008	16 (3, 20)
Holladay2 DK	0.024	12 (2, 19)
Masket	0.070	6 (1, 17)
Modified Masket	0.142	5 (1, 15)
Shammas-PL	0.013	8 (2, 16)
SRKT A-P	0.171	4 (1, 13)
SRKT C-P	0.199	3 (1, 13)
SRKT DK	0.002	11 (4, 17)
SRKT Feiz-Mannis	0.018	13 (2, 19)
SRKT K	0.001	17 (7, 20)
SRKT Ladas-Stark	0.024	12 (2, 19)
SRKT TNP	0.001	13 (5, 19)

506

## Meta-analysis and network meta-analysis results

---



507

**Figure 69: Myopic corneal refractive surgery: within 0.5D – rank probability histograms**

508

**Table 116: Myopic corneal refractive surgery: within 0.5D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
27.42 (compared to 26 datapoints)	117.472	91.607	25.865	143.337	0.955 (95%CI: 0.065, 1.925)


509

**Table 117: Myopic corneal refractive surgery: within 0.5D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

510

**PROPORTION WITHIN 1.0 DIOPTRE – random effects model**



511

**Figure 70: Myopic corneal refractive surgery: within 1.0D – evidence network**

512

513

**Table 118: Myopic corneal refractive surgery: within 1.0D – input data**


	<b>SRKT Clinical history</b>	<b>BESSt</b>	<b>Camellin-Calossi</b>	<b>Double-K</b>	<b>Feiz-Mannis</b>	<b>Haigis-L</b>	<b>HofferQ DK</b>	<b>HofferQ K</b>	<b>HofferQ TNP</b>	<b>Holladay2 DK</b>	<b>Masket</b>	<b>Modified Masket</b>	<b>Shammas-PL</b>	<b>SRKT A-P</b>	<b>SRKT C-P</b>	<b>SRKT DK</b>	<b>SRKT Feiz-Mannis</b>	<b>SRKT K</b>	<b>SRKT Ladas-Stark</b>	<b>SRKT TNP</b>
Xu et al. (2014)									14/37	3/37								8/37		5/37
Huang et al. (2013)						36/46							39/46							
Kim et al. (2013)						38/47												16/47		
Saiki et al. (2013)		12/28	14/19	8/12	6/12	13/25					10/12	9/12	20/28	21/28	17/25	14/28				17/28
Fam & (2008)	11/37						28/37			30/37						25/37	23/37		23/37	

514  
515**Table 119: Myopic corneal refractive surgery: within 1.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT Clinical history</b>	<b>BESSt</b>	<b>Camellin-Calossi</b>	<b>Double-K</b>	<b>Feiz-Mannis</b>	<b>Haigis-L</b>	<b>HofferQ DK</b>	<b>HofferQ K</b>	<b>HofferQ TNP</b>	<b>Holladay2 DK</b>	<b>Masket</b>	<b>Modified Masket</b>	<b>Shammas-PL</b>	<b>SRKT A-P</b>	<b>SRKT C-P</b>	<b>SRKT DK</b>	<b>SRKT Feiz-Mannis</b>	<b>SRKT K</b>	<b>SRKT Ladas-Stark</b>	<b>SRKT TNP</b>
SRKT Clinical history	-	-	-	-	-	7.35 (2.63, 20.60)	-	-	10.13 (3.43, 29.93)	-	-	-	-	-	4.92 (1.84, 13.19)	3.88 (1.47, 10.23)	-	3.88 (1.47, 10.23)	-	
BESSt	3.81 (0.06, 227.60)	3.73 (1.05, 13.24)	2.67 (0.65, 10.97)	1.33 (0.34, 5.18)	1.44 (0.49, 4.27)	-	-	-	-	6.67 (1.23, 36.23)	4.00 (0.89, 18.03)	3.33 (1.10, 10.12)	4.00 (1.28, 12.46)	2.83 (0.92, 8.73)	1.33 (0.47, 3.82)	-	-	-	2.06 (0.71, 5.98)	
Camellin-Calossi	15.54 (0.26, 888.10)	4.05 (0.21, 78.19)	0.71 (0.15, 3.45)	0.36 (0.08, 1.64)	0.39 (0.11, 1.40)	-	-	-	-	1.79 (0.29, 11.13)	1.07 (0.20, 5.63)	0.89 (0.24, 3.31)	1.07 (0.28, 4.06)	0.76 (0.20, 2.85)	0.36 (0.10, 1.26)	-	-	-	0.55 (0.15, 1.97)	

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
Double-K	10.98 (0.17, 731.40)	2.87 (0.15, 59.91)	0.70 (0.03, 15.96)		0.50 (0.10, 2.60)	0.54 (0.13, 2.27)	-	-	-	2.50 (0.36, 17.32)	1.50 (0.25, 8.84)	1.25 (0.29, 5.35)	1.50 (0.34, 6.55)	1.06 (0.25, 4.60)	0.50 (0.12, 2.05)	-	-	-	0.77 (0.19, 3.20)	
Feiz-Mannis	5.22 (0.08, 311.00)	1.37 (0.07, 27.48)	0.34 (0.02, 7.02)	0.48 (0.02, 10.31)		1.08 (0.27, 4.29)	-	-	-	5.00 (0.75, 33.21)	3.00 (0.53, 16.90)	2.50 (0.62, 10.11)	3.00 (0.73, 12.39)	2.13 (0.52, 8.70)	1.00 (0.26, 3.87)	-	-	-	1.55 (0.40, 6.03)	
Haigis-L	9.30 (0.19, 449.10)	2.43 (0.18, 33.65)	0.60 (0.04, 8.86)	0.85 (0.05, 12.83)	1.79 (0.12, 26.69)		-	-	-	4.62 (0.84, 25.49)	2.77 (0.60, 12.71)	1.87 (0.86, 4.06)	2.77 (0.87, 8.84)	1.96 (0.62, 6.19)	0.92 (0.31, 2.72)	-	0.12 (0.05, 0.31)	-	1.43 (0.48, 4.25)	
HofferQ DK	7.79 (0.44, 134.90)	2.06 (0.03, 120.40)	0.51 (0.01, 30.84)	0.71 (0.01, 45.22)	1.50 (0.02, 99.39)	0.84 (0.02, 42.06)		-	-	1.38 (0.45, 4.20)	-	-	-	-	0.67 (0.24, 1.85)	0.53 (0.19, 1.44)	-	0.53 (0.19, 1.44)		
HofferQ K	11.10 (0.11, 1221.00)	2.94 (0.08, 119.80)	0.73 (0.02, 30.60)	1.02 (0.02, 42.35)	2.15 (0.05, 94.42)	1.20 (0.05, 27.15)	1.44 (0.01, 159.70)		0.14 (0.04, 0.56)	-	-	-	-	-	-	-	0.45 (0.16, 1.27)	-	0.26 (0.08, 0.81)	
HofferQ TNP	1.41 (0.01, 169.20)	0.36 (0.01, 17.53)	0.09 (0.00, 4.53)	0.13 (0.00, 6.43)	0.27 (0.01, 13.24)	0.15 (0.01, 4.11)	0.18 (0.00, 21.37)	0.13 (0.01, 2.40)		-	-	-	-	-	-	-	3.13 (0.76, 12.89)	-	1.77 (0.39, 8.02)	
Holladay2 DK	10.95 (0.63, 198.80)	2.91 (0.05, 163.90)	0.70 (0.01, 43.02)	1.00 (0.01, 66.08)	2.09 (0.03, 126.40)	1.18 (0.02, 56.26)	1.41 (0.08, 24.39)	0.98 (0.01, 101.70)	7.78 (0.06, 909.80)		-	-	-	-	-	0.49 (0.17, 1.42)	0.38 (0.13, 1.10)	-	0.38 (0.13, 1.10)	
Masket	32.02 (0.46, 2442.00)	8.29 (0.35, 219.80)	2.03 (0.08, 61.95)	2.90 (0.11, 84.96)	6.01 (0.23, 186.40)	3.37 (0.19, 75.67)	4.05 (0.06, 306.10)	2.82 (0.06, 150.30)	22.62 (0.40, 1487.00)	2.95 (0.04, 216.80)		0.60 (0.08, 4.45)	0.50 (0.09, 3.43)	0.60 (0.11, 2.41)	0.43 (0.07, 1.08)	0.20 (0.04, 0.80)	-	-	-	0.31 (0.06, 1.69)
Modified Masket	17.37 (0.27, 1161.00)	4.50 (0.22, 100.40)	1.12 (0.05, 27.63)	1.59 (0.06, 40.92)	3.31 (0.15, 87.14)	1.85 (0.11, 34.73)	2.21 (0.03, 143.70)	1.56 (0.03, 76.63)	12.41 (0.23, 690.50)	1.57 (0.02, 106.70)	0.55 (0.02, 15.91)		0.83 (0.18, 4.77)	1.00 (0.21, 3.90)	0.71 (0.15, 3.35)	0.33 (0.07, 1.50)	-	-	-	0.52 (0.11, 2.33)
Shammas-PL	13.84 (0.28, 686.00)	3.59 (0.25, 53.09)	0.89 (0.05, 14.03)	1.26 (0.07, 21.07)	2.63 (0.16, 44.96)	1.47 (0.20, 11.10)	1.76 (0.03, 85.45)	1.24 (0.04, 37.72)	9.73 (0.28, 351.80)	1.27 (0.03, 61.34)	0.44 (0.02, 8.57)	0.80 (0.04, 13.41)		1.20 (0.37, 3.92)	0.85 (0.26, 2.75)	0.40 (0.13, 1.21)	-	-	-	0.62 (0.20, 1.89)
SRKT A-P	16.35 (0.28, 935.50)	4.26 (0.24, 78.67)	1.06 (0.05, 20.89)	1.51 (0.07, 29.39)	3.10 (0.16, 65.42)	1.74 (0.13, 24.64)	2.08 (0.04, 119.80)	1.46 (0.04, 56.51)	11.52 (0.26, 512.40)	1.49 (0.03, 86.26)	0.52 (0.02, 11.81)	0.95 (0.04, 19.81)	1.18 (0.08, 17.37)		0.71 (0.21, 2.35)	0.33 (0.11, 1.03)	-	-	-	0.52 (0.16, 1.62)

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Hairis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
SRKT C-P	11.16 (0.20, 666.50)	2.99 (0.16, 52.55)	0.73 (0.04, 14.10)	1.03 (0.05, 21.10)	2.18 (0.11, 44.03)	1.23 (0.09, 16.46)	1.45 (0.02, 83.72)	1.02 (0.03, 39.19)	8.14 (0.17, 371.30)	1.03 (0.02, 57.93)	0.36 (0.01, 8.30)	0.66 (0.03, 13.48)	0.82 (0.05, 12.32)	0.70 (0.04, 12.77)		0.47 (0.15, 1.44)	-	-	0.73 (0.23, 2.26)	
SRKT DK	5.13 (0.30, 90.12)	1.35 (0.08, 23.55)	0.33 (0.02, 6.31)	0.47 (0.02, 9.54)	0.99 (0.05, 19.41)	0.55 (0.04, 7.31)	0.66 (0.04, 11.39)	0.46 (0.01, 17.53)	3.68 (0.08, 168.00)	0.47 (0.03, 8.18)	0.16 (0.01, 3.82)	0.30 (0.01, 5.98)	0.37 (0.03, 5.39)	0.31 (0.02, 5.78)	0.46 (0.03, 7.87)		0.79 (0.30, 2.05)	-	0.79 (0.30, 2.05)	1.55 (0.54, 4.46)
SRKT Feiz-Mannis	4.01 (0.23, 68.91)	1.06 (0.02, 61.32)	0.26 (0.00, 15.85)	0.37 (0.01, 23.36)	0.78 (0.01, 46.62)	0.43 (0.01, 20.86)	0.52 (0.03, 8.69)	0.36 (0.00, 35.39)	2.88 (0.02, 332.60)	0.37 (0.02, 6.33)	0.13 (0.00, 8.85)	0.23 (0.00, 15.16)	0.29 (0.01, 14.21)	0.25 (0.00, 14.64)	0.36 (0.01, 19.83)	0.78 (0.05, 12.83)		-	1.00 (0.39, 2.56)	
SRKT K	2.80 (0.04, 216.40)	0.74 (0.03, 19.53)	0.18 (0.01, 4.91)	0.26 (0.01, 7.12)	0.54 (0.02, 14.87)	0.30 (0.03, 3.14)	0.36 (0.01, 28.41)	0.25 (0.02, 3.79)	2.02 (0.11, 38.82)	0.26 (0.00, 20.06)	0.09 (0.00, 2.91)	0.16 (0.01, 4.87)	0.20 (0.01, 3.39)	0.17 (0.01, 4.29)	0.25 (0.01, 6.02)	0.54 (0.02, 12.99)	0.70 (0.01, 53.95)		-	0.57 (0.17, 1.93)
SRKT Ladas-Stark	4.06 (0.24, 70.52)	1.07 (0.02, 62.02)	0.26 (0.00, 15.31)	0.37 (0.01, 22.91)	0.77 (0.01, 48.40)	0.44 (0.01, 21.22)	0.52 (0.03, 8.77)	0.36 (0.00, 35.32)	2.91 (0.03, 336.20)	0.37 (0.02, 6.26)	0.13 (0.00, 8.54)	0.23 (0.00, 14.58)	0.29 (0.01, 14.89)	0.25 (0.00, 14.05)	0.36 (0.01, 20.29)	0.79 (0.05, 13.65)	1.00 (0.06, 16.65)	1.45 (0.02, 96.99)		-
SRKT TNP	4.85 (0.09, 239.20)	1.27 (0.08, 19.62)	0.31 (0.02, 5.20)	0.44 (0.02, 7.52)	0.92 (0.05, 16.07)	0.52 (0.05, 4.81)	0.62 (0.01, 32.52)	0.44 (0.03, 6.58)	3.46 (0.18, 61.45)	0.44 (0.01, 22.90)	0.15 (0.01, 3.15)	0.28 (0.01, 5.18)	0.35 (0.03, 4.09)	0.30 (0.02, 4.59)	0.43 (0.03, 6.30)	0.93 (0.06, 13.63)	1.22 (0.06, 60.79)	1.72 (0.16, 16.40)	1.20 (0.02, 58.13)	



517

**Figure 71:** Myopic corneal refractive surgery: within 1.0D – relative effect of all options versus common comparator


518

519

**Table 120: Myopic corneal refractive surgery: within 1.0D – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT Clinical history	0.001	19 (6, 20)
BESSt	0.003	14 (4, 20)
Camellin-Calossi	0.080	6 (1, 18)
Double-K	0.053	8 (1, 19)
Feiz-Mannis	0.010	13 (2, 20)
Haigis-L	0.008	9 (2, 17)
HofferQ DK	0.052	10 (1, 19)
HofferQ K	0.091	8 (1, 19)
HofferQ TNP	0.004	18 (4, 20)
Holladay2 DK	0.095	8 (1, 19)
Masket	0.290	3 (1, 16)
Modified Masket	0.119	6 (1, 18)
Shammas-PL	0.038	7 (1, 17)
SRKT A-P	0.080	6 (1, 17)
SRKT C-P	0.039	8 (1, 18)
SRKT DK	0.001	13 (4, 18)
SRKT Feiz-Mannis	0.016	14 (2, 20)
SRKT K	0.002	16 (4, 20)
SRKT Ladas-Stark	0.015	14 (2, 20)
SRKT TNP	0.002	13 (4, 19)

520



**Figure 72: Myopic corneal refractive surgery: within 1.0D – rank probability histograms**

522

**Table 121: Myopic corneal refractive surgery: within 1.0D – model fit statistics**


Residual deviance	Dbar	Dhat	pD	DIC	tau
27.01 (compared to 26 datapoints)	119.699	93.504	26.195	145.894	1.213 (95%CI: 0.294, 1.954)

523

**Table 122: Myopic corneal refractive surgery: within 1.0D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

524


**PAIRWISE COMPARISONS: PROPORTION WITHIN 1.5 DIOPTRES AND 2.0 DIOPTRES**

525

526

527

**PROPORTION WITHIN 2.0 DIOPTRE – fixed effects model**



528

**Figure 73:** Myopic corneal refractive surgery: within 2.0D – evidence network

529

**Table 123:** Myopic corneal refractive surgery: within 2.0D – input data

	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
Fam & (2008)	33/37	35/37	34/37	35/37	32/37	35/37


530

531

532  
533**Table 124: Myopic corneal refractive surgery: within 2.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Clinical history	2.12 (0.36, 12.36)	1.37 (0.29, 6.61)	2.12 (0.36, 12.36)	0.78 (0.19, 3.15)	2.12 (0.36, 12.36)	
HofferQ DK	2.32 (0.39, 19.84)	0.65 (0.10, 4.12)	1.00 (0.13, 7.50)	0.37 (0.07, 2.02)	1.00 (0.13, 7.50)	
Holladay2 DK	1.42 (0.27, 8.24)	0.61 (0.07, 4.32)		1.54 (0.24, 9.82)	0.56 (0.12, 2.56)	1.54 (0.24, 9.82)
SRKT DK	2.33 (0.39, 19.87)	1.00 (0.10, 9.99)	1.63 (0.23, 15.74)		0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
SRKT Feiz-Mannis	0.76 (0.17, 3.29)	0.33 (0.04, 1.74)	0.53 (0.10, 2.50)	0.33 (0.04, 1.81)		2.73 (0.50, 15.09)
SRKT Ladas-Stark	2.30 (0.39, 19.99)	0.99 (0.10, 9.99)	1.62 (0.23, 14.79)	0.99 (0.10, 10.03)	3.02 (0.56, 26.29)	

534



535 **Figure 74:** Myopic corneal refractive surgery: within 2.0D – relative effect of all options versus common comparator


536

537

**Table 125:** Myopic corneal refractive surgery: within 2.0D – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.029	5 (1, 6)
HofferQ DK	0.292	2 (1, 6)
Holladay2 DK	0.093	4 (1, 6)
SRKT DK	0.294	2 (1, 6)
SRKT Feiz-Mannis	0.008	6 (2, 6)
SRKT Ladas-Stark	0.284	2 (1, 6)

538



539 **Figure 75: Myopic corneal refractive surgery: within 2.0D – rank probability histograms**

540

541

**Table 126: Myopic corneal refractive surgery: within 2.0D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
6.394 (compared to 6 datapoints)	23.465	17.567	5.898	29.364	

542


**Table 127: Myopic corneal refractive surgery: within 2.0D – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

543 H.3.3.3 Sensitivity analyses: no historical data methods only

544

Proportion within 0.5D – random effects model



545

Figure 76: Myopic CRS No historical data methods: within 0.5D – evidence network

546

547

**Table 128: Myopic CRS No historical data methods: within 0.5D – input data**


	<b>SRKT K</b>	<b>BESSt</b>	<b>Haigis-L</b>	<b>HofferQ K</b>	<b>HofferQ TNP</b>	<b>Shammas-PL</b>	<b>SRKT A-P</b>	<b>SRKT C-P</b>	<b>SRKT TNP</b>
Xu et al. (2014)	4/37			6/37	3/37				3/37
Huang et al. (2013)			21/46			21/46			
Kim et al. (2013)	5/47		30/47						
Saiki et al. (2013)		3/28	6/25			7/28	13/28	12/25	5/28

548  
549**Table 129: Myopic CRS No historical data methods: within 0.5D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT K</b>	<b>BESSt</b>	<b>Haigis-L</b>	<b>HofferQ K</b>	<b>HofferQ TNP</b>	<b>Shammas-PL</b>	<b>SRKT A-P</b>	<b>SRKT C-P</b>	<b>SRKT TNP</b>
SRKT K		-		14.82 (4.93, 44.61)	1.60 (0.41, 6.20)	0.73 (0.15, 3.50)	-	-	0.73 (0.15, 3.50)
BESSt	1.91 (0.08, 36.38)			2.63 (0.58, 11.90)	-	-	2.78 (0.64, 12.10)	7.22 (1.76, 29.56)	7.69 (1.84, 32.20)
Haigis-L	7.71 (0.83, 59.26)	3.99 (0.33, 55.38)		-	-	1.02 (0.51, 2.02)	2.74 (0.84, 8.94)	2.92 (0.87, 9.78)	0.69 (0.18, 2.61)
HofferQ K	2.94 (0.20, 38.58)	1.54 (0.05, 61.70)	0.38 (0.02, 8.18)		0.46 (0.10, 1.98)	-	-	-	0.46 (0.10, 1.98)
HofferQ TNP	1.25 (0.07, 17.11)	0.66 (0.02, 24.84)	0.16 (0.01, 3.45)	0.42 (0.02, 6.30)		-	-	-	1.00 (0.19, 5.31)
Shammas-PL	6.54 (0.44, 72.95)	3.38 (0.27, 48.07)	0.86 (0.14, 4.80)	2.21 (0.08, 50.70)	5.22 (0.21, 135.60)		2.60 (0.84, 8.07)	2.77 (0.87, 8.84)	0.65 (0.18, 2.37)
SRKT A-P	15.89 (0.76, 273.70)	8.16 (0.55, 144.60)	2.06 (0.19, 21.26)	5.34 (0.16, 156.30)	12.65 (0.36, 447.50)	2.43 (0.22, 26.60)		1.07 (0.36, 3.14)	0.25 (0.07, 0.85)
SRKT C-P	16.96 (0.78, 285.30)	8.84 (0.60, 153.10)	2.23 (0.20, 24.06)	5.74 (0.17, 166.20)	13.68 (0.40, 460.80)	2.58 (0.23, 29.24)	1.08 (0.08, 14.84)		0.24 (0.07, 0.82)

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
SRKT TNP	2.20 (0.21, 18.06)	1.16 (0.08, 19.14)	0.29 (0.04, 2.33)	0.75 (0.05, 9.28)	1.78 (0.12, 27.68)	0.34 (0.04, 3.41)	0.14 (0.01, 1.77)	0.13 (0.01, 1.72)	

550



551

**Figure 77:** Myopic CRS No historical data methods: within 0.5D – relative effect of all options versus common comparator

552

**Table 130:** Myopic CRS No historical data methods: within 0.5D – rankings for each comparator


	Probability best	Median rank (95%CI)
SRKT K	0.002	8 (4, 9)
BESSt	0.008	7 (2, 9)
Haigis-L	0.061	3 (1, 7)
HofferQ K	0.057	6 (1, 9)
HofferQ TNP	0.015	8 (2, 9)

Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Shammas-PL	0.043	4 (1, 8)
SRKT A-P	0.379	2 (1, 7)
SRKT C-P	0.430	2 (1, 7)
SRKT TNP	0.004	6 (3, 9)

553



554

**Figure 78: Myopic CRS No historical data methods: within 0.5D – rank probability histograms**

555

556

**Table 131: Myopic CRS No historical data methods: within 0.5D – model fit statistics**


Residual deviance	Dbar	Dhat	pD	DIC	tau
14.86 (compared to 14 datapoints)	64.031	50.43	13.601	77.632	0.942 (95%CI: 0.066, 1.925)

557

**Table 132: Myopic CRS No historical data methods: within 0.5D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

558

**Proportion within 1.0D – random effects model**

559

**Figure 79: Myopic CRS No historical data methods: within 1.0D – evidence network**

560

561

**Table 133: Myopic CRS No historical data methods: within 1.0D – input data**


	<b>SRKT K</b>	<b>BESSt</b>	<b>Haigis-L</b>	<b>HofferQ K</b>	<b>HofferQ TNP</b>	<b>Shammas-PL</b>	<b>SRKT A-P</b>	<b>SRKT C-P</b>	<b>SRKT TNP</b>
Xu et al. (2014)	8/37			14/37	3/37				5/37
Huang et al. (2013)			36/46			39/46			
Kim et al. (2013)	16/47		38/47						
Saiki et al. (2013)		12/28	13/25			20/28	21/28	17/25	17/28

562  
563**Table 134: Myopic CRS No historical data methods: within 1.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT K</b>	<b>BESSt</b>	<b>Haigis-L</b>	<b>HofferQ K</b>	<b>HofferQ TNP</b>	<b>Shammas-PL</b>	<b>SRKT A-P</b>	<b>SRKT C-P</b>	<b>SRKT TNP</b>
SRKT K		-		8.18 (3.18, 21.03)	2.21 (0.79, 6.16)	0.32 (0.08, 1.32)	-	-	0.57 (0.17, 1.93)
BESSt	1.36 (0.06, 29.93)			1.44 (0.49, 4.27)	-	-	3.33 (1.10, 10.12)	4.00 (1.28, 12.46)	2.83 (0.92, 8.73)
Haigis-L	3.30 (0.32, 30.30)	2.40 (0.18, 32.35)		-	-	1.87 (0.86, 4.06)	2.77 (0.87, 8.84)	1.96 (0.62, 6.19)	1.43 (0.48, 4.25)
HofferQ K	3.93 (0.26, 60.17)	2.89 (0.07, 114.80)	1.20 (0.06, 28.92)		0.14 (0.04, 0.56)	-	-	-	0.26 (0.08, 0.81)
HofferQ TNP	0.50 (0.03, 8.27)	0.37 (0.01, 16.64)	0.15 (0.01, 4.08)	0.13 (0.01, 2.49)		-	-	-	1.77 (0.39, 8.02)
Shammas-PL	4.89 (0.29, 73.62)	3.59 (0.25, 51.59)	1.49 (0.20, 10.83)	1.23 (0.04, 37.75)	9.68 (0.28, 348.20)		1.20 (0.37, 3.92)	0.85 (0.26, 2.75)	0.62 (0.20, 1.89)
SRKT A-P	5.77 (0.23, 130.60)	4.24 (0.24, 76.73)	1.76 (0.13, 23.75)	1.46 (0.04, 56.18)	11.34 (0.26, 561.10)	1.19 (0.08, 16.70)		0.71 (0.21, 2.35)	0.52 (0.16, 1.62)
SRKT C-P	4.00 (0.16, 91.84)	2.94 (0.16, 53.66)	1.22 (0.09, 16.85)	1.00 (0.02, 39.47)	7.88 (0.18, 378.80)	0.82 (0.05, 12.06)	0.69 (0.04, 12.78)		0.73 (0.23, 2.26)

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
SRKT TNP	1.72 (0.16, 16.54)	1.27 (0.08, 19.13)	0.52 (0.06, 4.77)	0.43 (0.03, 6.28)	3.37 (0.19, 61.78)	0.35 (0.03, 4.05)	0.30 (0.02, 4.49)	0.43 (0.03, 6.83)	

564



565

**Figure 80:** Myopic CRS No historical data methods: within 1.0D – relative effect of all options versus common comparator

566

**Table 135:** Myopic CRS No historical data methods: within 1.0D – rankings for each comparator


	Probability best	Median rank (95%CI)
SRKT K	0.008	7 (2, 9)
BESSt	0.022	7 (2, 9)
Haigis-L	0.053	4 (1, 8)
HofferQ K	0.233	4 (1, 8)
HofferQ TNP	0.010	9 (2, 9)

Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Shammas-PL	0.190	3 (1, 8)
SRKT A-P	0.303	2 (1, 8)
SRKT C-P	0.169	4 (1, 9)
SRKT TNP	0.012	6 (2, 9)

567



568 **Figure 81: Myopic CRS No historical data methods: within 1.0D – rank probability histograms**

569

570 **Table 136: Myopic CRS No historical data methods: within 1.0D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
14.54 (compared to 14 datapoints)	66.007	52.117	13.89	79.897	1.204 (95%CI: 0.298, 1.951)


**Table 137: Myopic CRS No historical data methods: within 1.0D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

572 H.3.3.4 Sensitivity analysis: historical data methods only

573

Mean absolute error – random effects model



574

Figure 82: Myopic CRS Historical data methods: mean absolute error – evidence network

575

576

**Table 138: Myopic CRS Historical data methods: mean absolute error – input data**

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Savini et al. (2010)	1.62 (1.25)				1.33 (1.03)	1.00 (0.57)	1.79 (1.13)	0.62 (0.52)	0.56 (0.45)	0.53 (0.46)	1.60 (0.98)	1.87 (1.44)	2.04 (1.48)	2.18 (1.52)	1.08 (0.86)	0.76 (0.49)	3.64 (1.45)	1.94 (1.01)
Fam & (2008)		0.75 (0.52)	0.75 (0.62)	1.32 (0.73)		0.76 (0.60)					0.93 (0.83)		0.80 (0.63)					

577  
578**Table 139: Myopic CRS Historical data methods: mean absolute error – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Clinical history	-	-	-	-0.29 (-0.89, 0.31)	-0.62 (-1.13, -0.11)	0.17 (-0.45, 0.79)	-1.00 (-1.50, -0.50)	-1.06 (-1.55, -0.57)	-1.09 (-1.58, -0.60)	-0.02 (-0.61, 0.57)	0.25 (-0.46, 0.96)	0.42 (-0.30, 1.14)	0.56 (-0.17, 1.29)	-0.54 (-1.10, 0.02)	-0.86 (-1.36, -0.36)	2.02 (1.31, 2.73)	0.32 (-0.28, 0.92)	
HofferQ DK	-0.07 (-2.66, 2.54)		0.00 (-0.26, 0.26)	0.57 (0.28, 0.86)	-	0.01 (-0.25, 0.27)	-	-	-	-	0.18 (-0.14, 0.50)	-	0.05 (-0.21, 0.31)	-	-	-	-	
Holladay2 DK	-0.08 (-2.63, 2.50)	0.00 (-2.16, 2.16)		0.57 (0.26, 0.88)	-	0.01 (-0.27, 0.29)	-	-	-	-	0.18 (-0.15, 0.51)	-	0.05 (-0.23, 0.33)	-	-	-	-	
SRKT Clinical history	0.50 (-2.04, 3.08)	0.57 (-1.59, 2.72)	0.57 (-1.63, 2.74)		-0.56 (-0.86, -0.26)	-	-	-	-	-	-0.39 (-0.75, -0.03)	-	-0.52 (-0.83, -0.21)	-	-	-	-	
SRKT Diehl	-0.30 (-2.52, 1.93)	-0.22 (-2.80, 2.29)	-0.22 (-2.77, 2.27)	-0.79 (-3.38, 1.74)		-0.33 (-0.77, 0.11)	0.46 (0.11, 1.03)	-0.71 (0.11, 1.03)	-0.77 (-1.14, -0.35)	-0.80 (-1.19, -0.38)	0.27 (-1.22, -0.26)	0.54 (0.12, 0.80)	0.71 (0.04, 1.38)	0.85 (0.17, 1.53)	-0.25 (-0.75, 0.25)	-0.57 (-0.99, 0.15)	2.31 (1.65, 2.97)	0.61 (0.08, 1.14)

Meta-analysis and network meta-analysis results

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rossa
SRKT DK	-0.35 (-2.38, 1.74)	-0.27 (-2.26, 1.69)	-0.27 (-2.22, 1.68)	-0.84 (-2.84, 1.14)	-0.05 (-2.08, 2.02)		0.79 (0.32, 1.26)	-0.38 (-0.67, -0.09)	-0.44 (-0.71, -0.17)	-0.47 (-0.74, 0.20)	0.60 (0.18, 1.02)	0.48 (-0.20, 1.16)	1.04 (0.45, 1.63)	0.58 (-0.54, 1.69)	0.08 (-0.30, 0.46)	-0.24 (-0.52, 0.04)	2.64 (2.06, 3.22)	0.94 (0.51, 1.37)
SRKT DK Awwad	0.16 (-2.08, 2.37)	0.24 (-2.40, 2.74)	0.24 (-2.29, 2.75)	-0.34 (-2.92, 2.19)	0.45 (-1.80, 2.68)	0.51 (-1.57, 2.47)		-1.17 (-1.63, 0.71)	-1.23 (-1.68, -0.78)	-1.26 (-1.71, 0.81)	-0.19 (-0.74, 0.36)	0.08 (-0.60, 0.76)	0.25 (-0.44, 0.94)	0.39 (-0.31, 1.09)	-0.71 (-1.24, 0.18)	-1.03 (-1.49, 0.57)	1.85 (1.17, 2.53)	0.15 (-0.41, 0.71)
SRKT DK Savini	-1.00 (-3.26, 1.18)	-0.93 (-3.48, 1.53)	-0.92 (-3.44, 1.56)	-1.50 (-4.07, 0.97)	-0.71 (-2.90, 1.49)	-0.66 (-2.70, 1.34)	-1.17 (-3.33, 1.05)		-0.06 (-0.31, 0.19)	-0.09 (-0.35, 0.17)	0.98 (0.57, 1.39)	1.25 (0.68, 1.82)	1.42 (0.84, 2.00)	1.56 (0.96, 2.16)	0.46 (0.09, 0.83)	0.14 (-0.12, 0.40)	3.02 (2.45, 3.59)	1.32 (0.90, 1.74)
SRKT DK Seitz/Speicher	-1.07 (-3.31, 1.13)	-0.99 (-3.57, 1.51)	-0.98 (-3.56, 1.47)	-1.57 (-4.14, 0.94)	-0.77 (-2.97, 1.44)	-0.72 (-2.79, 1.25)	-1.23 (-3.44, 0.99)	-0.06 (-2.27, 2.15)		-0.03 (-0.27, 0.21)	1.04 (0.64, 1.44)	1.31 (0.75, 1.87)	1.48 (0.91, 2.05)	1.62 (1.03, 2.21)	0.52 (0.16, 0.88)	0.20 (-0.05, 0.45)	3.08 (2.52, 3.64)	1.38 (0.97, 1.79)
SRKT DK Seitz/Speicher/Savini	-1.10 (-3.32, 1.12)	-1.02 (-3.59, 1.46)	-1.02 (-3.56, 1.49)	-1.59 (-4.16, 0.92)	-0.80 (-3.03, 1.41)	-0.75 (-2.77, 1.23)	-1.26 (-3.44, 0.96)	-0.09 (-2.29, 2.10)	-0.03 (-2.24, 2.19)		1.07 (0.67, 1.47)	1.34 (0.78, 1.90)	1.51 (0.94, 2.08)	1.65 (1.06, 2.24)	0.55 (0.19, 0.91)	0.23 (-0.02, 0.48)	3.11 (2.55, 3.67)	1.41 (1.00, 1.82)
SRKT DK Shammas	-0.03 (-2.26, 2.22)	0.05 (-2.57, 2.55)	0.05 (-2.51, 2.56)	-0.52 (-3.16, 2.01)	0.26 (-1.94, 2.45)	0.32 (-1.74, 2.33)	-0.19 (-2.44, 2.08)	0.97 (-1.25, 3.22)	1.04 (-1.18, 3.25)	1.07 (-1.14, 3.29)		0.27 (-0.38, 0.92)	0.44 (-0.22, 1.10)	0.58 (-0.09, 1.25)	-0.52 (-1.00, 0.04)	-0.84 (-1.25, 0.43)	2.04 (1.39, 2.69)	0.34 (-0.18, 0.86)
SRKT Feiz-Mannis	0.17 (-1.88, 2.25)	0.24 (-1.79, 2.24)	0.24 (-1.76, 2.21)	-0.34 (-2.37, 1.66)	0.46 (-1.57, 2.55)	0.51 (-1.02, 2.10)	0.00 (-2.01, 2.11)	1.17 (-0.81, 3.24)	1.24 (-0.77, 3.30)	1.26 (-0.74, 3.32)	0.20 (-1.81, 2.24)		0.17 (-0.59, 0.93)	-0.05 (-0.38, 0.27)	-0.79 (-1.41, 0.17)	-1.11 (-1.67, 0.55)	1.77 (1.01, 2.53)	0.07 (-0.58, 0.72)
SRKT Feiz-Mannis nomogram	0.41 (-1.85, 2.68)	0.49 (-2.16, 3.01)	0.49 (-2.12, 3.02)	-0.09 (-2.72, 2.46)	0.71 (-1.55, 2.93)	0.76 (-1.32, 2.78)	0.25 (-1.98, 2.51)	1.42 (-0.78, 3.64)	1.48 (-0.73, 3.72)	1.51 (-0.72, 3.77)	0.44 (-1.83, 2.73)	0.25 (-1.84, 2.31)		0.14 (-0.65, 0.93)	-0.96 (-1.59, 0.33)	-1.28 (-1.86, 0.70)	1.60 (0.83, 2.37)	-0.10 (-0.76, 0.56)
SRKT Ladas-Stark	0.20 (-1.77, 2.31)	0.27 (-1.70, 2.30)	0.28 (-1.63, 2.28)	-0.29 (-2.28, 1.73)	0.50 (-1.47, 2.59)	0.55 (-0.98, 2.12)	0.05 (-1.91, 2.15)	1.21 (-0.73, 3.30)	1.27 (-0.68, 3.41)	1.30 (-0.66, 3.42)	0.23 (-1.75, 2.35)	0.04 (-1.49, 1.65)	-0.20 (-2.23, 1.91)		-1.10 (-1.75, 0.45)	-1.42 (-2.01, 0.83)	1.46 (0.68, 2.24)	-0.24 (-0.92, 0.44)

Meta-analysis and network meta-analysis results

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Manis	SRKT Feiz-Manis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
SRKT Latkany	-0.55 (-2.77, 1.63)	-0.47 (-3.02, 2.01)	-0.47 (-3.02, 2.03)	-1.05 (-3.60, 1.46)	-0.25 (-2.47, 1.94)	-0.20 (-2.26, 1.80)	-0.70 (-2.92, 1.54)	0.46 (-1.71, 2.65)	0.53 (-1.67, 2.71)	0.56 (-1.62, 2.76)	-0.51 (-2.71, 1.69)	-0.71 (-2.74, 1.30)	-0.96 (-3.18, 1.25)	-0.75 (-2.82, 1.21)		-0.32 (-0.69, 0.05)	2.56 (1.94, 3.18)	0.86 (0.37, 1.35)
SRKT Masket	-0.87 (-3.06, 1.34)	-0.79 (-3.34, 1.71)	-0.78 (-3.36, 1.71)	-1.36 (-3.93, 1.13)	-0.57 (-2.78, 1.61)	-0.52 (-2.56, 1.44)	-1.03 (-3.22, 1.20)	0.14 (-2.03, 2.29)	0.20 (-1.97, 2.40)	0.23 (-1.95, 2.43)	-0.84 (-3.03, 1.33)	-1.03 (-3.08, 0.94)	-1.28 (-3.52, 0.97)	-1.07 (-3.15, 0.87)	-0.32 (-2.50, 1.83)		2.88 (2.31, 3.45)	1.18 (0.76, 1.60)
SRKT SK Ferrara	2.01 (-0.24, 4.26)	2.08 (-0.53, 4.62)	2.09 (-0.49, 4.66)	1.52 (-1.09, 4.09)	2.31 (0.09, 4.55)	2.36 (0.29, 4.42)	1.86 (-0.36, 4.13)	3.02 (0.85, 5.24)	3.08 (0.88, 5.31)	3.11 (0.92, 5.36)	2.04 (-0.20, 4.28)	1.85 (-0.26, 3.93)	1.61 (-0.66, 3.86)	1.80 (-0.33, 3.83)	2.55 (0.35, 4.80)	2.87 (0.71, 5.11)		-1.70 (- 2.35, - 1.05)
SRKT SK Rosa	0.31 (-1.94, 2.54)	0.39 (-2.21, 2.92)	0.39 (-2.20, 2.89)	-0.18 (-2.73, 2.34)	0.61 (-1.56, 2.83)	0.66 (-1.41, 2.69)	0.15 (-2.02, 2.38)	1.32 (-0.86, 3.51)	1.39 (-0.81, 3.56)	1.41 (-0.79, 3.63)	0.35 (-1.84, 2.57)	0.16 (-1.92, 2.17)	-0.10 (-2.35, 2.14)	0.12 (-2.00, 2.07)	0.86 (-1.34, 3.06)	1.18 (-1.01, 3.40)	-1.69 (-3.96, 0.53)	





Figure 83: Myopic CRS Historical data methods: mean absolute error – relative effect of all options versus common comparator

582

**Table 140: Myopic CRS Historical data methods: mean absolute error – rankings for each comparator**

	Probability best	Median rank (95%CI)
Clinical history	0.013	11 (2, 17)
HofferQ DK	0.027	10 (1, 17)
Holladay2 DK	0.027	10 (1, 17)
SRKT Clinical history	0.008	15 (3, 18)
SRKT Diehl	0.027	8 (1, 17)
SRKT DK	0.011	7 (2, 15)
SRKT DK Awwad	0.007	12 (3, 17)
SRKT DK Savini	0.191	3 (1, 14)
SRKT DK Seitz/Speicher	0.231	3 (1, 13)
SRKT DK Seitz/Speicher/Savini	0.257	3 (1, 13)
SRKT DK Shammas	0.013	10 (2, 17)
SRKT Feiz-Mannis	0.002	12 (4, 17)
SRKT Feiz-Mannis nomogram	0.005	14 (4, 18)
SRKT Ladas-Stark	0.001	12 (5, 17)
SRKT Latkany	0.050	6 (1, 16)
SRKT Masket	0.125	4 (1, 14)
SRKT SK Ferrara	0.000	18 (12, 18)
SRKT SK Rosa	0.005	13 (3, 17)

583



**Figure 84: Myopic CRS Historical data methods: mean absolute error – rank probability histograms**

585

586

**Table 141: Myopic CRS Historical data methods: mean absolute error – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
21.08 (compared to 21 datapoints)	-20.673	-41.582	20.909	0.237	0.816 (95%CI: 0.246, 1.896)


587

**Table 142: Myopic CRS Historical data methods: mean absolute error – notes**

- Continuous (normal; identity link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

588

**Proportion within 0.5D – fixed effects model**



589

**Figure 85: Myopic CRS Historical data methods: within 0.5D – evidence network**

590

591

**Table 143: Myopic CRS Historical data methods: within 0.5D – input data**


	<b>SRKT Clinical history</b>	<b>Double-K</b>	<b>Feiz-Mannis</b>	<b>HofferQ DK</b>	<b>Holladay2 DK</b>	<b>Masket</b>	<b>Modified Masket</b>	<b>SRKT DK</b>	<b>SRKT Feiz-Mannis</b>	<b>SRKT Ladas-Stark</b>
Saiki et al. (2013)		4/12	1/12			4/12	5/12	5/28		
Fam & (2008)	5/37			13/37	17/37			19/37	15/37	17/37

592  
593**Table 144: Myopic CRS Historical data methods: within 0.5D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT Clinical history</b>	<b>Double-K</b>	<b>Feiz-Mannis</b>	<b>HofferQ DK</b>	<b>Holladay2 DK</b>	<b>Masket</b>	<b>Modified Masket</b>	<b>SRKT DK</b>	<b>SRKT Feiz-Mannis</b>	<b>SRKT Ladas-Stark</b>
SRKT Clinical history		-	-	3.47 (1.09, 11.05)	5.44 (1.73, 17.06)	-	-	6.76 (2.16, 21.16)	4.36 (1.38, 13.76)	5.44 (1.73, 17.06)
Double-K	17.01 (2.37, 129.10)		0.18 (0.02, 1.95)	-	-	1.00 (0.18, 5.46)	1.43 (0.27, 7.52)	0.43 (0.09, 2.03)	-	-
Feiz-Mannis	2.25 (0.06, 27.09)	0.14 (0.00, 1.31)		-	-	5.50 (0.51, 59.01)	7.86 (0.75, 82.13)	2.39 (0.25, 23.01)	-	-
HofferQ DK	3.64 (1.18, 13.11)	0.22 (0.03, 1.40)	1.63 (0.15, 54.84)		1.57 (0.62, 4.00)	-	-	1.95 (0.77, 4.96)	1.26 (0.49, 3.23)	1.57 (0.62, 4.00)
Holladay2 DK	5.79 (1.90, 20.76)	0.35 (0.05, 2.21)	2.59 (0.24, 86.40)	1.59 (0.62, 4.16)		-	-	1.24 (0.50, 3.09)	0.80 (0.32, 2.02)	1.00 (0.40, 2.50)
Masket	17.16 (2.30, 133.70)	1.01 (0.17, 5.95)	7.55 (0.74, 251.90)	4.69 (0.70, 31.09)	2.93 (0.43, 19.25)		1.43 (0.27, 7.52)	0.43 (0.09, 2.03)	-	-
Modified Masket	24.98 (3.69, 185.20)	1.47 (0.27, 8.50)	11.05 (1.18, 359.00)	6.82 (1.10, 44.26)	4.31 (0.70, 27.60)	1.47 (0.26, 8.61)		0.30 (0.07, 1.37)	-	-
SRKT DK	7.18 (2.39, 25.50)	0.43 (0.09, 2.14)	3.19 (0.38, 96.87)	1.97 (0.78, 5.25)	1.24 (0.50, 3.19)	0.43 (0.09, 2.21)	0.29 (0.06, 1.39)		0.65 (0.26, 1.62)	0.81 (0.32, 2.01)
SRKT Feiz-Mannis	4.61 (1.50, 16.22)	0.28 (0.04, 1.75)	2.04 (0.19, 70.47)	1.26 (0.49, 3.31)	0.80 (0.31, 2.03)	0.27 (0.04, 1.80)	0.18 (0.03, 1.16)	0.64 (0.25, 1.62)		1.25 (0.50, 3.13)

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Ladas-Stark	5.77 (1.90, 20.17)	0.35 (0.05, 2.18)	2.59 (0.24, 86.28)	1.59 (0.62, 4.11)	1.00 (0.40, 2.51)	0.34 (0.05, 2.27)	0.23 (0.04, 1.45)	0.80 (0.32, 2.02)	1.25 (0.50, 3.17)	

594



595

**Figure 86:** Myopic CRS Historical data methods: within 0.5D – relative effect of all options versus common comparator

596

**Table 145:** Myopic CRS Historical data methods: within 0.5D – rankings for each comparator


	Probability best	Median rank (95%CI)
SRKT Clinical history	0.000	10 (9, 10)
Double-K	0.230	2 (1, 8)
Feiz-Mannis	0.003	9 (3, 10)
HofferQ DK	0.001	8 (4, 9)

## Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2 DK	0.011	6 (2, 9)
Masket	0.234	2 (1, 8)
Modified Masket	0.503	1 (1, 6)
SRKT DK	0.005	4 (2, 8)
SRKT Feiz-Mannis	0.003	7 (3, 9)
SRKT Ladas-Stark	0.010	6 (2, 9)

597



598

**Figure 87: Myopic CRS Historical data methods: within 0.5D – rank probability histograms**

599

600

**Table 146: Myopic CRS Historical data methods: within 0.5D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
11.44 (compared to 11 datapoints)	48.9	37.768	11.132	60.032	

**Table 147: Myopic CRS Historical data methods: within 0.5D – notes**

- |  |
|--|
| <ul style="list-style-type: none"><li>• Dichotomous synchronic (binomial; logit link); fixed effects</li><li>• 50000 burn-ins; 10000 recorded iterations (thinned from 500000)</li></ul> |
|--|

602

Proportion within 1.0 – fixed effects model




Figure 88: Myopic CRS Historical data methods: within 1.0D – evidence network

603

604

605

**Table 148: Myopic CRS Historical data methods: within 1.0D – input data**

	<b>SRKT Clinical history</b>	<b>Double-K</b>	<b>Feiz-Mannis</b>	<b>HofferQ DK</b>	<b>Holladay2 DK</b>	<b>Masket</b>	<b>Modified Masket</b>	<b>SRKT DK</b>	<b>SRKT Feiz-Mannis</b>	<b>SRKT Ladas-Stark</b>
Saiki et al. (2013)		8/12	6/12			10/12	9/12	14/28		
Fam & (2008)	11/37			28/37	30/37			25/37	23/37	23/37

606


607

**Table 149: Myopic CRS Historical data methods: within 1.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	<b>SRKT Clinical history</b>	<b>Double-K</b>	<b>Feiz-Mannis</b>	<b>HofferQ DK</b>	<b>Holladay2 DK</b>	<b>Masket</b>	<b>Modified Masket</b>	<b>SRKT DK</b>	<b>SRKT Feiz-Mannis</b>	<b>SRKT Ladas-Stark</b>
SRKT Clinical history		-	-	7.35 (2.63, 20.60)	10.13 (3.43, 29.93)	-	-	4.92 (1.84, 13.19)	3.88 (1.47, 10.23)	3.88 (1.47, 10.23)
Double-K	10.80 (1.92, 69.43)		0.50 (0.10, 2.60)	-	-	2.50 (0.36, 17.32)	1.50 (0.25, 8.84)	0.50 (0.12, 2.05)	-	-
Feiz-Mannis	5.20 (0.93, 28.97)	0.48 (0.08, 2.57)		-	-	5.00 (0.75, 33.21)	3.00 (0.53, 16.90)	1.00 (0.26, 3.87)	-	-
HofferQ DK	7.76 (2.82, 23.22)	0.72 (0.11, 4.27)	1.51 (0.27, 8.84)		1.38 (0.45, 4.20)	-	-	0.67 (0.24, 1.85)	0.53 (0.19, 1.44)	0.53 (0.19, 1.44)
Holladay2 DK	10.94 (3.78, 34.76)	1.02 (0.15, 6.16)	2.14 (0.36, 12.56)	1.41 (0.45, 4.37)		-	-	0.49 (0.17, 1.42)	0.38 (0.13, 1.10)	0.38 (0.13, 1.10)
Masket	30.55 (4.54, 309.80)	2.80 (0.40, 27.85)	5.91 (0.92, 57.06)	3.89 (0.56, 40.10)	2.77 (0.38, 29.29)		0.60 (0.08, 4.45)	0.20 (0.04, 1.08)	-	-
Modified Masket	16.88 (2.84, 124.70)	1.56 (0.25, 11.03)	3.27 (0.58, 22.60)	2.19 (0.34, 15.67)	1.55 (0.24, 11.70)	0.55 (0.06, 4.51)		0.33 (0.07, 1.50)	-	-
SRKT DK	5.12 (1.93, 14.38)	0.48 (0.10, 1.98)	1.00 (0.25, 4.05)	0.66 (0.23, 1.83)	0.47 (0.15, 1.37)	0.17 (0.02, 0.86)	0.31 (0.05, 1.31)		0.79 (0.30, 2.05)	0.79 (0.30, 2.05)
SRKT Feiz-Mannis	4.02 (1.53, 11.17)	0.37 (0.06, 2.07)	0.78 (0.14, 4.30)	0.52 (0.18, 1.41)	0.37 (0.12, 1.05)	0.13 (0.01, 0.89)	0.24 (0.03, 1.38)	0.79 (0.30, 2.05)		1.00 (0.39, 2.56)

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Ladas-Stark	4.02 (1.54, 11.05)	0.38 (0.06, 2.06)	0.78 (0.14, 4.32)	0.52 (0.18, 1.42)	0.37 (0.12, 1.04)	0.13 (0.01, 0.89)	0.24 (0.03, 1.39)	0.78 (0.29, 2.08)	1.00 (0.39, 2.58)	

608



609

**Figure 89:** Myopic CRS Historical data methods: within 1.0D – relative effect of all options versus common comparator

610

**Table 150:** Myopic CRS Historical data methods: within 1.0D – rankings for each comparator


	Probability best	Median rank (95%CI)
SRKT Clinical history	0.000	10 (9, 10)
Double-K	0.076	4 (1, 9)
Feiz-Mannis	0.007	7 (2, 10)
HofferQ DK	0.021	5 (2, 8)

## Meta-analysis and network meta-analysis results

---

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2 DK	0.078	4 (1, 7)
Masket	0.592	1 (1, 5)
Modified Masket	0.225	2 (1, 8)
SRKT DK	0.000	7 (4, 9)
SRKT Feiz-Mannis	0.000	8 (4, 9)
SRKT Ladas-Stark	0.000	8 (4, 9)

611



**Figure 90: Myopic CRS Historical data methods: within 1.0D – rank probability histograms**

612

613

614

**Table 151: Myopic CRS Historical data methods: within 1.0D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
11.31 (compared to 11 datapoints)	49.357	38.204	11.152	60.509	

615


**Table 152: Myopic CRS Historical data methods: within 1.0D – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

616

617

**Proportion within 2.0 – fixed effects model**



618

**Figure 91:** Myopic CRS Historical data methods: within 2.0D – evidence network

619

**Table 153:** Myopic CRS Historical data methods: within 2.0D – input data


	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
Fam & (2008)	33/37	35/37	34/37	35/37	32/37	35/37

620

621  
622**Table 154: Myopic CRS Historical data methods: within 2.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Clinical history	2.12 (0.36, 12.36)	1.37 (0.29, 6.61)	2.12 (0.36, 12.36)	0.78 (0.19, 3.15)	2.12 (0.36, 12.36)	
HofferQ DK	2.32 (0.39, 19.84)		0.65 (0.10, 4.12)	1.00 (0.13, 7.50)	0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
Holladay2 DK	1.42 (0.27, 8.24)	0.61 (0.07, 4.32)		1.54 (0.24, 9.82)	0.56 (0.12, 2.56)	1.54 (0.24, 9.82)
SRKT DK	2.33 (0.39, 19.87)	1.00 (0.10, 9.99)	1.63 (0.23, 15.74)		0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
SRKT Feiz-Mannis	0.76 (0.17, 3.29)	0.33 (0.04, 1.74)	0.53 (0.10, 2.50)	0.33 (0.04, 1.81)		2.73 (0.50, 15.09)
SRKT Ladas-Stark	2.30 (0.39, 19.99)	0.99 (0.10, 9.99)	1.62 (0.23, 14.79)	0.99 (0.10, 10.03)	3.02 (0.56, 26.29)	

623



624

**Figure 92: Myopic CRS Historical data methods: within 2.0D – relative effect of all options versus common comparator**


625

626

**Table 155: Myopic CRS Historical data methods: within 2.0D – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.029	5 (1, 6)
HofferQ DK	0.292	2 (1, 6)
Holladay2 DK	0.093	4 (1, 6)
SRKT DK	0.294	2 (1, 6)
SRKT Feiz-Mannis	0.008	6 (2, 6)
SRKT Ladas-Stark	0.284	2 (1, 6)

627



628 **Figure 93: Myopic CRS Historical data methods: within 2.0D – rank probability histograms**

629

630

**Table 156: Myopic CRS Historical data methods: within 2.0D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
6.394 (compared to 6 datapoints)	23.465	17.567	5.898	29.364	

631

**Table 157: Myopic CRS Historical data methods: within 2.0D – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

## 632 H.3.4 Intraocular lens constant optimisation – Network meta-analysis results

## 633 H.3.4.1 Model fit statistics for all outcomes

634

**Table 158: Model fit statistics used to select fixed or random effect models for all comparisons and outcomes**

<b>Studies</b>	<b>Outcome</b>	<b>Model</b>	<b>Total model DIC</b>	<b>Total model DIC (FE – RE)</b>	<b>Total residual deviance</b>	<b>No. of data-points</b>	<b>Between-study SD (95% CrI)</b>	<b>Preferred model</b>
4 (Charalampidou, Day, Lee, Sharma)	Mean absolute error	FE	-21.74	2.116	17.87	14	-	FE
		RE	-23.856		13.56		0.216 (0.028, 1.093)	
3 (Aristodemou, Day, Eom)	Within 0.25D	FE	537.2	426.3	446.4	16	-	RE
		RE	110.9		15.3		1.05 (0.59, 1.87)	
6 (Aristodemou, Charalampidou, Day, Eom, Fam, Lee)	Within 0.5D	FE	254.756	112.652	137.4	20	-	RE
		RE	142.104		19.72		0.900 (0.473, 1.776)	
7 (Aristodemou, Charalampidou, Day, Eom, Fam, Lee, Sharma)	Within 1.0D	FE	204.06	54.239	80.73	24	-	RE
		RE	149.821		22.77		0.611 (0.284, 1.489)	
<b>1 (Lee – pairwise comparison)</b>	Within 1.5D	FE	-	-	-	-	-	FE

635 H.3.4.2 Full dataset

636

**MEAN ABSOLUTE ERROR – random effects model**



637

**Figure 94: Mean absolute error (RE) – evidence network**

638

639

**Table 159: Mean absolute error (RE) – input data**

	<b>StandardOLC</b>	<b>OptimisedLenstar</b>	<b>Pezero</b>	<b>ULIB</b>	<b>ULIBpersonalised</b>
Sharma et al. (2014)	0.56 (0.40)			0.49 (0.50)	
Day et al. (2012)	0.47 (0.39)		0.46 (0.39)		
Day et al. (2012)	0.84 (0.53)		0.50 (0.37)		
Day et al. (2012)	0.89 (0.80)		0.74 (0.58)		
Day et al. (2012)	0.88 (0.53)		0.83 (0.61)		
Charalampidou et al. (2010)				0.38 (0.31)	0.36 (0.30)
Lee et al. (2015)	0.67 (0.52)	0.55 (0.49)			

640


641

**Table 160: Mean absolute error (RE) – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	<b>StandardOLC</b>	<b>OptimisedLenstar</b>	<b>Pezero</b>	<b>ULIB</b>	<b>ULIBpersonalised</b>
StandardOLC		-0.12 (-0.26, 0.02)	-0.13 (-0.33, 0.06)	-0.07 (-0.25, 0.11)	-
OptimisedLenstar	-0.12 (-0.26, 0.02)		-	-	-
Pezero	-0.08 (-0.17, 0.02)	0.05 (-0.12, 0.21)		-	-

	StandardIOLC	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
ULIB	-0.07 (-0.25, 0.10)	0.05 (-0.17, 0.27)	0.01 (-0.19, 0.20)		-0.02 (-0.08, 0.04)
ULIBpersonalised	-0.09 (-0.27, 0.09)	0.03 (-0.20, 0.26)	-0.01 (-0.22, 0.19)	-0.02 (-0.08, 0.04)	

642



643

**Figure 95:** Mean absolute error (RE) – relative effect of all options versus common comparator


644

645

**Table 161:** Mean absolute error (RE) – rankings for each comparator

	Probability best	Median rank (95%CI)
StandardIOLC	0.001	5 (3, 5)
OptimisedLenstar	0.494	2 (1, 5)
Pezero	0.167	3 (1, 5)
ULIB	0.063	3 (1, 5)
ULIBpersonalised	0.275	2 (1, 5)

646



647 **Figure 96:** Mean absolute error (RE) – rank probability histograms

648

649

**Table 162:** Mean absolute error (RE) – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
17.87 (compared to 14 datapoints)	-32.725	-43.709	10.948	-21.740

650

651

**Table 163: Mean absolute error (FE) – notes**

- Continuous (normal; identity link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

652

653

**PROPORTION WITHIN 0.25 DIOPTRES – random effects model**



654

**Figure 97: Within 0.25 dioptres (RE) – evidence network**

655

656

**Table 164:** Within 0.25 dioptres (RE) – input data


	StandardOLC	OptimisedK	Pezero
Eom et al. (2013)	34/123	38/123	
Eom et al. (2013)	49/114	62/114	
Day et al. (2012)	4/32		10/32
Day et al. (2012)	33/100		39/100
Day et al. (2012)	2/19		3/19
Day et al. (2012)	2/12		4/12
Aristodemou et al. (2011)	1170/6159		2525/6159
Aristodemou et al. (2011)	585/1949		1735/1949

657

**Table 165:** Within 0.25 dioptres (RE) – relative effectiveness of all pairwise combinations (RR and 95% credible interval)

	StandardOLC	OptimisedK	Pezero
StandardOLC		1.37 (0.94, 2.00)	<b>3.36</b> <b>(1.11, 10.14)</b>
OptimisedK	1.37 (0.25, 7.44)		-
Pezero	<b>3.66</b> <b>(1.21, 10.00)</b>	2.66 (0.35, 19.12)	

658



659 **Figure 98:** Within 0.25 dioptres (RE) – relative effect of all options versus common comparator


660

661

**Table 166:** Within 0.25 dioptres (RE) – rankings for each comparator

	Probability best	Median rank (95%CI)
StandardIOLC	0.005	3 (2, 3)
OptimisedK	0.147	2 (1, 3)
Pezero	0.848	1 (1, 2)

662



663 **Figure 99:** Within 0.25 dioptres (RE) – rank probability histograms

664

665

**Table 167: Within 0.25 dioptres (RE) – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
15.33 (compared to 16 datapoints)	96.113	81.324	14.789	110.903	1.049 (95%CI: 0.585, 1.870)


666

**Table 168: Within 0.25 dioptres (RE) – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

667

**PROPORTION WITHIN 0.5 DIOPTRES – random effects model**



668

**Figure 100: Within 0.5 dioptres (RE) – evidence network**

669

670

**Table 169: Within 0.5 dioptres (RE) – input data**

	<b>StandardOLC</b>	<b>OptimisedK</b>	<b>OptimisedKAL</b>	<b>OptimisedLensstar</b>	<b>Pezero</b>
Eom et al. (2013)	68/123	78/123			
Eom et al. (2013)	84/114	90/114			
Day et al. (2012)	10/32				18/32
Day et al. (2012)	62/100				60/100
Day et al. (2012)	8/19				9/19
Day et al. (2012)	4/12				4/12
Aristodemou et al. (2011)	2587/6159				4373/6159
Aristodemou et al. (2011)	1111/1949				1793/1949
Fam & (2009)	43/90		57/90		
Lee et al. (2015)	46/100			62/100	

671


672

673

**Table 170: Within 0.5 dioptres (RE) – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	StandardOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero
StandardOLC		1.38 (0.93, 2.04)	1.89 (1.04, 3.43)	1.92 (1.09, 3.37)	2.51 (1.31, 4.81)
OptimisedK	1.37 (0.31, 6.35)		-	-	-
OptimisedKAL	1.91 (0.21, 16.86)	1.38 (0.10, 18.75)		-	-
OptimisedLenstar	1.92 (0.22, 16.46)	1.40 (0.10, 19.34)	1.01 (0.05, 21.58)		-
Pezero	2.49 (0.92, 5.88)	1.81 (0.28, 9.91)	1.30 (0.12, 13.16)	1.30 (0.12, 12.99)	

674



675

**Figure 101: Within 0.5 dioptres (RE) – relative effect of all options versus common comparator**


676

677

**Table 171: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – rankings for each comparator**

	Probability best	Median rank (95%CI)
StandardOLC	0.001	4 (2, 5)
OptimisedK	0.103	3 (1, 5)
OptimisedKAL	0.282	3 (1, 5)
OptimisedLenstar	0.282	3 (1, 5)
Pezero	0.332	2 (1, 4)

678



679

**Figure 102: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – rank probability histograms**

680

681

**Table 172: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
19.72 (compared to 20 datapoints)	123.021	103.938	19.083	142.104	0.900 (95%CI: 0.473, 1.776)

682

683

**Table 173: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – notes**


- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations

684

685

#### PROPORTION WITHIN 1.0 DIOPTRE – random effects model

686



687

Figure 103: Within 1.0 dioptre (RE) – evidence network

688

**Table 174: Within 1.0 dioptre (RE) – input data**

	<b>StandardOLC</b>	<b>OptimisedK</b>	<b>OptimisedKAL</b>	<b>OptimisedLenst ar</b>	<b>Pezero</b>	<b>ULIB</b>	<b>ULIBpersonalis ed</b>
Sharma et al. (2014)	44/51					44/51	
Eom et al. (2013)	106/123	111/123					
Eom et al. (2013)	110/114	111/114					
Day et al. (2012)	23/32				28/32		
Day et al. (2012)	91/100				92/100		
Day et al. (2012)	12/19				14/19		
Day et al. (2012)	6/12				6/12		
Aristodemou et al. (2011)	4989/6159				5851/6159		
Aristodemou et al. (2011)	1735/1949				1813/1949		
Charalampidou et al. (2010)						205/214	205/214
Fam & (2009)	69/90		81/90				
Lee et al. (2015)	76/100			82/100			


689

690

**Table 175: Within 1.0 dioptre (RE) – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	StandardOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
StandardOLC		1.45 (0.72, 2.92)	2.74 (1.18, 6.37)	1.44 (0.72, 2.86)	2.01 (1.03, 3.91)	1.00 (0.32, 3.09)	-
OptimisedK	1.45 (0.38, 5.49)		-	-	-	-	-
OptimisedKAL	2.86 (0.50, 16.69)	1.96 (0.22, 18.33)		-	-	-	-
OptimisedLenstar	1.45 (0.28, 7.79)	1.01 (0.12, 8.56)	0.51 (0.04, 5.71)		-	-	-
Pezero	2.12 (0.97, 4.17)	1.46 (0.30, 6.42)	0.74 (0.11, 4.55)	1.47 (0.22, 8.37)		-	-
ULIB	1.02 (0.15, 7.02)	0.69 (0.07, 7.62)	0.36 (0.03, 4.93)	0.70 (0.06, 9.19)	0.48 (0.06, 4.03)		1.00 (0.39, 2.57)
ULIBpersonalised	1.03 (0.07, 15.11)	0.71 (0.04, 15.08)	0.37 (0.01, 8.83)	0.72 (0.03, 17.42)	0.49 (0.03, 8.03)	1.02 (0.17, 6.18)	

691



**Figure 104:** Within 1.0 dioptre (RE) – relative effect of all options versus common comparator


693

694

**Table 176:** Within 1.0 dioptre (RE) – rankings for each comparator

	Probability best	Median rank (95%CI)
StandardIOLC	0.000	5 (3, 7)
OptimisedK	0.089	4 (1, 7)
OptimisedKAL	0.452	2 (1, 7)
OptimisedLenstar	0.121	4 (1, 7)
Pezero	0.155	3 (1, 6)
ULIB	0.046	5 (1, 7)
ULIBpersonalised	0.137	5 (1, 7)

695



**Figure 105:** Within 1.0 dioptre (RE) – rank probability histograms

697

698

**Table 177: Within 1.0 dioptre (RE) – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
22.77 (compared to 24 datapoints)	128.075	106.33	21.746	149.821	0.611 (95%CI: 0.284, 1.489)

699


700

**Table 178: Within 1.0 dioptre (RE) – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations

701


702

**PROPORTION WITHIN 1.5D – pairwise comparison**

703

704 H.3.4.3 Wang 2011 (people with axial lengths >25mm): unconnected to networks


705 Prediction error



706

707 Proportion of eyes with a hyperopic refractive outcome

708




709

## 710 H.3.5 Other considerations in biometry: Forest plots of outcomes

### 711 H.3.5.1 Second eye prediction refinement


#### 712 50% adjusted of first eye prediction error vs unadjusted prediction

#### 713 Mean absolute prediction errors




714

#### 715 Cumulative proportion of eyes within various ranges of absolute prediction errors



716


#### 717 Mean prediction errors



718


719 H.3.5.2 Comparison of results from using 100% adjusted and 50% adjusted first eye prediction error

721 Mean absolute prediction errors




722

723 Cumulative proportion of eyes within various ranges of absolute prediction errors



724

725


**Mean prediction errors**726  
727

- 728 **H.4 Intraocular lens selection**
- 729 • Are different lens design (aspheric vs. spheric, plate vs. loop) effective in improving  
730 postoperative vision (refractive outcomes, optical aberrations) in cataract surgery?
- 731 • Are different lens design (square-edged vs. round-edge, plate vs. loop) and material  
732 (hydrophilic acrylic, hydrophobic acrylic, collagen, hydroxyethyl methacrylate-based vs.  
733 silicone-based) effective in preventing posterior capsule opacification in cataract surgery?
- 734 • Are tinted lenses effective in preventing the progression of age-related macular  
735 degeneration compared with colourless lenses in cataract surgery?
- 736 • What is the optimal strategy to facilitate simultaneous distance and near vision following  
737 cataract surgery?
- 738 • What is the optimal strategy to address pre-existing astigmatism in people undergoing  
739 cataract surgery?

740 **H.4.1 Lens design**


741 **H.4.1.1 PMMA versus silicone**

742 **PCO score**



743


744 **Nd:YAG capsulotomy rate**



745

746 H.4.1.2 PMMA versus hydrophobic acrylic


747 PCO score



748

749

Nd:YAG capsulotomy rate




750

751 H.4.1.3 Hydrophobic acrylic versus silicone

752


BCDVA (decimal acuity)



753


754

PCO score




755

756

**Nd:YAG capsulotomy rate**



757

758

**Lens decentration (mm)**


759


760

**Lens tilt (degrees)**


761


**762 H.4.1.4 Hydrophobic acrylic versus hydrophilic acrylic**

763

**BCDVA (logMAR)**



764

765

**BCDVA (decimal acuity)**



766

767

**PCO score**


768


769

**Nd:YAG capsulotomy rate**


770

**771 H.4.1.5 Network meta-analyses (lens material)**

772

**PCO score (hydrophobic acrylic as reference category)**


773



797

**PCO score (without hydrophilic acrylic - hydrophobic acrylic as reference category)**

798

799

**Pairwise mean differences from NMA**

	Silicone	Hydrophobic acrylic	PMMA
Silicone	N/A		
Hydrophobic acrylic	0.15 (-0.24, 0.55)	N/A	
PMMA	3.10 (2.42, 3.78)	2.95 (2.27, 3.62)	N/A


800

Quantifying heterogeneity/inconsistency:

801

 $\tau^2 = 0.1441$ ;  $I^2 = 91.7\%$ 

802

**Network graph**

803

**Comparison of direct and indirect evidence**

804

Random effects model:

805

806

	comparison	prop	nma	direct	indir.	Diff	z	p-value
Hydrophobic acrylic:PMMA	0.83	2.9449	3.1022	2.1545	0.9477	1.03	0.3040	
Hydrophobic acrylic:Silicone	1.00	-0.1549	-0.1978	12.4062	-12.6040	-3.63	0.0003	
PMMA:Silicone	0.82	-3.0998	-2.8300	-4.3079	1.4780	1.66	0.0976	

807

808

809

810

811

812

813

814

815

816

Legend:

comparison - Treatment comparison

prop - Direct evidence proportion

nma - Estimated treatment effect (MD) in network meta-analysis


direct - Estimated treatment effect (MD) derived from direct evidence

indir. - Estimated treatment effect (MD) derived from indirect evidence

Diff - Difference between direct and indirect treatment estimates

817 z - z-value of test for disagreement (direct versus indirect)  
 818 p-value - p-value of test for disagreement (direct versus indirect)

819 **Nd:YAG capsulotomy rate (hydrophobic acrylic as reference category)**



820


821 **Pairwise relative risks from NMA**

	Silicone	Hydrophobic acrylic	PMMA	Hydrophilic acrylic
Silicone	N/A			
Hydrophobic acrylic	0.90 (0.43, 1.87)	N/A		
PMMA	3.15 (1.51, 6.58)	3.50 (1.64, 7.48)	N/A	
Hydrophilic acrylic	3.29 (1.20, 8.97)	3.65 (1.63, 8.17)	1.04 (0.41, 2.65)	N/A

822 Quantifying heterogeneity/inconsistency:

823  $\tau^2 = 0.4919$ ;  $I^2 = 52.3\%$

824 **Network graph**



825

826 **Comparison of direct and indirect evidence**


827 Random effects model:

	comparison	prop	nma	direct	indir.	RoR	z	p-value
829	Hydrophilic acrylic:Hydrophobic acrylic	0.76	0.2746	0.2216	0.5327	0.4160	-0.92	0.3587
830	Hydrophilic acrylic:PMMA	0.45	0.9558	1.5472	0.6437	2.4035	0.92	0.3587
831	Hydrophilic acrylic:Silicone	0.00	0.3030		0.3030	.	.	.
832	Hydrophobic acrylic:PMMA	0.49	3.4810	7.1831	1.7205	4.1749	1.85	0.0647
833	Hydrophobic acrylic:Silicone	0.77	1.1034	0.7331	4.4474	0.1648	-2.03	0.0425
834	PMMA:Silicone	0.73	0.3170	0.5413	0.0754	7.1818	2.34	0.0194

835 Legend:  
 836 comparison - Treatment comparison  
 837 prop - Direct evidence proportion  
 838 nma - Estimated treatment effect (RR) in network meta-analysis  
 839 direct - Estimated treatment effect (RR) derived from direct evidence  
 840 indir. - Estimated treatment effect (RR) derived from indirect evidence  
 841 RoR - Ratio of Ratios (direct versus indirect)  
 842 z - z-value of test for disagreement (direct versus indirect)  
 843 p-value - p-value of test for disagreement (direct versus indirect)


#### 844 H.4.1.6 Square-edge versus round-edge

##### 845 BCDVA (decimal acuity)




846

##### 847 PCO score



848


849

**Nd:YAG capsulotomy rate**

850


**851 H.4.1.7 Loop versus 3-piece**

852

**UCDVA (logMAR)**


853

854

**BCDVA (logMAR)**


855

856

**BCDVA (decimal acuity)**


857

858

**PCO score**



859

860

**Nd:YAG capsulotomy rate**



861

862

**Lens decentration (mm)**


863


864

**Lens tilt (degrees)**


865


866 H.4.1.8 Aspheric versus spheric

867 UCDVA (logMAR)




868

869 BCDVA (logMAR)




870

871 BCDVA (decimal acuity)




872

873 Contrast sensitivity (Pelli-Robson test)




874

875

**Spherical aberrations**


876

877

**Higher-order aberrations**


878

879

**Comatic aberrations**

880

881

**PCO score**


882

883

884 H.4.2 Multifocal vs monofocal intraocular lenses

885 H.4.2.1 Multifocal versus monofocal

886 Uncorrected distance visual acuity worse than 6/6




Footnotes

- (1) 2 to 4 months, study eye
- (2) 3 to 6 months, study eye
- (3) 4 to 6 months, study eye
- (4) 12 months, study eye
- (5) 5 months, study eye
- (6) 3 month, binocular
- (7) 1 month, by eye (35 people in multifocal and 40 people in monofocal group, not adjusted for within-person correlation)
- (8) 6 weeks, binocular

887

888 Corrected distance visual acuity worse than 6/6




Footnotes

- (1) 2 to 4 months, study eye
- (2) 3 to 6 months, study eye
- (3) 4 to 6 months, study eye
- (4) 12 months, study eye
- (5) 5 months, study eye
- (6) 3 months, unclear whether eyes/people reported
- (7) 3 months, binocular
- (8) 1 month, by eye (35 people in multifocal and 40 people in monofocal group, not adjusted for within-person correlation)

889

890


891

**Uncorrected near visual acuity worse than J3/J4 or equivalent**Footnotes

- (1) 2 to 4 months, study eye
- (2) 4 to 6 months, study eye
- (3) 12 months, study eye
- (4) 5 months, study eye
- (5) 3 or 6 months, binocular
- (6) 3 months, binocular, could not read N5 size print
- (7) 6 weeks, binocular
- (8) 3 months, unclear whether eyes/people reported

892


893

**Mean uncorrected distance visual acuity (logMAR)**Footnotes

- (1) 3 months, binocular
- (2) 3 months, unclear whether eyes/people reported
- (3) 3 months, binocular
- (4) 18 months, binocular
- (5) 6 months, binocular
- (6) 12 months, unclear whether eyes/people reported

894


895

**Mean corrected distance visual acuity**Footnotes

- (1) 3 months, binocular
- (2) 3 months, unclear whether eyes/people reported
- (3) 18 months, binocular
- (4) 3 months, binocular
- (5) 12 months, unclear whether eyes/people reported
- (6) 6 months, binocular


896

897

**Mean uncorrected near visual acuity**

Footnotes  
(1) 3 months, binocular  
(2) 3 months, binocular  
(3) 18 months, binocular  
(4) 6 months, binocular  
(5) 12 months, unclear whether eyes/people reported


898

**Mean corrected near visual acuity**

Footnotes  
(1) 3 months, binocular  
(2) 3 months, binocular  
(3) 18 months, binocular  
(4) 3 months, binocular  
(5) 6 months, binocular  
(6) 12 months, unclear whether eyes/people reported

900


901

**Spectacle dependence (any)**

Footnotes  
(1) "What visual aid do you use to improve vision?" "None" (event swapped in figure) at 3 to 6 months  
(2) "Required no spectacles" (event swapped for figure) at 12 months  
(3) "Reported never using spectacles for distance or near" (event swapped in this figure) 5 months  
(4) "Reported never wearing glasses" (event swapped in figure) at 3 to 6 months  
(5) "Complete freedom from glasses" (event swapped in figure) at 12 months  
(6) "Completely spectacle independent" (event swapped in figure) at 18 months  
(7) "Complete spectacle independence" (event swapped in this figure) at 12 months  
(8) "Reported being spectacle independent" (event swapped in figure) at 6 months  
(9) "Reported overall spectacle independence" (event swapped for figure) at 6 months

902


903

**Spectacle dependence (distance or near)**Footnotes

- (1) "Never used spectacles for distance" (event swapped in the figure) at 5 months
- (2) "Reported wore glasses none of the time for distance vision" (event swapped in figure) at 3 to 6 months
- (3) "Reported using spectacles for distance vision always/most of the time/quite often" at 3 months
- (4) "Reported spectacle independence for distance vision" (event swapped in figure) at 6 months
- (5) "Never used spectacles for near tasks" (event swapped in the figure) at 5 months
- (6) "Reported wore glasses none of the time for near vision" (event swapped in figure) at 3 to 6 months
- (7) "Do you need additional glasses for near work?" at 3 months
- (8) "Reported using spectacles for near vision always/most of the time/quite often" at 3 months
- (9) "Dependence on near correction" at 3 months
- (10) "Reported spectacle independence for near vision" (event swapped in figure) at 6 months

904

905


**Contrast sensitivity**Footnotes

- (1) Pelli-Robson chart, 18 months
- (2) Binocular, Pelli-Robson chart at 1 metre, follow-up 6 weeks, recalc SD
- (3) Pelli-Robson test, 0.05 to 2.25 logunits, 12 months
- (4) Vision Contrast Test System at 6 cycles per degree, 1 month

906

907

## Visual function




### Footnotes

- (1) Modified VF-7 score at 12 months
- (2) VF-14 at 3 months
- (3) Change in VF-7 score at 1 month
- (4) VF-7 score at 6 months

908

909

## Patient satisfaction




### Footnotes

- (1) 5-point scale at 12 months, 1=very dissatisfied, 5=very satisfied
- (2) 5 point scale (satisfaction minus expectations) at 3 months
- (3) 10 point scale at 6 months (1=incapacitating, 10=excellent)
- (4) 4 point scale (multiplied by -1 as higher scores worse) at 1 month
- (5) 7 point scale (multiplied by -1 as higher scores worse) at 3 to 6 months,
- (6) 5 point scale at 6 months,

910

911

## Glare



### Footnotes

- (1) 4 to 6 months
- (2) 12 months
- (3) 5 months
- (4) 3 months
- (5) 1 month
- (6) 12 months
- (7) 18 months


912

913

914

915

## Halos



### Footnotes


- (1) 12 months
- (2) 5 months
- (3) 3 months
- (4) 4 to 6 months
- (5) 12 months
- (6) 1 month
- (7) 6 months

916

## 917 H.4.2.2 Multifocal versus monovision

918

## Visual acuity




919

Test for subgroup differences: Chi $\chi^2 = 18.51$ , df = 2 ( $P < 0.0001$ ), I $\mathbf{^2} = 89.2\%$

920

921

## Spectacle dependence



### Footnotes


(1) Follow-up 6 months; outcome was "spectacle-free patients" (event swapped in the figure)

(2) Follow-up: 4 months. Outcome was "reported never wearing glasses" (event swapped in figure)

922

923

## Contrast sensitivity



### Footnotes

(1) Follow-up: 6 months


(2) Follow-up: 4 months

924

925 H.4.2.3 Refractive vs diffractive multifocal lenses

926


## Uncorrected distance visual acuity



927

928


### Spectacle dependence



929

930


### Glare



931

932


### Halo



933


## 934 H.4.2.4 Bifocal versus trifocal intraocular lenses

## 935 Uncorrected visual acuity



936


## 937 Corrected visual acuity

938  
939

940 **H.4.3 Multifocal vs monofocal intraocular lenses: network meta-analyses (monofocal**  
 941 **lenses used as reference category)**

942 **H.4.3.1 Uncorrected distance visual acuity**

943 **Class-level analysis**




944  
 945 **Pairwise mean differences from NMA (higher number favour column)**

	Monovision	Monofocal	Multifocal
<b>Monovision</b>	N/A		
<b>Monofocal</b>	0.01 (-0.09, 0.11)	N/A	
<b>Multifocal</b>	0.02 (-0.07, 0.11)	0.01 (-0.03, 0.05)	N/A

946 Quantifying heterogeneity/inconsistency:

947  $\tau^2 = 0.0017$ ;  $I^2 = 74.3\%$

948 **Network graph**



949  
 950 **Comparison of direct and indirect evidence**

951 Random effects model:

952 comparison prop nma direct indir. Diff z p-value

953 Monofocal:Monovision 0 -0.0126 . -0.0126 . .  
 954 Monofocal:Multifocal 1 0.0074 0.0074 . . .  
 955 Monovision:Multifocal 1 0.0200 0.0200 . . .

956 Legend:


957 comparison - Treatment comparison

958 prop - Direct evidence proportion

959 nma - Estimated treatment effect (MD) in network meta-analysis

960      direct    - Estimated treatment effect (MD) derived from direct evidence  
 961      indir.   - Estimated treatment effect (MD) derived from indirect evidence  
 962      Diff      - Difference between direct and indirect treatment estimates  
 963      z          - z-value of test for disagreement (direct versus indirect)  
 964      p-value   - p-value of test for disagreement (direct versus indirect)

## 965 Subdivided analysis




966  
 967 Pairwise mean differences from NMA (higher numbers favour column)

	Refractive	Monofocal	Monovision	Diffractive
<b>Refractive</b>	N/A			
<b>Monofocal</b>	0.01 (-0.03, 0.04)	N/A		
<b>Monovision</b>	0.02 (-0.06, 0.10)	0.01 (-0.07, 0.09)	N/A	
<b>Diffractive</b>	0.04 (0.01, 0.07)	0.03 (-0.00, 0.07)	0.02 (-0.05, 0.09)	N/A

968 Quantifying heterogeneity/inconsistency:

969  $\tau^2 = 0.0010$ ;  $I^2 = 64.3\%$

## 970 Network graph



971  
 972 Comparison of direct and indirect evidence

973 Random effects model:


comparison	prop	nma	direct	indir.	Diff	z	p-value
Diffractive:Monofocal	0.68	-0.0311	-0.0190	-0.0567	0.0377	0.98	0.3255
Diffractive:Monovision	1.00	-0.0200	-0.0200		.	.	.
Diffractive:Refractive	0.90	-0.0393	-0.0460	0.0241	-0.0702	-1.50	0.1335
Monofocal:Monovision	0.00	0.0111		0.0111	.	.	.

## Meta-analysis and network meta-analysis results

979                   Monofocal:Refractive 0.78 -0.0082 0.0107 -0.0755 0.0862 2.06 0.0394  
980                   Monovision:Refractive 0.00 -0.0193 . -0.0193 . . .  
981                   Legend:  
982                   comparison - Treatment comparison  
983                   prop - Direct evidence proportion  
984                   nma - Estimated treatment effect (MD) in network meta-analysis  
985                   direct - Estimated treatment effect (MD) derived from direct evidence  
986                   indir. - Estimated treatment effect (MD) derived from indirect evidence  
987                   Diff - Difference between direct and indirect treatment estimates  
988                   z - z-value of test for disagreement (direct versus indirect)  
989                   p-value - p-value of test for disagreement (direct versus indirect)

### 990 H.4.3.2 Uncorrected near visual acuity

#### 991 Class-level analysis




#### 992 993 Pairwise mean differences from NMA (higher number favour column)

	Multifocal	Monovision	Monofocal
Multifocal	N/A		
Monovision	0.04 (-0.39, 0.47)	N/A	
Monofocal	0.22 (0.03, 0.42)	0.18 (-0.29, 0.66)	N/A

994 Quantifying heterogeneity/inconsistency:

995  $\tau^2 = 0.0487$ ;  $I^2 = 98.4\%$

#### 996 Network graph



997

#### 998 Comparison of direct and indirect evidence

999

Random effects model:


1000 comparison prop nma direct indir. Diff z p-value

## Meta-analysis and network meta-analysis results

---

1001            Monofocal:Monovision    0 -0.1817        . -0.1817    . .  
1002            Monofocal:Multifocal    1 -0.2217 -0.2217        . . .  
1003            Monovision:Multifocal    1 -0.0400 -0.0400        . . .  
1004            Legend:  
1005            comparison - Treatment comparison  
1006            prop        - Direct evidence proportion  
1007            nma        - Estimated treatment effect (MD) in network meta-analysis  
1008            direct      - Estimated treatment effect (MD) derived from direct evidence  
1009            indir.     - Estimated treatment effect (MD) derived from indirect evidence  
1010            Diff       - Difference between direct and indirect treatment estimates  
1011            z          - z-value of test for disagreement (direct versus indirect)  
1012            p-value    - p-value of test for disagreement (direct versus indirect)

### 1013 Subdivided analysis




1014  
1015            Pairwise mean differences from NMA (higher numbers favour column)

	Diffractive	Monovision	Refractive	Monofocal
Diffractive	N/A			
Monovision	0.04 (-0.30, 0.38)	N/A		
Refractive	0.25 (-0.01, 0.50)	0.21 (-0.22, 0.63)	N/A	
Monofocal	0.38 (0.15, 0.61)	0.34 (-0.07, 0.75)	0.13 (-0.04, 0.30)	N/A

1016            Quantifying heterogeneity/inconsistency:

1017            tau^2 = 0.0300; I^2 = 97.3%

1018            Network graph



1019

### Comparison of direct and indirect evidence

Random effects model:


	comparison	prop	nma	direct	indir.	Diff	z	p-value
1023	Diffractive:Monofocal	0.90	0.3804	0.3888	0.3077	0.0811	0.21	0.8324
1024	Diffractive:Monovision	1.00	0.0400	0.0400	.	.	.	.
1025	Diffractive:Refractive	0.55	0.2484	0.1376	0.3858	-0.2482	-0.95	0.3425
1026	Monofocal:Monovision	0.00	-0.3404	.	-0.3404	.	.	.
1027	Monofocal:Refractive	0.96	-0.1320	-0.1077	-0.7954	0.6877	1.46	0.1439
1028	Monovision:Refractive	0.00	0.2084	.	0.2084	.	.	.

Legend:

1030	comparison	- Treatment comparison
1031	prop	- Direct evidence proportion
1032	nma	- Estimated treatment effect (MD) in network meta-analysis
1033	direct	- Estimated treatment effect (MD) derived from direct evidence
1034	indir.	- Estimated treatment effect (MD) derived from indirect evidence
1035	Diff	- Difference between direct and indirect treatment estimates
1036	z	- z-value of test for disagreement (direct versus indirect)
1037	p-value	- p-value of test for disagreement (direct versus indirect)

### H.4.3.3 Spectacle dependence

#### Class-level analysis



1040


#### Pairwise relative risks from NMA (higher number favour column)

	<b>Multifocal</b>	<b>Monofocal</b>	<b>Monovision</b>
<b>Multifocal</b>	N/A		
<b>Monofocal</b>	1.56 (1.38, 1.76)	N/A	
<b>Monovision</b>	2.48 (1.75, 3.53)	1.60 (1.10, 2.32)	N/A

1042 Quantifying heterogeneity/inconsistency:

1043  $\tau^2 = 0.0189$ ;  $I^2 = 54.0\%$

#### 1044 Network graph



1045

#### 1046 Comparison of direct and indirect evidence

1047 Random effects model:

1048 comparison prop nma direct indir. RoR z p-value

1049 Monofocal:Monovision 0 1.5950 . 1.5950 .. .

1050 Monofocal:Multifocal 1 0.6422 0.6422 . . .

1051 Monovision:Multifocal 1 0.4027 0.4027 . . .

1052 Legend:

1053 comparison - Treatment comparison

1054 prop - Direct evidence proportion

1055 nma - Estimated treatment effect (RR) in network meta-analysis

1056 direct - Estimated treatment effect (RR) derived from direct evidence

1057 indir. - Estimated treatment effect (RR) derived from indirect evidence


1058 RoR - Ratio of Ratios (direct versus indirect)

1059 z - z-value of test for disagreement (direct versus indirect)

1060 p-value - p-value of test for disagreement (direct versus indirect)

1061

#### Subdivided analysis



1062

1063

**Pairwise mean differences from NMA (higher numbers favour column)**

	Diffractive	Refractive	Monofocal	Monovision
Diffractive	N/A			
Refractive	1.88 (1.45, 2.42)	N/A		
Monofocal	2.41 (1.90, 3.06)	1.29 (1.08, 1.54)	N/A	
Monovision	3.13 (2.06, 4.76)	1.67 (1.08, 2.59)	1.30 (0.83, 2.02)	N/A

1064


Quantifying heterogeneity/inconsistency:

1065

$$\tau^2 = 0.0389; I^2 = 61.0\%$$

1066

**Network graph**



1067

**Comparison of direct and indirect evidence**

1068

Random effects model:

1069

	comparison	prop	nma	direct	indir.	RoR	z	p-value
1070	Diffractive:Monofocal	0.70	2.4127	2.0668	3.4717	0.5953	-1.95	0.0514
1071	Diffractive:Monovision	0.66	3.1320	2.5830	4.5505	0.5676	-1.26	0.2085
1072	Diffractive:Refractive	0.37	1.8757	3.2234	1.3605	2.3693	3.19	0.0014
1073	Monofocal:Monovision	0.00	1.2981	.	1.2981	.	.	.
1074	Monofocal:Refractive	0.87	0.7775	0.7197	1.2903	0.5578	-2.19	0.0286
1075	Monovision:Refractive	0.43	0.5989	0.4345	0.7655	0.5676	-1.26	0.2085

1076

Legend:

1077

comparison - Treatment comparison

1078

prop - Direct evidence proportion

1079

nma - Estimated treatment effect (RR) in network meta-analysis

1080

direct - Estimated treatment effect (RR) derived from direct evidence

1081

indir. - Estimated treatment effect (RR) derived from indirect evidence

1082

RoR - Ratio of Ratios (direct versus indirect)

1083

z - z-value of test for disagreement (direct versus indirect)


1084

p-value - p-value of test for disagreement (direct versus indirect)

1085

1086 H.4.3.4 Contrast sensitivity

1087 Class-level analysis



1088

1089 Pairwise relative risks from NMA (higher number favour row)

	Multifocal	Monovision	Monofocal
Multifocal	N/A		
Monovision	0.04 (0.00, 0.07)	N/A	
Monofocal	0.09 (-0.08, 0.26)	0.05 (-0.12, 0.22)	N/A

1090


Quantifying heterogeneity/inconsistency:

1091

$\tau^2 = 0.0010$ ;  $I^2 = 23.8\%$

1092

Network graph



1093

1094 Comparison of direct and indirect evidence

1095

Fixed effect model:

comparison	prop	nma	direct	indir.	Diff	z	p-value
Monofoal:Monovision	0	-0.0520	.	-0.0520	.	.	.
Monofoal:Multifocal	1	-0.0894	-0.0894	.	.	.	.
Monovision:Multifocal	1	-0.0373	-0.0373	.	.	.	.

1100

Legend:

1101

comparison - Treatment comparison

1102

prop - Direct evidence proportion

1103

nma - Estimated treatment effect (MD) in network meta-analysis

1104

direct - Estimated treatment effect (MD) derived from direct evidence

1105

indir. - Estimated treatment effect (MD) derived from indirect evidence

1106


Diff - Difference between direct and indirect treatment estimates

1107

z - z-value of test for disagreement (direct versus indirect)

1108 p-value - p-value of test for disagreement (direct versus indirect)

### 1109 Subdivided analysis



1110

### 1111 Pairwise mean differences from NMA (higher numbers favour row)

	Diffractive	Monovision	Refractive	Monofocal
<b>Diffractive</b>	N/A			
<b>Monovision</b>	0.06 (0.02, 0.11)	N/A		
<b>Refractive</b>	0.07 (-0.01, 0.15)	0.01 (-0.06, 0.08)	N/A	
<b>Monofocal</b>	0.15 (0.04, 0.27)	0.09 (-0.02, 0.20)	0.08 (-0.00, 0.17)	N/A

1112


Quantifying heterogeneity/inconsistency:

1113

$\tau^2 = 0.0016$ ;  $I^2 = 2.9\%$

1114

### Network graph



1115

### 1116 Comparison of direct and indirect evidence

1117 Fixed effect model:

	comparison	prop	nma	direct	indir.	Diff	z	p-value
1119	Diffractive:Monofocal	0	0.1524	.	0.1524	.	.	.
1120	Diffractive:Monovision	1	0.0600	0.0600	.	.	.	.
1121	Diffractive:Refractive	0	0.0700	.	0.0700	.	.	.
1122	Monofocal:Monovision	0	-0.0924	.	-0.0924	.	.	.
1123	Monofocal:Refractive	1	-0.0824	-0.0824	.	.	.	.
1124	Monovision:Refractive	1	0.0100	0.0100	.	.	.	.

1125 Legend:


```

1126 comparison - Treatment comparison
1127 prop      - Direct evidence proportion
1128 nma       - Estimated treatment effect (MD) in network meta-analysis
1129 direct    - Estimated treatment effect (MD) derived from direct evidence
1130 indir.   - Estimated treatment effect (MD) derived from indirect evidence
1131 Diff      - Difference between direct and indirect treatment estimates
1132 z         - z-value of test for disagreement (direct versus indirect)
1133 p-value   - p-value of test for disagreement (direct versus indirect)

```

#### 1134 H.4.3.5 Glare

##### 1135 Class-level analysis



1136

##### 1137 Pairwise relative risks from NMA (higher number favour column)

	Monofocal	Monovision	Multifocal
Monofocal	N/A		
Monovision	1.00 (0.68, 1.16)	N/A	
Multifocal	1.41 (1.03, 1.93)	1.41 (1.14, 1.73)	N/A

1138

Quantifying heterogeneity/inconsistency:

1139

$\tau^2 = 0$ ;  $I^2 = 0\%$

1140

##### Network graph



1141

##### 1142 Comparison of direct and indirect evidence

1143

Fixed effect model:

1144

1145

comparison prop nma direct indir. RoR z p-value

Monofocal:Monovision 0 0.9989 . 0.9989 . .

1146


Monofocal:Multifocal 1 1.4064 1.4064 . . .

1147 Monovision:Multifocal 1 1.4079 1.4079 . . .

1148 Legend:

1149 comparison - Treatment comparison  
 1150 prop - Direct evidence proportion  
 1151 nma - Estimated treatment effect (RR) in network meta-analysis  
 1152 direct - Estimated treatment effect (RR) derived from direct evidence  
 1153 indir. - Estimated treatment effect (RR) derived from indirect evidence  
 1154 RoR - Ratio of Ratios (direct versus indirect)  
 1155 z - z-value of test for disagreement (direct versus indirect)  
 1156 p-value - p-value of test for disagreement (direct versus indirect)

## 1157 Subdivided analysis



1158

## 1159 Pairwise mean differences from NMA (higher numbers favour row)

	Monovision	Monofocal	Diffractive	Refractive
<b>Monovision</b>	N/A			
<b>Monofocal</b>	1.18 (0.75, 1.85)	N/A		
<b>Diffractive</b>	1.41 (1.14, 1.73)	1.19 (0.80, 1.78)	N/A	
<b>Refractive</b>	1.80 (1.31, 2.46)	1.52 (1.09, 2.13)	1.28 (1.01, 1.61)	N/A

1160


Quantifying heterogeneity/inconsistency:

1161

$\tau^2 = 0$ ;  $I^2 = 0\%$

1162

## Network graph



1163

## 1164 Comparison of direct and indirect evidence

1165

Fixed effect model:

## Meta-analysis and network meta-analysis results

---


1166 comparison prop nma direct indir. RoR z p-value  
 1167 Diffractive:Monofocal 0.16 0.8379 0.7466 0.8565 0.8717 -0.25 0.8040  
 1168 Diffractive:Monovision 1.00 0.7103 0.7103 . . .  
 1169 Diffractive:Refractive 0.96 1.2754 1.2878 1.0311 1.2489 0.38 0.7058  
 1170 Monofocal:Monovision 0.00 0.8477 . 0.8477 . . .  
 1171 Monofocal:Refractive 0.91 1.5222 1.4984 1.7697 0.8467 -0.28 0.7772  
 1172 Monovision:Refractive 0.00 1.7957 . 1.7957 . . .

Legend:

1174 comparison - Treatment comparison  
 1175 prop - Direct evidence proportion  
 1176 nma - Estimated treatment effect (RR) in network meta-analysis  
 1177 direct - Estimated treatment effect (RR) derived from direct evidence  
 1178 indir. - Estimated treatment effect (RR) derived from indirect evidence  
 1179 RoR - Ratio of Ratios (direct versus indirect)  
 1180 z - z-value of test for disagreement (direct versus indirect)  
 1181 p-value - p-value of test for disagreement (direct versus indirect)

### 1182 H.4.3.6 Halo

#### 1183 Subdivided analysis



1184

#### 1185 Pairwise relative risks from NMA (higher number favour column)

	<b>Monofocal</b>	<b>Diffractive</b>	<b>Refractive</b>
<b>Monofocal</b>	N/A		
<b>Diffractive</b>	2.42 (1.55, 3.76)	N/A	
<b>Refractive</b>	3.54 (2.20, 5.67)	1.46 (1.19, 1.79)	N/A

1186


Quantifying heterogeneity/inconsistency:

1187

$\tau^2 = 0$ ;  $I^2 = 0\%$

1188

**Network graph**



1189

### Comparison of direct and indirect evidence

1190

Fixed effect model:

1191

1192

	comparison	prop	nma	direct	indir.	RoR	z	p-value
1193	Diffractive:Monofocal	0.86	0.4135	0.4299	0.3271	1.3144	0.42	0.6721
1194	Diffractive:Refractive	0.97	1.4644	1.4516	1.9610	0.7402	-0.49	0.6251
1195	Monofocal:Refractive	0.19	3.5413	4.6034	3.3255	1.3843	0.53	0.5940

1196

Legend:

1197

comparison - Treatment comparison

1198

prop - Direct evidence proportion

1199

nma - Estimated treatment effect (RR) in network meta-analysis

1200

direct - Estimated treatment effect (RR) derived from direct evidence

1201

indir. - Estimated treatment effect (RR) derived from indirect evidence

1202

RoR - Ratio of Ratios (direct versus indirect)

1203

z - z-value of test for disagreement (direct versus indirect)


1204

p-value - p-value of test for disagreement (direct versus indirect)

1205


## 1206 H.4.4 Optimal strategy to address pre-existing astigmatism

## 1207 Mean Visual Acuity – uncorrected distance (logMAR)



1208

## 1209 Residual astigmatism (Refractive cylinder dioptres)



1210

1211 Note: Non OECD country studies removed for meta-analysis

1212    **H.5 Wrong lens implant errors**


- 1213    • What are the procedural causes of wrong lens implant errors?  
1214    • What strategies should be adopted to reduce the risk of wrong lens implant errors?

1215              There were no meta-analyses conducted for these questions.  
1216

- 1217 **H.6 Surgical timing and technique**
- 1218 • What is the effectiveness of laser-assisted phacoemulsification cataract surgery compared  
1219 with standard ultrasound phacoemulsification cataract surgery?
- 1220 • What is the effectiveness of bilateral simultaneous (rapid sequential) cataract surgery  
1221 compared with unilateral eye surgery?
- 1222 • What is the appropriate timing of second eye surgery, taking into account issues such as  
1223 refractive power after first eye surgery?


1224 **H.6.1 Laser-assisted cataract surgery**

1225 **H.6.1.1 Intra-operative complications**



1226  
1227


## 1228 H.6.1.2 Post-operative complications




1229

Test for subgroup differences:  $\text{Chi}^2 = 0.36$ , df = 2 ( $P = 0.84$ ),  $I^2 = 0\%$

## 1230 H.6.1.3 Visual acuity (logMAR)



## 1232 H.6.1.4 Duration of procedure (minutes)




1233

1234

1235 H.6.2 Bilateral surgery


1236 H.6.2.1 Bilateral simultaneous versus unilateral cataract surgery

1237 Any intraoperative complication




1238

1239 Any postoperative complication




1240

1241 Any intra- or postoperative complication




1242

1243 Serious postoperative complications



1244


1245 Visual function



1246

1247 H.6.2.2 Second-eye surgery versus no second-eye surgery


1248 Visual acuity (logMAR)



1249

1250


Contrast sensitivity



1251

1252

Visual function



1253


1254

- 1255 **H.7 Anaesthesia**
- 1256 • What is the optimal type and administration of anaesthesia for cataract surgery?
- 1257 • What is the effectiveness of sedation as an adjunct to local anaesthesia during cataract
- 1258 surgery?
- 1259 • What is the effectiveness of hyaluronidase as an adjunct to local anaesthesia during
- 1260 cataract surgery?
- 1261 • In what circumstances should general anaesthesia be considered in phacoemulsification
- 1262 cataract surgery?

1263 **H.7.1 Type and administration of anaesthesia**


1264 **H.7.1.1 Pain on application**

1265 **Warmed (37 degrees) vs room temperature anaesthetic**




1266

1267 **Topical vs peribulbar anaesthesia**



1268

1269 **Topical vs sub-Tenon's**




1270

1271 **H.7.1.2 Pain during surgery**


1272

1272 **Topical versus peribulbar**




1273

1274

**Topical versus retrobulbar**

1275


1276

**Topical versus topical with intracameral**

1277


1278

1279

**Topical versus sub-Tenon's**

1280


1281

**Peribulbar versus retrobulbar**

1282


1283 H.7.1.3 Surgical complications

1284 Topical versus topical with intracameral (adverse surgical event)



1285

1286 Peribulbar vs retrobulbar (conjunctival chemosis)




1287

1288 H.7.2 Network meta-analyses

1289 H.7.2.1 Anaesthetic drug (lidocaine used as reference category)

1290 Pain on application



1291

1292 Pairwise mean differences from NMA

	Benoxinate	Bupivacaine	Lidocaine	Levobupivacaine
<b>Benoxinate</b>	N/A			
<b>Bupivacaine</b>	5.00 (3.61, 6.39)	N/A		
<b>Lidocaine</b>	19.40 (16.08, 29.72)	14.40 (11.98, 16.82)	N/A	
<b>Levobupivacaine</b>	22.90 (17.03, 21.77)	17.90 (11.06, 24.74)	3.50 (-2.89, 9.89)	N/A

1293


Quantifying heterogeneity/inconsistency:

1294

$\tau^2 = 0$ ;  $I^2 = 0\%$

1295

Network graph



1296

1297

### Comparison of direct and indirect evidence

1298

Fixed effect model:

1299

1300

1301

1302

1303

1304

1305

1306

Legend:

1307

comparison - Treatment comparison

1308

prop - Direct evidence proportion

1309

nma - Estimated treatment effect (MD) in network meta-analysis

1310

direct - Estimated treatment effect (MD) derived from direct evidence

1311

indir. - Estimated treatment effect (MD) derived from indirect evidence

1312

Diff - Difference between direct and indirect treatment estimates

1313


z - z-value of test for disagreement (direct versus indirect)

1314

p-value - p-value of test for disagreement (direct versus indirect)

1315

### Pain during surgery



1316

### Pairwise mean differences from NMA

	Benoxinate	Bupivacaine	Lidocaine	Levobupivacaine
Benoxinate	N/A			

<b>Bupivacaine</b>	-30.00 (-39.53, -20.47)	N/A		
<b>Lidocaine</b>	-55.00 (-63.66, -46.34)	-25.00 (-35.40, -14.60)	N/A	
<b>Levobupivacaine</b>	-59.00 (-68.71, -49.29)	-29.00 (-40.29, -17.71)	-4.00 (-8.39, 0.39)	N/A

1318


Quantifying heterogeneity/inconsistency:

1319

$\tau^2 = 0$ ;  $I^2 = 0\%$

1320

**Network graph**



1321

### Comparison of direct and indirect evidence

1322

Fixed effect model:

1323

	comparison	prop	nma	direct	indir.	Diff	z	p-value
1324	Benoxinate:Bupivacaine	1	-30.0000	-30.0000	.	.	.	.
1325	Benoxinate:Levobupivacaine	0	-59.0000	.	-59.0000	.	.	.
1326	Benoxinate:Lidocaine	1	-55.0000	-55.0000	.	.	.	.
1327	Bupivacaine:Levobupivacaine	0	-29.0000	.	-29.0000	.	.	.
1328	Bupivacaine:Lidocaine	1	-25.0000	-25.0000	.	.	.	.
1329	Levobupivacaine:Lidocaine	1	4.0000	4.0000	.	.	.	.

1330

Legend:

1331

comparison - Treatment comparison

1332

prop - Direct evidence proportion

1333

nma - Estimated treatment effect (MD) in network meta-analysis

1334

direct - Estimated treatment effect (MD) derived from direct evidence

1335

indir. - Estimated treatment effect (MD) derived from indirect evidence

1336

Diff - Difference between direct and indirect treatment estimates

1337

z - z-value of test for disagreement (direct versus indirect)


1338

p-value - p-value of test for disagreement (direct versus indirect)

1339

1340 H.7.2.2 Method of anaesthesia (topical used as reference category)

1341 Pain on application



1342

1343

#### Pairwise mean differences from NMA

	Topical	sub-Tenon's	Peribulbar	Retrobulbar
Topical	N/A			
sub-Tenon's	6.15 (-4.81, 17.11)	N/A		
Peribulbar	8.86 (-4.57, 17.11)	2.71 (-14.63, 20.04)	N/A	
Retrobulbar	49.10 (29.94, 68.26)	42.95 (20.88, 65.02)	40.24 (16.85, 63.64)	N/A

1344


Quantifying heterogeneity/inconsistency:

1345

$\tau^2 = 89.5629$ ;  $I^2 = 96.4\%$

1346

#### Network graph



1347

#### Comparison of direct and indirect evidence

1348 Random effects model:

1349

1350

comparison prop nma direct indir. Diff z p-value

1351

Peribulbar:Retrobulbar 0 40.2431 . 40.2431 . .

1352

Peribulbar:sub-Tenon's 0 -2.7073 . -2.7073 . .

1353

Peribulbar:Topical 1 -8.8569 -8.8569 . . .

1354

Retrobulbar:sub-Tenon's 0 -42.9504 . -42.9504 . .

1355

Retrobulbar:Topical 1 -49.1000 -49.1000 . . .

1356


sub-Tenon's:Topical 1 -6.1496 -6.1496 . . .

1357

Legend:

1358 comparison - Treatment comparison  
 1359 prop - Direct evidence proportion  
 1360 nma - Estimated treatment effect (MD) in network meta-analysis  
 1361 direct - Estimated treatment effect (MD) derived from direct evidence  
 1362 indir. - Estimated treatment effect (MD) derived from indirect evidence  
 1363 Diff - Difference between direct and indirect treatment estimates  
 1364 z - z-value of test for disagreement (direct versus indirect)  
 1365 p-value - p-value of test for disagreement (direct versus indirect)

## 1366 Pain during surgery



1367

## 1368 Pairwise mean differences from NMA

	Topical	Topical + intracameral	Peribulbar	Retrobulbar	sub-Tenon's
Topical	N/A				
Topical + intracameral	-2.73 (-7.84, 2.39)	N/A			
Peribulbar	-6.49 (-10.96, -2.02)	-3.76 (-10.55, 3.03)	N/A		
Retrobulbar	-7.50 (-12.28, -2.72)	-4.77 (-11.77, 2.23)	-1.01 (-6.62, 4.61)	N/A	
sub-Tenon's	-12.97 (-21.62, -4.31)	-10.24 (-20.29, -0.19)	-6.48 (-16.21, 3.26)	-5.47 (-15.35, 4.41)	N/A

1369


Quantifying heterogeneity/inconsistency:

1370

$\tau^2 = 26.0174$ ;  $I^2 = 82.2\%$

1371

## Network graph



1372

1373

### Comparison of direct and indirect evidence

1374

Random effects model:

1375

	comparison	prop	nma	direct	indir.	Diff	z	p-value
--	------------	------	-----	--------	--------	------	---	---------

1376

Peribulbar:Retrobulbar	0.42	-1.0076	-0.3423	-1.4877	1.1454	0.20	0.8435
------------------------	------	---------	---------	---------	--------	------	--------

1377

Peribulbar:sub-Tenon's	0.00	-6.4774	.	-6.4774	.	.	.
------------------------	------	---------	---	---------	---	---	---

1378

Peribulbar:Topical	0.81	6.4896	6.2715	7.4172	-1.1457	-0.20	0.8435
--------------------	------	--------	--------	--------	---------	-------	--------

1379

Peribulbar:Topical + intracameral	0.00	3.7619	.	3.7619	.	.	.
-----------------------------------	------	--------	---	--------	---	---	---

1380

Retrobulbar:sub-Tenon's	0.00	-5.4699	.	-5.4699	.	.	.
-------------------------	------	---------	---	---------	---	---	---

1381

Retrobulbar:Topical	0.77	7.4972	7.7593	6.6139	1.1454	0.20	0.8435
---------------------	------	--------	--------	--------	--------	------	--------

1382

Retrobulbar:Topical + intracameral	0.00	4.7695	.	4.7695	.	.	.
------------------------------------	------	--------	---	--------	---	---	---

1383

sub-Tenon's:Topical	1.00	12.9671	12.9671	.	.	.	.
---------------------	------	---------	---------	---	---	---	---

1384

sub-Tenon's:Topical + intracameral	0.00	10.2393	.	10.2393	.	.	.
------------------------------------	------	---------	---	---------	---	---	---

1385

Topical:Topical + intracameral	1.00	-2.7277	-2.7277	.	.	.	.
--------------------------------	------	---------	---------	---	---	---	---

1386

Legend:

1387

comparison - Treatment comparison

1388

prop - Direct evidence proportion

1389

nma - Estimated treatment effect (MD) in network meta-analysis

1390

direct - Estimated treatment effect (MD) derived from direct evidence

1391

indir. - Estimated treatment effect (MD) derived from indirect evidence

1392

Diff - Difference between direct and indirect treatment estimates

1393

z - z-value of test for disagreement (direct versus indirect)


1394

p-value - p-value of test for disagreement (direct versus indirect)

- 1395 **H.8 Preventing and managing complications**
- 1396 • What is the effectiveness of interventions (for example, prophylactic laser surgery) to  
1397 prevent retinal detachment in people with myopia undergoing cataract surgery?
- 1398 • What is the effectiveness of capsular tension rings applied during phacoemulsification  
1399 cataract surgery?
- 1400 • What is the effectiveness of interventions to increase pupil size to improve visual  
1401 outcomes and reduce complications during phacoemulsification cataract surgery?
- 1402 • What is the effectiveness of postoperative eye shields to prevent complications after  
1403 cataract extraction?
- 1404 • What is the effectiveness of prophylactic antiseptics (for example, topical iodine) and  
1405 antibiotics to prevent endophthalmitis after cataract surgery?
- 1406 • What is the effectiveness of prophylactic topical corticosteroids and/or NSAIDs to prevent  
1407 inflammation and cystoid macular oedema after phacoemulsification cataract surgery?
- 1408 • What is the effectiveness of interventions to reduce the impact of perioperative posterior  
1409 capsule rupture?
- 1410 • What is the effectiveness of interventions used to manage cystoid macular oedema  
1411 following cataract surgery?
- 1412 **H.8.1 Capsular tension rings**
- 1413 **H.8.1.1 Full population**
- 1414 **CDVA (3 months postoperatively)**
- | Study or Subgroup     | CTR  |       |           | No CTR |       |           | Weight        | Mean Difference<br>IV, Random, 95% CI | Mean Difference<br>IV, Random, 95% CI |
|-----------------------|------|-------|-----------|--------|-------|-----------|---------------|---------------------------------------|---------------------------------------|
|                       | Mean | SD    | Total     | Mean   | SD    | Total     |               |                                       |                                       |
| Alio 2012             | 0.02 | 0.06  | 47        | 0.05   | 0.1   | 43        | 46.6%         | -0.03 [-0.06, 0.00]                   |                                       |
| Park 2016             | 0.03 | 0.051 | 26        | 0.02   | 0.051 | 26        | 53.4%         | 0.01 [-0.02, 0.04]                    |                                       |
| <b>Total (95% CI)</b> |      |       | <b>73</b> |        |       | <b>69</b> | <b>100.0%</b> | <b>-0.01 [-0.05, 0.03]</b>            |                                       |
- Heterogeneity:  $Tau^2 = 0.00$ ;  $Chi^2 = 3.14$ ,  $df = 1$  ( $P = 0.08$ );  $I^2 = 68\%$   
Test for overall effect:  $Z = 0.43$  ( $P = 0.67$ )
- 1415 **UDVA (3 months postoperatively)**
- | Study or Subgroup     | CTR  |       |           | No CTR |       |           | Weight        | Mean Difference<br>IV, Random, 95% CI | Mean Difference<br>IV, Random, 95% CI |
|-----------------------|------|-------|-----------|--------|-------|-----------|---------------|---------------------------------------|---------------------------------------|
|                       | Mean | SD    | Total     | Mean   | SD    | Total     |               |                                       |                                       |
| Alio 2012             | 0.19 | 0.28  | 47        | 0.15   | 0.21  | 43        | 22.9%         | 0.04 [-0.06, 0.14]                    |                                       |
| Park 2016             | 0.09 | 0.102 | 26        | 0.1    | 0.102 | 26        | 77.1%         | -0.01 [-0.07, 0.05]                   |                                       |
| <b>Total (95% CI)</b> |      |       | <b>73</b> |        |       | <b>69</b> | <b>100.0%</b> | <b>0.00 [-0.05, 0.05]</b>             |                                       |
- Heterogeneity:  $Tau^2 = 0.00$ ;  $Chi^2 = 0.72$ ,  $df = 1$  ( $P = 0.40$ );  $I^2 = 0\%$   
Test for overall effect:  $Z = 0.06$  ( $P = 0.95$ )
- 1416 **H.8.1.2 People with pseudoexfoliation**
- 1417 **Zonular dehiscence**
- | Study or Subgroup     | CTR      |           |           | No CTR    |               |                          | Weight | Risk Ratio<br>M-H, Random, 95% CI | Risk Ratio<br>M-H, Random, 95% CI |
|-----------------------|----------|-----------|-----------|-----------|---------------|--------------------------|--------|-----------------------------------|-----------------------------------|
|                       | Events   | Total     | Events    | Total     | Weight        |                          |        |                                   |                                   |
| Bayraktar 2001        | 0        | 39        | 5         | 39        | 21.8%         | 0.09 [0.01, 1.59]        |        |                                   |                                   |
| Kocabora 2007         | 2        | 41        | 7         | 43        | 78.2%         | 0.30 [0.07, 1.36]        |        |                                   |                                   |
| <b>Total (95% CI)</b> | <b>2</b> | <b>80</b> | <b>12</b> | <b>82</b> | <b>100.0%</b> | <b>0.23 [0.06, 0.88]</b> |        |                                   |                                   |
- Heterogeneity:  $Tau^2 = 0.00$ ;  $Chi^2 = 0.55$ ,  $df = 1$  ( $P = 0.46$ );  $I^2 = 0\%$   
Test for overall effect:  $Z = 2.15$  ( $P = 0.03$ )

1421

### IOL in the bag successfully



1422


1423

1424 H.8.2 Intervention to prevent cystoid macular oedema

1425 H.8.2.1 Pairwise meta-analyses

1426 NSAIDs plus steroids vs steroids

1427 Poor vision due to CMO



Test for subgroup differences: Not applicable

Footnotes


(1) Follow-up: 6 weeks, "clinically significant macular oedema associated with vision loss" (cutpoint not defined)

(2) Follow-up: 6 weeks, fundoscopy and Amsler grid test "no evidence of clinically significant CME"

(3) Follow-up: 4 weeks, OCT-confirmed CMO with visual acuity <6/9.

1428

1429 CMO



Footnotes

(1) Follow-up: 1 month. OCT used but CMO not defined.

(2) Follow-up: day 42. "Clinically significant MO" via fundoscopy and Amsler grid test.

(3) Follow-up: 2 weeks. "Clinically significant CME"

(4) Follow-up: 2 months, "obvious CMO confirmed by OCT"

(5) Follow-up: 1 month, "clinically significant CME" unclear if OCT-verified


(6) Follow-up: 4 weeks, clinical and OCT-based

(7) Follow-up: 3 months, "Slight fluorescein leakage into the cystic space without enclosing the entire centralfovea or complete fluorescein accumulation..."

(8) Follow-up: 6 weeks, OCT verified but not defined

1430

1431 Inflammation (events)




Footnotes

(1) Follow-up: 6 weeks, "inflammatory cells greater than 1+ during first week of postoperative visits."

(2) Follow-up: day 28, corneal oedema or Tyndall reaction or conjunctival hyperemia, by day 35 had disappeared.

1432


1433

**BCVA [logMAR]**

1434

**NSAIDs vs steroids**


1435

**CMO****Footnotes:**

- (1) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification
- (2) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification
- (3) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification

1437

1438


**Inflammation (flare) [photons/ms]**

- Footnotes:**
- (1) Follow-up: 8 weeks
  - (2) Follow-up: 5 weeks
  - (3) Follow-up: 8 weeks
  - (4) Follow-up: 5 weeks

1439

1440

### BCVA [logMAR]




Footnotes:  
 (1) Follow up: 8 weeks; final value  
 (2) Follow up: 6 weeks

1441

### NSAIDs plus steroids vs steroids (population with diabetic retinopathy)


1443

### CMO




1444

### BCVA [logMAR]



1446


### Proportion losing 5 or more letters of BCVA



1448

## 1449 H.8.2.2 Network meta-analyses (steroids used as reference category)

## 1450 BCVA [logMAR]



Number of studies: k=9

Number of treatments: n=3

Number of pairwise comparisons: m=11

### Differences between treatments – mean and 95% confidence interval

	NSAIDs	NSAIDs + steroids	Steroids
NSAIDs		0.0038 [-0.0298, 0.0373]	-0.0044 [-0.0319, 0.0232]
NSAIDs + Steroids	-0.0038 [-0.0373, 0.0298]		-0.0081 [-0.0273, 0.0110]
Steroids	0.0044 [-0.0232, 0.0319]	0.0081 [-0.0110, 0.0273]	


Quantifying heterogeneity/inconsistency:

$\tau^2 = 0.0003$ ;  $I^2 = 63.2\%$

Test of heterogeneity/inconsistency:

Q d.f. p-value

21.72 8 0.005

**Network graph****Comparison of direct and indirect evidence**


Random effects model:

comparison	prop	nma	direct	indir.	Diff	z	p-value
NSAIDS:NSAIDS + steroids	0	-0.0038	-0.1050	-0.0033	-0.1017	-0.38	0.7029
NSAIDS:steroids	1	0.0044	0.0046	-0.1175	0.1220	0.32	0.7456
NSAIDS + steroids :steroids	1	0.0081	0.0081	.	.	.	.

Legend:

- comparison - Treatment comparison
- prop - Direct evidence proportion
- nma - Estimated treatment effect (MD) in network meta-analysis
- direct - Estimated treatment effect (MD) derived from direct evidence
- indir. - Estimated treatment effect (MD) derived from indirect evidence
- Diff - Difference between direct and indirect treatment estimates
- z - z-value of test for disagreement (direct versus indirect)
- p-value - p-value of test for disagreement (direct versus indirect)

1452

**CMO**

1453

Number of studies: k=12

1455

Number of treatments: n=3

1456

Number of pairwise comparisons: m=14

## Meta-analysis and network meta-analysis results

1457

1458

### Differences between treatments – mean and 95% confidence interval

	NSAIDs	NSAIDs + steroids	Steroids
NSAIDs		1.0869 [0.5102, 2.3156]	0.2639 [0.1694, 0.4109]
NSAIDs + steroids	0.9200 [0.4319, 1.9600]		0.2428 [0.1310, 0.4500]
Steroids	3.7897 [2.4336, 5.9016]	4.1191 [2.2225, 7.6343]	

1459

1460

Quantifying heterogeneity/inconsistency:

tau<sup>2</sup> = 0; I<sup>2</sup> = 0%

1461

1462

1463

Test of heterogeneity/inconsistency:

Q d.f. p-value


4.68 11 0.9455

1464

### Network graph

1465

1466



1467

### Comparison of direct and indirect evidence

Random effects model:

1468

comparison	prop	nma	direct	indir.	RoR	z	p-value
------------	------	-----	--------	--------	-----	---	---------

1469

NSAIDS:NSAIDS + steroids	0.04	0.9200	1.0417	0.9155	1.1378	0.06	0.9490
--------------------------	------	--------	--------	--------	--------	------	--------

1470

1471

NSAIDS:steroids	1.00	3.7897	3.7776	18.8152	0.2008	-0.32	0.7509
-----------------	------	--------	--------	---------	--------	-------	--------

1472

1473

NSAIDS + steroids :steroids	1.00	4.1191	4.1019	11.6442	0.3523	-0.21	0.8343
-----------------------------	------	--------	--------	---------	--------	-------	--------

1474

Legend:

1475

comparison - Treatment comparison


1476

prop - Direct evidence proportion

## Meta-analysis and network meta-analysis results

1477	nma	- Estimated treatment effect (RR) in network meta-analysis
1478	direct	- Estimated treatment effect (RR) derived from direct evidence
1479	indir.	- Estimated treatment effect (RR) derived from indirect evidence
1480	RoR	- Ratio of Ratios (direct versus indirect)
1481	z	- z-value of test for disagreement (direct versus indirect)
1482	p-value	- p-value of test for disagreement (direct versus indirect)

### 1483 Inflammation (flare) [photons/ms]



1484

1485 Number of studies: k=5

1486 Number of treatments: n=3

1487 Number of pairwise comparisons: m=7

1488

### 1489 Differences between treatments – Mean and 95% confidence interval

	NSAIDs	NSAIDs + steroids	Steroids
NSAIDs		2.1419 [-1.1857, 5.4694]	-1.6413 [-3.4897, 0.2070]
NSAIDs + steroids	-2.1419 [-5.4694, 1.1857]		-3.7832 [-7.2631, -0.3033]
Steroids	1.6413 [-0.2070, 3.4897]	3.7832 [0.3033, 7.2631]	

1490

1491 Quantifying heterogeneity/inconsistency:

1492  $\tau^2 = 2.8678$ ;  $I^2 = 68.5\%$

1493


1494 Test of heterogeneity/inconsistency:

1495 Q d.f. p-value

1496

12.69 4 0.0129

1497

**Network graph**

1498

**Comparison of direct and indirect evidence**

1499

Random effects model:

1500

	comparison	prop	nma	direct	indir.	Diff	z	p-value
1501	NSAIDS:NSAIDS + steroids	0.85	-2.1419	-2.4000	-0.6558	-1.7442	-0.36	0.7152
1502	NSAIDS:steroids	1.00	1.6413	1.6413		.	.	.
1503	NSAIDS + steroids :steroids	0.64	3.7832	3.3000	4.6516	-1.3516	-0.36	0.7152

1504

Legend:

1505

comparison - Treatment comparison

1506

prop - Direct evidence proportion

1507

nma - Estimated treatment effect (MD) in network meta-analysis

1508

direct - Estimated treatment effect (MD) derived from direct evidence

1509

indir. - Estimated treatment effect (MD) derived from indirect evidence

1510

Diff - Difference between direct and indirect treatment estimates

1511

z - z-value of test for disagreement (direct versus indirect)

1512

p-value - p-value of test for disagreement (direct versus indirect)

1513


1514

## 1515 H.9 Postoperative assessment

- What are the early and late complications of cataract surgery?
- What should the postoperative assessment include?
- Who and in what setting should carry out the postoperative assessment?
- What issues should be considered when organising postoperative care?
- What is the appropriate time to assess outcomes in the postoperative period?
- If the postoperative assessment and care are undertaken outside of the hospital, how should outcomes between surgical units and these providers be effectively communicated?


### 1524 H.9.1 Details of postoperative assessment

#### 1525 H.9.1.1 Complications




1526

#### 1527 H.9.1.2 CDVA



1528

#### 1529 H.9.1.3 Unscheduled visits



1530